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ABSTRACT  
 
Novel strategies to stimulate the expansion of β-cell mass in situ are 
warranted for diabetes therapy. Cell-replacement therapies for the treatment 
of diabetes have become a focal point in recent years.  Endogenous 
regeneration of β-cell mass has been demonstrated using human multipotent 
stromal cells (hMSC). However, the secretory factors responsible for initiating 
endogenous regeneration remain unknown. Successful large-scale proteomic 
applications to address these questions have been limited in part by 
difficulties in correctly selecting the appropriate methodologies. Thus the goal 
of this thesis was a combination of assessing different proteomic workflows to 
facilitate investigation into hMSC biology, applying these methods to identify 
important factors secreted by hMSC for β-cell regeneration, as well as 
functionally investigating candidate proteins and refining current models of 
hMSC mediated β-cell regeneration.  
In working towards these goals, we first assessed the advantages and 
disadvantages of multiple fractionation techniques to help guide future 
experimental designs in general proteomic workflows. By applying these 
methodologies, we probed the secretome of hMSC and identified candidate 
regulators responsible for regeneration of β-cell mass. In particular, Wnt-
signaling we identified as an important contributor for islet regenerative 
capacity. In addition, we recognized the clinical applicability of determining 
protein signatures that could be used to screen hMSC that possessed islet 
regenerative capacity. Therefore, a robust quantitative proteomics method 
was developed to screen hMSC that could be used in downstream clinical 
 
 
ii 
 
applications for β-cell regeneration. Taking cues from these proteomic 
screens, we demonstrate that intrapancreatic-delivery of concentrated hMSC 
conditioned media (CM) can independently mediate endogenous islet 
regeneration, without injecting cells. The therapeutic effect was augmented by 
increasing protein dose and by the activation of Wnt-signaling during CM 
generation. The mechanisms of islet regeneration were multi-factorial, with 
evidence of glucagon+ cells emerging from the ductal niche within one day of 
CM injection, followed by α-β-cell conversion with NKX6.1-expression in 
transitioning β-cells, and augmented β-cell proliferation to generate 
functionally mature neoislet that respond to glucose. Altogether, these studies 
provide an extraordinary view of how this dynamic cell type can be used in 
clinical settings, to stimulate the expansion of β-cell mass and tip the balance 
in favor of islet regeneration versus destruction during diabetes. 
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Chapter 1 
 
Introduction 
 
1.1  Diabetes Mellitus 
Diabetes mellitus encompasses a group of metabolic diseases characterized 
by high blood glucose [1], caused by the inability of the pancreas to produce 
enough insulin, or by the body to respond effectively to the insulin produced 
[2]. Diabetes can be further sub-classified into two main types: (1) type one 
diabetes (T1D), also known as juvenile diabetes, which results from 
autoimmune destruction of insulin producing β-cells within the islets of 
Langerhans, and (2) type two diabetes (T2D), also known as adult-onset 
diabetes, is characterized by insulin resistance in peripheral tissues, often 
leading to improper insulin production by β-cells [3]. T2D is the most prevalent 
form of diabetes and accounts for approximately 90% of all diabetes cases 
worldwide. The World Health Organization  estimates that more than 300 
million people have been diagnosed with diabetes, and this number is 
projected to increase to 550 million by 2030 [4]. The International Diabetes 
Federation (IDF) has reported that annual health care spending to treat 
diabetes was upwards of 650 billion dollars in 2015, and that diabetes results 
in 5 million deaths per year, making diabetes a worldwide epidemic [5]. 
Currently there is no accepted cure for diabetes. However, there are various 
treatments and strategies that can help manage living with diabetes. In T2D, 
management mostly focuses on controlling circulating blood glucose levels by 
adapting diets to less carbohydrate rich foods, as well as increasing energy 
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expenditure through daily exercise. However, in cases where insulin 
resistance is high, or insulin secretion is exhausted, exogenous administration 
of insulin is ultimately required [6].  T1D is a multi-factorial disease with 
contributions from genetics and environmental stimuli, and unlike T2D is not 
caused by poor management of diet and exercise. T1D occurs through auto 
immune destruction of β-cells mediated by T-helper and cytotoxic T-
lymphocytes and auto-antibodies generated towards epitomes present 
specifically on β-cells [7,8]. Patients diagnosed with T1D must also alter their 
diets, and exogenous administration of insulin is mandatory. The amount of 
insulin and the timing of insulin injections, in both types of diabetes, are 
determined by residual islet function, age, lifestyle, meal plans and general 
health of the patient [9].  
1.2  Architecture of the pancreas 
 The pancreas is an important glandular organ that is located in the 
abdominal cavity behind the stomach which participates in the digestive and 
endocrine systems in vertebrates [10]. The majority of the pancreas is 
comprised of exocrine cells (98%), which secrete products through ducts; the 
remaining 2% is composed of endocrine cells, which secrete endocrine 
hormones directly into the blood stream [11]. The primary role of the 
endocrine pancreas is regulation of blood glucose levels. Highly organized 
structures called islets of Langerhans are present in the pancreas. Within 
these islets exists at least five main cell types that are involved in the 
regulation of blood glucose levels through the secretion of various hormones. 
These five main types are as follows: (1) α-cells, which are responsible for 
increasing blood glucose levels through the secretion of glucagon, (2) β-cells, 
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which are responsible for decreasing blood glucose through the secretion of 
insulin, (3) delta-cells, which regulate both α and β-cell function through the 
secretion of somatostatin, (4) gamma-cells, which regulates both pancreatic 
secretion activities as well as hepatic glycogen levels through the secretion of 
pancreatic polypeptide, and (5) epsilon-cells, which secrete grehlin, one of the 
main hormone involved in hunger stimuli [12]. Insulin is a protein hormone 
that is secreted as a prohormone, and contains a cleavable connecting 
peptide, called C-peptide. Therefore, the functional form of insulin and C-
peptide are found in equimolar amounts during insulin secretion, and the 
amount of C-peptide secreted into the serum has showed great clinical utility 
in assessing residual insulin secretion in patients with diabetes [13].  Glucose 
homeostasis is tightly controlled by the secretion of insulin and the function of 
glucose transporters. Adipose and muscles cells are largely responsible for 
the uptake of glucose from the blood stream via the highly specialized glucose 
receptor (GLUT4). When insulin binds its receptor, a downstream 
phosphorylation cascade occurs, signaling the synthesis and recruitment of 
GLUT4 to the cell surface for glucose uptake. In contrast, β-cells function 
primarily through a bidirectional glucose transporter (GLUT2). GLUT2 is a free 
flowing glucose receptor and is required so that β-cells can accurately gauge 
serum glucose levels and secrete insulin accordingly [14]. These two highly 
conserved signaling events occur in unison to help achieve glucose 
homeostasis in vertebrates. 
1.3  Treatments for diabetes 
Islet replacement therapy via the Edmonton Protocol has provided 
proof-of-concept that islet transplantation can temporarily reduce insulin 
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dependence in severe T1D patients [15]. Briefly, cadaveric pancreata are 
harvested and the islets are isolated using a mixture of enzymes called 
Liberase. Islets are then infused into the patient via the hepatic portal vein, 
and secrete insulin after engraftment in the liver [16]. Although this is an 
attractive strategy to combat diabetes, there are two main drawbacks 
preventing the widespread use of this therapy: (1) a critical shortage of 
cadaveric donor islet cells, and (2) eventual rejection of the implanted cells by 
the body’s immune system [16]. Patients treated with transplanted islet cells 
are administered immunosuppressive drugs to prevent allogenic islet 
rejections, but these drugs are known to have serious side effects and the use 
of exogenous insulin is ultimately required in most recipients after one year 
post transplantation [17] .Safer ways to control rejection and autoimmunity as 
well as the development of a renewable source of β-cells needs to be 
achieved before islet replacement therapies can become a widespread cure.  
1.3.1  Cell-replacement therapies for diabetes 
 Cell-replacement therapies for the treatment of diabetes have become 
a focal point for researchers in recent years. Many different potential sources 
of cells exist, such as pluripotent human embryonic stem cells or adult stem 
cells, all of which focus on generating enormous quantities of transplantable 
β-cells [12]. Embryonic stem (ES) cells are pluripotent meaning they can 
undergo differentiation into the three main germ layers: ectoderm, endoderm 
and mesoderm, and therefore human ES cells can potentially differentiate into 
insulin secreting beta-like cells [18]. Mouse ES cells have been successfully 
induced to differentiate into insulin-producing cells that self-assemble to form 
three-dimensional pancreatic islets. Although at a low frequency, these beta-
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like cells can secrete insulin in response to glucose [19]. Subsequently, a 
similar approach was taken using human ES cells that produced insulin 
secreting beta-like cells at a much higher frequency [20]. The efficiency of 
differentiating human ES cells into β-cells has been met with many 
challenges. One of the main drawbacks with this approach is that direct 
differentiation into β-cells cannot be achieved, instead long, strict multistage 
differentiation regimes are needed [21]. As a result, generated cells often 
resemble immature β-cells, and fail to perform insulin secretion in vitro. In 
addition, human ES cell-derived beta-like cells often do not express 
appropriate β-cell-specific markers or transcription factors, and are often 
found to be poly-hormonal, ultimately leading to delayed or limited insulin 
secretion when transplanted in vivo [22,23]. As proof-of-concept, in 2014 the 
approval for phase I/II clinical trials involving differentiated human ES cells 
was conducted. ViaCyte Inc. used a device that provided immunoprotection 
from the recipient’s immune system, that also contained pours big enough for 
the insulin to be released [24]. Although this trial is still ongoing, many 
challenges have surfaces: rejection of human ES cells, inefficient maturation 
of insulin producing β-cells and lack of vascularization within the device to 
allow for adequate insulin transport to periphery [25]. 
An alternative approach to generate β-cells is the use of induced 
pluripotent stem cells (iPSCs), which have the potential to be an unlimited 
source of human insulin secreting cells that can be generated efficiently using 
allogenic and autologous sources [26]. Induced pluripotent stem cells were 
first introduced in 2006 from mouse somatic cells by using a mixture of four 
transcription factors, now termed the “Yamanaka factors”, to generate cells 
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with gene expression profiles and development potential similar to ES cells 
[27]. In addition, iPSCs have also been generated using approaches involving 
small molecules [28]. Since then, many groups have demonstrated the vast 
potential of iPSCs to generate human disease-in-a-dish models and the 
development of patient specific transplantable cell sources for regenerative 
medicine [29]. The direct differentiation of multiple human iPSCs, using small 
molecules, has been shown to produce insulin secreting cells that co-express 
transcription factors of mature β-cells, and have been successfully used in 
mouse models to revert hyperglycemia [23,30]. Lastly, modulation of several 
key signaling pathways and the use of three-dimensional culture system has 
generated glucose responsive, mono-hormonal insulin-producing cells that 
mimic the function of human islets both in vitro and in vivo [22].  Although 
these techniques generate a large number of transplantable cells, they do so 
with the risk of tumorigenicity. Since the starting population of cells is 
pluripotent, benign growths, or teratomas, are possible due to undifferentiated 
cells that are still present after differentiated cultures [31]. All the 
aforementioned strategies rely on the generation of cells that can secrete 
insulin and do not harness the innate endogenous regenerative potential of 
the pancreas.  
1.3.2  Endogenous islet regeneration  
β-cell mass under normal healthy conditions has been shown to be 
very dynamic throughout the life span of several mammalian species [32] . 
For example, β-cell are capable of undergoing self replication during obesity 
and pregnancy [33]. Therefore, the potential for endogenous restoration of 
islet function is theoretically possible. Two mechanisms for β-cell expansion 
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have been proposed: (1) pre-existing β-cells undergo proliferation to generate 
more β-cell mass [34,35], and (2) β-cell regeneration is initiated at the ductal 
epithelium through islet neogenesis [36–38]. During pancreatic development, 
ductal cells show great plasticity and can give rise to both endocrine and 
exocrine cells types [39]. After 10 weeks of gestation, a large increase in cell 
proliferation and differentiation occurs, accompanied by the budding/shedding 
of the terminal duct cells that give rise to pancreatic islets [40]. After 
pancreatic damage, either surgical or chemical, the emergence of small islet 
clusters that line the ductal epithelium has argued that this is indirect evidence 
for islet neogenesis in the adult organism [41].  Alternatively, a large body of 
literature suggests that multipotent differentiation can occur from progenitor 
cells that give rise to new islet clusters [42–44]. Multi-lineage differentiation 
has been observed from endocrine progenitors that share common regulatory 
factors such as pancreatic duodenal homeobox protein 1 (PDX1) and 
homeobox protein Nkx2.2 (NKX2.2), both of which are present in every cell 
that forms the islet [45]. Therefore, it has been proposed that α-β-cell trans-
differentiation may be responsible for regeneration of β-cell mass after STZ-
mediated β-cell ablation [46].  Although, many possible avenues exist, the 
factors responsible for initiating regeneration have not yet been determined.  It 
is unlikely that a single effectors could be responsible for endogenous 
pancreas regeneration, but instead, the mechanisms mentioned above may 
act synergistically to increase β-cell mass and alleviate hyperglycemia. 
The most compelling evidence of endogenous pancreas regeneration 
was presented during the Joslin Medalist Study. This study involved the 
evaluation of pancreatic β-cell function in a large number of insulin-dependent 
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patients that have had the disease for more than 50 years [47]. Random 
serum C-peptide levels were monitored and showed that 67.4% of all 
participants had minimal or sustained ranges. Moreover, post-mortem 
examination of pancreata from multiple Medalists showed that islets contained 
proliferating β-cells as well as β-cells undergoing apoptosis, suggesting 
residual β-cell mass experienced steady-state turnover in the face of ongoing 
autoimmune destruction [47].  
1.4  Multipotent stromal cells 
 Multipotent stromal cells (MSC), also referred to as mesenchymal 
stromal cells or mesenchymal stem cells, were first identified by A. J. 
Friedenstein in 1976 [48,49]. These cell types were initially identified by their 
ability to adhere to tissue culture plastic, and differentiate into several 
mesodermal tissue types [50]. Multipotent stromal cells are adult stem cells 
and are multipotent, meaning they can differentiate into restricted lineages 
such as adipocytes, osteoblasts and chondrocytes [51–53]. Although, there is 
no single cell surface epitope that can selectively identify MSC, the 
International Society for Cellular Therapy has provided criteria that all cells 
must meet to be considered MSC [54]. To be classified as MSC, cells must 
express CD105, CD73 and CD90 and must lack the expression of 
hematopoietic markers CD45, CD34, CD14 and CD19 [52]. In addition to 
being routinely generated from bone marrow, MSC can also be expanded 
from adipose tissue, cord blood, placenta, amniotic fluid, as well as feta blood, 
liver, kidney, lung and spleen tissue (reviewed in [55]). MSC are considered 
good candidates for cellular therapies for several reasons: (1) they are easily 
obtained and isolated from bone marrow aspirates from either autologous or 
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allogenic donors, (2) can be efficiently expanded under normal culture 
conditions, (3) they are multipotent and non-tumorigenic [56] , (4) they are 
part of the body’s natural repair mechanisms and have been shown to home 
to sites of injury, and lastly (5) secrete a plethora of trophic factors that 
mediate cell differentiation, migrations and survival [57]. Therefore, MSC have 
become one of the most predominant cell types used in clinical trials 
worldwide. 
1.4.1  MSC in clinical trials 
 Clinical grade manufacturing of MSC is a routine and simple procedure 
that can be performed in normal tissue culture flasks or expanded for large-
scale applications using bioreactors [58]. MSC have been used in clinical 
trials for approximately 15 years now to treat a variety of diseases, mainly 
involved in tissue injury or immune disorders [59]. MSC have been clinically 
used in diseases that include, osteogenesis imperfect, cartilage defects, 
hematopoietic stem cell transplants, graft-versus-host disease, multiple 
sclerosis, Crohns disease as well as diabetes (reviewed in [60]). In 2014, the 
International Federation for Cell Biology (IFCB) identified 313 clinical trials 
that involved MSC, majority of which were in phase I/II (41.7%), with only a 
small percentage in phase III (4.2%). A more recent investigation using data 
from the United States of America based registry (ClinicalTrials.gov) returned 
493 clinical studies that involved the use of MSC. Geographical assessment 
of MSC clinical trials show that China, Europe and the United States of 
America account for approximately 73% of all trials worldwide 
(www.BioInformant.com). As mentioned previously, MSC have the ability to 
home to sites of injury and secrete a wide variety of bio-active factors that 
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influence the surrounding microenvironment. Although it is widely accepted 
that the regenerative and therapeutic effect elicited by MSC is largely due to 
secreted factors, the breadth of factors involved in initiating regeneration have 
not been fully elucidated. 
1.4.2  Differentiation of MSC into insulin producing cells 
Like embryonic stem (ES) cells and inducible pluripotent stem cell 
(iPSCs), it has been reported that MSC can be differentiated into insulin 
producing cells, after endocrine specific transcription factor over expression 
[61]. Under physiological conditions, MSC are restricted to the production of 
cells of the mesoderm (bone, cartilage, fat, muscle), and the insulin producing 
cells derived from MSC do not respond correctly to increased glucose levels, 
and do not show increases in C-peptide levels [62]. Furthermore, 
differentiation of MSC isolated from rats into insulin producing cells has been 
demonstrated using protein mixtures obtained from pancreatic extracts. Rat 
MSC were bathed in media that was supplemented with pancreatic extract 
and after one week of culture, MSC spontaneously assembled into islet-like 
structures [63]. In addition, the use of more defined culture media, 
spontaneous differentiation of MSC into insulin contained cells was also 
demonstrated, although at a very low frequency (1/200 cell) [64].  Lastly, MSC 
harvested from rats were trans-differentiated into insulin secreting cells that 
eventually aggregated to form islet-like clusters using complete media 
supplemented with high glucose. Interestingly, these clusters showed 
pancreatic gene expression profiles that were similar to mature β-cells and 
possessed the ability to revert hyperglycemia in hyperglycemic mouse models 
[65]. Although a promising avenue for the treatment of diabetes, the frequency 
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at which MSC differentiate into insulin producing cell is very low, and does not 
meet the requirements needed for human therapies. 
1.4.3  Endogenous β-cell regeneration using MSC 
Since MSC have been show to have immunomodulatory and tissue 
microenvironment modifying properties, direct infusion of MSC has been 
reported to promoted the survival and regeneration of endogenous β-cells 
[66,67].  In fact, using a mouse model of chemically induced pancreatic 
damage that caused hyperglycemia, direct intravenous (IV) transplantation of 
bone marrow-derived murine cells containing MSC initiated endogenous 
pancreatic regeneration [68]. More importantly, it has been shown that human 
MSC (hMSC) derived from adult bone marrow can potently initiate 
endogenous pancreatic regeneration. Briefly, hMSC were intravenously 
transplanted into chemically-induced hyperglycemic mice and were able to 
recover glucose control within 7 days of treatment. Serum insulin levels 
increased in mice reverting hypoinsulinemia. It is also important to note that 
transplanted hMSC did not differentiate into β-cells in vivo, but activated the 
regeneration of recipient islets in the murine pancreas [69]. Interestingly, 
transplantation of regenerative MSC samples increased the number of small 
islets that were associated with the ductal regions. Collectively, these data 
suggested that hMSC stimulate a putative islet neogenic mechanism [70]. 
However, of the different donor-derived hMSC lines transplanted, only 
approximately 25% could revert hyperglycemia after transplantation, 
suggesting regenerative capacity was cell line and donor specific [70]. It was 
hypothesized that hMSC with regenerative capacity secrete unique islet 
neogenic proteins into the microenvironment that form a niche permitting 
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endogenous islet formation. Lastly, the use of autologous hMSC has been 
evaluated in a clinical setting with newly diagnosed T1D patients. Twenty 
adult patients 10 of which received only insulin treatment, and 10 which 
received hMSC treatment, were assessed for C-peptide levels for up to one 
year [71]. Patients that received hMSC treatment showed stable or elevated 
C-peptide levels compared to insulin only treated patients, showing that 
hMSC treatment had no adverse affects and could effectively delay the 
severity of disease progression [71]. 
Preliminary global mRNA microarray analyses revealed Wnt-signaling 
to be elevated at the transcript level in regenerative MSC [70]. As part of this 
study, detailed proteomic analysis of secretory factors deposited into the 
regenerative niche by hMSC was performed to confirm these findings. 
However, activation of Wnt-signaling has been shown to increase the 
proliferation rate of adult human β-cells and more than double the β-cell mass 
in rodent models [72,73]. The use of protein factors or media conditioned by 
hMSC to treat diabetes has recently gained traction in pre-clinical studies. 
Multiple intravenous injection of conditioned media (CM) in T2D rats 
effectively reduced systemic blood glucose levels, through the induction of 
proliferation of residual β-cells [74]. In addition, Gao et. al. demonstrated the 
CM could initiate recovery of T1D mice through the activation of the pAKT 
survival pathway in β-cells, and successfully showed that harvested islets 
bathed in CM can undergo β-cell proliferation in vitro [75]. Both the above 
mentioned studies used IV injections their mode of delivery and did not 
investigate whether more directed delivery to the site of injury would increase 
the islet regenerative effect of the CM. Other modes of delivery have been 
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investigated. Intraperitoneal injection of periostin, a protein secreted at high 
levels in hMSC, resulted in an increased number of islets and improvement of 
long-term glucose homeostasis in vivo, which was also shown to have potent 
islet regenerative effects via delivery through the common bile duct [76]. 
These findings suggested for the first time that activation of endogenous 
regenerative mechanisms could be achieved via protein-based therapies 
based on secreted effectors derived from hMSC. 
1.5  Overview of the Wnt-Signaling Pathway 
 Wnt-signaling is an evolutionarily conserved pathway that regulates 
aspects of cell migration, cell fate determination, proliferation, cell polarity, 
neural patterning, organogenesis as well as stem cell differentiation and self 
renewal [77]. Extracellular Wnt-ligands are responsible for stimulating several 
intra-cellular signal transduction cascades that include both canonical Wnt-
signaling, dependent on β-catenin signaling, and non-canonical Wnt-signaling, 
which is independent of β-catenin signaling [78]. The canonical Wnt-signaling 
pathways can be broken down into three major components (Figure 1.1): (1) 
extracellular region that contains Wnt ligands which are secreted 
glycoproteins that bind the cysteine-rich domain of the corresponding receptor 
called Frizzled and co-receptor LRP5/6 [79], (2) intracellular region where 
signal transduction is regulated by a protein complex that is referred to as the 
“destruction complex” [80], and lastly (3) the nuclear region, where dynamic 
nuclear shuttling of β-catenin and eventual transcription of downstream 
products of Wnt-signaling occur [81]. In an inactive cell (Figure 1.1a); most of 
the endogenous β-catenin that is presented is found interacting with E-
cadherin. Excess β-catenin that is produced is rapidly turned over by the 
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destruction complex. The destruction complex consists of multiple subunits 
that include the scaffolding protein Axin, adenomatous polyposis coli (APC) 
protein, disheveled, and serine threonine kinases glycogen synthase kinase 
(GSK3) and casein kinase 1 (CK1) [80]. Degradation of β-catenin occurs in 
two steps. The first involves two phosphorylation events by CK1 and GSK3. 
CK1 phosphorylation on serine 45 occurs first, which is a primer for the main 
phosphorylation even by GSK3 at threonine 41 and serine 37 and 33 [82].  
The second involves recruitment of an E3-ubiquitin ligase which poly-
ubiquitinates β-catenin, marking it for degradation by the proteosome, 
rendering Wnt-signaling inactive. In the active state (Figure 1.1b), Wnt ligands 
bind the frizzled receptor, which recruits the cytoplasmic effecter disheveled to 
the receptor. Disheveled is responsible for interacting with Axin and 
recruitment of the destruction complex to the frizzled receptor [83]. Once in 
close proximity, phosphorylation mediated by CK1 and GSK3 occurs on 
LRP5/6, binding it to Axin.  In this state, the destruction complex cannot 
interact with excess β-catenin; therefore no phosphorylation and no 
degradation can occur [84]. 
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Figure 1.1 The basic elements involved in canonical Wnt-signaling. In 
its simplest form, Wnt-signaling can be broken down into two states. (a) With 
no presence of Wnt ligands, free β-catenin is bound to the destruction 
complex. The destruction complex is comprised of Axin, Disheveled, CK1 and 
GSK3 subunits. Once bound to the destruction complex, phosphorylation of β-
catenin occurs, marking it for degradation by the proteosome. (b) In the active 
state, Wnt ligands bind to their corresponding receptor called frizzled and its 
co-receptor LRP5/6. Recruitment of disheveled to the receptor occurs placing 
Axin in close proximity to LRP5/6. Phosphorylation of Axin binds it to the LRP, 
preventing beta catenin degradation and allowing accumulation on free β-
catenin. Beta catenin can then translocate across the nuclear membrane and 
turn on transcription of downstream Wnt target genes. 
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1.5.1  Modulation of Wnt-signaling 
 Modulation of Wnt-signaling can occur using a variety of Wnt ligand as 
well as a plethora of small molecules. One feature common to all cells that are 
activated by Wnt-signaling is increases in the intracellular levels of β-catenin.  
One of the most common ways of activating Wnt using ligands is by over 
expression of WNT3A or WNT1. Over expression of these ligands have been 
demonstrated in gliomas and glioma stem cells that rapidly increased tumor 
progression [85]. Interestingly, activation of Wnt signaling by WNT3A or by 
WNT5A has also been demonstrated by bathing cultured cells in conditioned 
medium generated from enteroendocrine L-cells. Human hematopoietic stem 
cells were exposed to conditioned media that contained WNT3A and over 7 
days the frequency of proliferating cells increased drastically [86]. A common 
problem with activating cells with Wnt ligands is that there are 19 known 
mammalian Wnt ligands that are cross-reactive with 10 frizzled receptors, 
making it very difficult to correctly choose a single ligand that will activate your 
cell type [87]. Furthermore, Wnt ligands undergo heavy post-translational 
modification, making them difficult to produce using bacterial expression 
systems. Palmitoylation, the attachment of fatty acids such as palmitic acid to 
cysteine residue, is essential for the secretion of Wnt ligands, making them 
extremely hydrophobic and difficult to purify [88]. Ultimately, whether or not 
cells will respond to Wnt signals largely depends on if they have the 
appropriate receptors present on their surfaces. Since full receptor profiling is 
very time consuming and not routinely performed, many have turned to 
alternative methods, such as small molecules, in an attempt to recapitulate 
active Wnt-signaling. The most common way of activating Wnt-signaling is by 
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modulation of the subunits that make up the destruction complex. The use of 
lithium chloride (LiCl) has been known to activate Wnt-signaling for over two 
decades. Lithium chloride exerts its affect on Wnt-signaling by inhibiting the 
activity of the enzyme GSK3, which as mentioned before, phosphorylates β-
catenin leading to degradation by the proteosome [89]. Since then, over 30 
different inhibitors of GSK3 that have IC50 values in the nanomolar ranges 
have been described, (reviewed in [90]). Of these small molecules, 
CHIR99201 has been widely used to activate Wnt-signaling in cells, and of 
particular interest, stem cells [91]. 
Upregulated Wnt-signaling is often found in cancers [92]. Therefore, 
inhibition of Wnt-signaling is seen as a therapy to arrest the growth or 
proliferation of tumors. Inhibition of Wnt-signaling can also be achieved 
through antagonistic ligands. A potent inhibitor of Wnt-signaling is a small 
ligand called dickkopf-1 (DKK1) that has been shown to bind to the co-
receptor of frizzled, LRP5/6, and leads to removal of this complex via 
endocytosis [93]. Wnt-inhibitory factor 1 (WIF-1) also inhibits Wnt-signaling 
although through a different mechanism. WIF-1 contains a lipid binding pocket 
that can interact with the palmitoyl moiety that is commonly found on Wnt 
ligand, decreasing their availability and binding to frizzled receptors [94]. 
Alternatively, inhibition of Wnt-signaling can also be achieved using small 
molecules. Through screening of a diverse synthetic chemical library, two new 
classes of small molecules that disrupt Wnt-signaling have been identified. 
The first class of molecules called IWP, inhibit Wnt-signaling by targeting the 
acyltransferase Porcupine, which is responsible for Wnt ligand Palmitoylation. 
The second class of molecules called IWR, inhibit Wnt-signaling by 
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abrogating Axin protein turnover, which is responsible for assembly of the 
destruction complex [95,96]. As described in chapters 3 and 5 of this thesis, 
modulation of Wnt-signaling can be recapitulated in vitro effectively using 
various small molecules or ligands. 
1.6  Mass spectrometry-based proteomics     
 Proteomic analysis of biological samples generally deals with 
identification of genes and cellular mRNA products at the protein level [97]. 
Largely, proteomic analyses are performed using three techniques: (1) 
Western blotting, which involves the use of specific antibodies to detect a 
single or few proteins of interest, (2) protein arrays, which include enzyme-
linked immunosorbent assays (ELISA), which can identify many proteins of 
interests using specific antibodies, and finally (3) mass spectrometry (MS)-
based proteomics, which measures thousands of proteins directly using mass 
derived from their peptides and fragments. What limits the first two techniques 
mentioned is that the direct measurement of the proteins of interest does not 
occur and throughput is often low. Instead measurement of a secondary 
signal, often the production of a light signal (fluorescence, 
chemiluminescence) occurs. Not subject to these limitations, mass 
spectrometry-based proteomics has become one of the most powerful tools 
for identifying the presence and quantitative abundance of expressed 
proteins, providing unprecedented insight into the molecular language of 
cellular biology [98,99]. 
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1.6.1  General MS-based proteomics workflow 
 Modern day analysis of complete proteomes has been facilitated by 
combining many analytical techniques. MS based proteomic analysis can be 
broken down into four general steps (Figure 1.2). The first involves enzymatic 
digestion of proteins into peptides using a site-specific protease which is 
termed “bottom-up” proteomics [100]. Trypsin, the gold standard for 
proteolysis of biological samples, generates multiply charged (≥2 charge 
state) peptides ~14 amino acids long making it highly suitable for bottom-up 
mass spectrometry applications [101]. The complexity of the sample 
determines how much useful information can be obtained from a single MS 
experiment. Depending on the desired depth of analysis, the second step 
often involves some form of pre-fractionation. Generally, fractionation 
techniques can be broken down into two main categories, fractionation at the 
protein level or at the peptide level. The third step involves separation of the 
complex peptide mixture via liquid chromatography (LC) coupled to a mass 
spectrometer. Liquid chromatography (most often reverse phase) is used to 
provide an additional depth of separation based on hydrophobic character of 
the peptides. This step also includes data acquisition using peptide fragment 
information generated by tandem mass spectrometry (MSMS). The last step 
in the proteomics pipeline is interpretation of data using fragmentation 
information generated by sequencing/matching of MSMS spectra [102]. Each 
peptide spectrum is matched to known databases or in silico digests of a 
sequenced database and statistical cut-offs are applied to ensure proper and 
accurate identification of their corresponding proteins [103]. 
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Figure 1.2 General proteomics workflow. For general protein 
identification in MS-based proteomics biological samples can be analyzed in 
two different ways. The first step involves extraction of the proteins from the 
biological sample. Next, the proteins can be fractionated, for example with 
SDS-PAGE. Protein bands are excised out of the gel and digested into 
peptide using trypsin. Alternatively, proteins can be digested using trypsin 
prior to fractionation. After digestion, the total peptide pool is fractionated, for 
example with basic reverse phase chromatography. The last step involves 
separation of the peptide by liquid chromatography (LC) that is coupled to 
mass spectrometry (MS). Peptides are fragmented by tandem MSMS analysis 
and the corresponding spectras are analyzed using matching to in silico 
databases  
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1.6.2  Fractionation strategies for MS-based proteomics 
The most commonly used protein based fractionation method is 
sodium-dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE). 
SDS-PAGE separates proteins based on molecular size. Protein bands can 
be easily excised out of the gel and subsequent trypsin digestions can be 
performed [104]. However, due to poor extraction of peptides from the 
acrylamide gels, other techniques that harness the resolution of PAGE 
separation have been investigated. One such method that has alleviated poor 
sample recovery from SDS-PAGE is termed Gel Elution Liquid Fraction 
Entrapment Electrophoresis (GELFrEE). GELFrEE fractionation also utilizes 
an acrylamide gel to separate proteins, but fully elutes them into a liquid 
collection chamber, that allows for in-solution digestion of proteins into 
peptides [105]. Another less popular separation technique is called size 
exclusion chromatography (SEC) which utilizes porous beads to separate 
proteins based on size [106]. Peptide based fractionation techniques occur 
after the initial proteolytic digest. Peptides can be separated into sequential 
fractions based on their physiochemical properties. Peptides are often 
fractionated by exploiting their inherent charges using strong cation exchange 
(SCX) or strong anion exchange (SAX) [107]. SCX fractionation relies on the 
affinity that peptides have for a solid support that is negatively charged, and 
SAX contains solid supports that are positively charged [108].  Peptides are 
eluted off the solid supports by changes in buffer pH or increases in salt 
concentrations. Most recently, the use of basic reverse phase (bRP) 
chromatography prior to MS-analysis has been implemented [109,110]. The 
pH difference in bRP causes the hydophobicity of certain amino acids to 
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change, resulting in a shift in retention times that is orthogonal to low pH 
reverse phase. Choosing the most appropriate fractionation technique will 
depend on time availability, amount of sample, complexity of the sample and 
the required proteomic depth needed to answer the biological question at 
hand. 
1.7  Quantitative MS-based proteomics 
 The accurate and quantitative assessment of protein or peptide levels 
in biological samples is one of the most challenging areas still being improved 
upon in MS-based proteomics. Quantification relies on the ability to assess 
minute changes in the abundance of proteins upon alterations of steady-
states [111]. In addition to assessing changes in biology, quantitative 
proteomics can also be used to account for technical variability at various 
stages of sample handling and preparation [112]. Quantitative proteomic 
applications have relied mostly on isotopic labels to distinguish the relative 
abundance levels between samples. Applications of isotopic labeling can be 
performed at the protein or peptide level, and samples can be mixed in pre-
defined ratios, prior to LC-MSMS analysis.  Label-based approaches are still 
the most widely accepted ways of making proteomics quantitative, but in 
recent years label-free approaches have become more popular, due to their 
simpler experimental design and lower overhead costs [113,114]. 
 The most popular isotopic labeling strategy used to study dynamic 
changes in biology is termed stable isotopic labeling in cell culture by amino 
acids (SILAC). SILAC relies on metabolic incorporation of amino acids with 
substituted stable isotopic nuclei, 13C and 15N, most commonly present on 
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arginine and lysine. This technique relies on cells prolonged exposure to the 
label, to ensure that the endogenous amino acids are replaced completely by 
the heavy amino acid [115]. In this fashion, the relative abundance of proteins 
within two samples can be measured by looking at the mass spectral signals 
that are obtained from heavy samples (labeled with 13C, 15N) compared to 
signals obtained from the light samples (labeled with 12C, 14N). One major 
hurdle to SILAC experiments is that the samples must be labeled at the 
cellular level. To overcome this, many isotopic labeling reagents have been 
developed that target primary amines and can be used post protein harvesting 
and digestion. Examples of these include isotope-coded affinity tags (iCAT) 
[116], isobaric tags for relative and absolute quantification (iTRAQ) [117] and 
tandem mass tags (TMT) [118]. In each method, an isotopic reporter ion is 
analyzed by MS that infers relative abundance levels for each sample they 
originated from. 
1.7.1  Targeted Proteomics 
Targeted proteomics can be performed in two different ways: (1) 
selected reaction monitoring (SRM), also known as multiple reactions 
monitoring (MRM) [119], or (2) by parallel reaction monitoring (PRM) [120]. 
Targeted proteomics has been widely used in drug screening, environmental 
toxicology and to identify metabolites as well as biomarkers for disease 
diagnostics [121]. SRM is performed by using MSMS fragment ion pairs that 
are known as transitions to identify peptide and their corresponding proteins. 
The biggest advantage SRM has over traditional data driven MS-based 
proteomic approaches is that only a few proteins are selected for 
quantification, and thus this affords greater selectivity and sensitivity [122]. A 
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selected list of fragment ions, called transitions, is selected and the MS only 
targets those peptides for subsequent MSMS analysis. A disadvantage of 
SRM is inherent in the experimental set up. Targeted lists must be generated 
prior to MS-analysis; therefore the investigator must know what they are 
looking for ahead of time. In addition, a retention time generated by LC 
separation is required to avoid co-isolation and fragmentation of equivalent 
masses. Lastly, the size of the targeted list is limited, and one fragment ion is 
monitored at a time, making it difficult to choose the correct transitions prior to 
MS-analysis. Recently, PRM has been introduced to overcome some of the 
challenges faced with SRM experiments [123]. Like SRM, PRM also utilizes a 
pre-defined set of targets. However, PRM methods are capably of monitoring 
all fragment ions from a single peptide. Thus peptides are selected for 
monitoring instead of transitions, eliminating the need for transition 
optimization normally found in SRM approaches. Another advantage that 
PRM approaches afford is that they are performed on high-resolution high 
mass accuracy instruments. Higher resolution instruments allow for less co-
isolation and therefore selected targets are easily distinguished from peptides 
of similar mass [124]. In general, targeted MS-based proteomic approach can 
be broken down into four steps: (1) selection of the targeted list of peptides 
that will be monitored, (2) MS-selection of the corresponding mass by 
isolation, (3) fragmentation of the selected ion, and (4) analysis of the 
fragment ions. In addition, the use of isotopically labeled “spiked-in” standards 
can be used for absolution quantification (reviewed in [125]). 
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1.8  Scope of thesis 
  Human multipotent stromal cells (hMSC) have been identified as 
extremely versatile cells for clinical use in regenerative medicine. Therefore, 
pre-clinical studies directed at large-scale proteomic analyses to determine 
the therapeutic potential of hMSC need to be undertaken. Understanding how 
hMSC exert their therapeutic effect through the secretion of bioactive 
molecules has not been studied in therapies aimed at endogenous β-cell 
regeneration. To date, large scale MS-based proteomic applications have not 
been successfully applied the hMSC biology. One potential reason for this is 
the difficulty in correctly selecting the appropriate methodologies to maximize 
complete proteome depth without sacrificing precious instrument time. In light 
of this, the goal of this thesis was to develop a combination of proteomic 
methods to assess queries into hMSC biology, as well as applying these 
techniques to identify specific therapeutic functions of hMSC, and to 
functionally validating candidate proteins of interest in application of β-cell 
regeneration.  
 Working towards these objectives, we first assessed the advantages 
and disadvantages of multiple fractionation techniques to help guide future 
experimental designs in general proteomic workflows (Chapter 2). By 
repeating four of the most common ways to perform fractionation, using a very 
complex sample (cell lysate), we identified the tradeoffs of each method in 
terms of cost, proteomic depth, instrument time and sample handling time. In 
light of this, using fractionation and proteomic techniques, we investigated 
what proteins are secreted by hMSC that possess islet regenerative potential 
compared to hMSC that show no improvement in systemic blood glucose, 
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after transplantation into immunodeficient mice rendered hyperglycemic by 
streptozotocin (STZ) treatment (Chapter 3). We discovered that hMSC 
signaled through several dynamic and complementary pathways that 
formulate a regenerative microenvironment applicable to the development of 
islet expansion therapies for diabetes. In addition to the discovery of key 
secretory hMSC regenerative pathways, active Wnt-signaling, was validated 
as playing a central role in hMSC-induction of β-cell survival and proliferation. 
Since the regenerative potential of hMSC was previously cell line-specific [70], 
lengthy in vivo characterization methods  to identify hMSC lines useful in 
regenerative applications of diabetes. Faster and higher throughput methods 
for screening hMSC potency for β-cell regeneration are needed. To address 
this need, we performed a targeted MS-based proteomic approach designed 
to predict the therapeutic potential of hMSC, in context of β-cell regeneration 
(Chapter 4). Using simple in vitro characterization assays in conjunction with 
secreted conditioned media generated from hMSC, we are able to identify 
subsets that possess β-cell regenerative and angiogenic potential. With our 
proteomic screen we successfully identified over 10 proteins that can be used 
reliably to classify hMSC based on their therapeutic potential and successfully 
classify 16 previously uncharacterized hMSC lines. Lastly combining our 
findings that regenerative hMSC secrete active Wnt products (Chapter 3), we 
demonstrated that Wnt-signaling could be modulated in non-regernative 
hMSC to increase their regenerative secretory potential, and validated the 
importance of Wnt-signaling using direct injection of CM into STZ-treated 
diabetic mouse models in vivo (Chapter 5). Herein, we showed for the first 
time that media conditioned by hMSC had the ability to induce endogenous β-
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cell regeneration, free of cells. In addition we found hyperglycemia-reducing 
effect correlated directly with protein concentration, and after activation of 
Wnt-signaling during CM generation, this therapeutic effect could be greatly 
enhanced. Lastly, we investigated secretory changes upon modulation of 
Wnt-signaling using MS-based proteomic approaches and identified key pro-
β-cell survival proteins that increase during activation of Wnt-signaling. Taken 
together, our studies improved the understanding of proteins secreted by 
hMSC capable of stimulating islet regeneration. We developed screening 
techniques to identify regenerative hMSC secretory patterns, and identified 
factors present in CM generated from hMSC that mediate endogenous β-cell 
regeneration. Altogether, these studies provide an extraordinary view of how 
this dynamic cell type can be used in clinical settings, to stimulate the 
expansion of β-cell mass and tip the balance in favor of islet regeneration 
versus destruction during diabetes. 
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Chapter 2 
 
Evaluation of Sample Fractionation Techniques for Large-Scale In-depth 
Proteomic Analysis1 
 
2.1  Introduction 
Sample preparation strategies employed in bottom-up proteomics can 
be broadly categorized into workflows which omit or implement fractionation at 
the protein or peptide level prior to LC-MSMS [1]. Prior limitations in mass 
spectrometry hardware and high pressure liquid chromatography rendered 
unfractionated preparations ineffective, necessitating the need for extensive 
fractionation to achieve deep proteome coverage [2]. Recent advances in 
instrumentation speed and sensitivity in conjunction with UPLC systems 
utilizing longer columns and smaller particles sizes has substantially improved 
characterization of complex, unfractionated proteomes [3]. This is exemplified 
by Nagaraj and colleagues and Pirmoradian et al., who detected over 3900 
yeast and 4800 HeLa proteins, respectively, by employing long gradients and 
50 cm reversed phase columns coupled to a high resolution Q Exactive mass 
spectrometer [3,4]. In fact, it is now possible to detect ~4000 yeast and ~4400 
HeLa proteins in approximately 1h with current state-of-the-art Orbitrap-based 
mass spectrometers (Orbitrap Fusion and Q Exactive High Field) [5,6].  
 
1 This chapter contains excerpts with permission from the following paper: 
Kuljanin M*, Dieters-Castator DZ*, Hess DA, Postovit LM, Lajoie GA. (2017) 
“Comparison of Sample Preparative Techniques for Large-Scale Proteomics”. 
Proteomics. 17:1-9. 
* Denotes equal author contribution 
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In contrast, fractionation approaches based on molecular weight (MW), 
charge, pI, or hydrophobicity require substantially more acquisition time and 
sample handling. Nonetheless, these workflows contribute to our 
understanding of biological systems by characterizing PTMs, enriching for low 
abundance species and quantifying expression for thousands of proteins [7–
10] 
SDS-PAGE protein separation coupled with in-gel digestion was 
commonly used in mass spectrometry-based proteomics [11,12]. Its 
robustness, low cost, high resolution and ability to handle detergent 
containing samples make it amenable to many workflows. Two recently 
published drafts of the human proteome utilized SDS-PAGE to obtain 
unprecedented protein expression profiles across several tissue types (84-
92% human proteome) [13,14]. However, SDS-PAGE is time consuming, 
manually intensive and subject to variable peptide extraction efficiencies [11]. 
Gel Eluted Liquid Fractionation Entrapment Electrophoresis (GELFrEE) 
technology, in part, overcomes these issues by combining gel-based 
separation with solution phase recovery to enable reproducible, semi-
automated fractionation with reduced sample handling and loss [15]. 
Moreover, several techniques utilizing peptide based fractionation have 
achieved exceptional proteome coverage which include multidimensional 
protein identification technology (MudPIT) [16], isoelectric focusing (IEF) 
[17,18], and more recently High-/Low-pH reversed phase chromatography 
(HpH or bRP) [6,19]. Alternatively, small scale peptide fractionation (C18, 
SCX, and SAX) can be readily performed in StageTips without requiring 
dedicated fractionation equipment [20–22].  
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Many large scale proteomic studies employ methodologies such as 
those listed but few have extensively compared their performance relative to 
one another [23–25]. In light of this, we compared HeLa proteomes obtained 
from unfractionated, SDS-PAGE, GELFrEE, SCX StageTip and HpH sample 
preparations across several parameters. With identical material and LC-MS 
time (except unfractionated samples), our findings reveal most workflows 
perform well but HpH consistently displayed the best overall performance. 
2.2  Results 
2.2.1  Proteome coverage of different workflows on a Q Exactive mass 
………spectrometer 
HeLa proteomes obtained from unfractionated, SDS-PAGE, GELFrEE, 
SCX StageTip and high pH reverse phase (HpH) sample preparations were 
systematically compared. Several modifications were made to each technique 
from its original protocol in order to allow for equal comparisons. In total, 10 
fractions were analyzed by LC-MS (~1ug per fraction) for each technique in 
biological triplicate. All fractions were run on a 4h gradient plus washing and 
re-equilibration. Replicates were searched both individually and grouped 
using the match between runs feature in MaxQuant. Where applicable, protein 
identifications containing ≥1 unique peptide in 2 out of 3 biological replicates 
was used for analysis [26]. In general, each method tested received more 
instrument time compared to previous reports and when necessary, utilized 
chloroform/methanol precipitation to remove SDS coupled with on-pellet, in 
solution digestion. 
Within each replicate for different workflows, ~7.1% of the total 
proteome was “matched-between-runs” and >95% was present in all 
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biological replicates suggesting high reproducibility for each technique. 
Moreover, only a small fraction of proteins were identified by one unique 
peptide (Figure 2.1a). In total, 5189, 6959, 5919, 7655, 8470 proteins were 
detected with unfractionated, SDS-PAGE, GELFrEE, SCX and HpH 
workflows, respectively. 
In terms of proteomic depth, nearly 5200 proteins were detected in 
unfractionated HeLa digests which is on par with previous reports [4,26]. 
Proteomic coverage with SDS-PAGE was also comparable to reports from 
other groups [27,28]. While Botelho et al. previously reported similar 
performance between GELFrEE and SDS-PAGE using an LTQ ion trap, SDS-
PAGE detected ~1,000 more proteins than GELFrEE [25]. We identified a 
respectable number of proteins with SCX StageTips (7655), which were less 
than that obtained by Kulak et al. by using a similar technique [22]. 
Differences in sample preparation (lysis buffer and digestion) as well as 
column size may be contributing factors.  The number of proteins identified 
with HpH was similar to Kelstrup et al. (8470 vs. 8500 IDs) and the highest out 
of all workflows tested [6]. Several proteomic studies reported increased 
proteome depth by incorporating data from multiple workflows and/or 
instrumentation [29–31]. Combining all sample preparative techniques yielded 
over 8700 unique proteins. This was an increase of ~3% over HpH, which 
alone had nearly 700 exclusive proteins (Figure 2.1b).  
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Figure 2.1 High confidence identification and large overlap between 
proteomes from different techniques. (a) Majority of the proteins (95%) 
were identified with high confidences (2 or more unique peptides, blue) for 
each technique. (b) Total proteins exclusive (11%) and common (50%) to five 
different preparative techniques analyzed on a Q Exactive. Gene symbols 
were used for analysis and proteins exclusive to one biological replicate were 
omitted.  
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2.2.2 Comparison of fractionation efficiency 
The capacity of pre-fractionation to resolve unique proteins or peptides 
into discrete packets reduces sample complexity and improves peptide 
detection and identification by MS [32]. To assess fractionation efficiency for 
each technique, we examined how many unique peptides, and proteins where 
applicable, were exclusive to 1, 2 or 3 or more fractions. For this analysis, 
biological replicates were searched individually without matching. 
In principle, SDS-PAGE displays good protein separation and 
resolution over a wide range of MWs, generally within a few kilo Daltons 
(kDa). Surprisingly, we found with SDS-PAGE that only 27.7% and 59.5% of 
proteins identified were exclusive to 1 or 2 fractions, respectively (Figure 
2.2a). However, at the peptide level, 58.2% and 82.8% were exclusive to 1 or 
2 fractions, respectively (Figure 2.2c). Of note, the GELFrEE protocol was 
less efficient at separating proteins than SDS-PAGE (Figure 2.2b, d). Silver 
stained GELFrEE fractions ran on 1D SDS-PAGE revealed moderate overlap 
between adjacent lanes (Figure 2.3a, b). Moreover, Box-and-Whisker plots of 
median fraction MW further illustrate limited separation with GELFrEE 
compared to SDS-PAGE (Figure 2.2c). In contrast, other studies utilizing 
SDS-PAGE or GELFrEE found 64-67% of proteins identified were exclusive to 
a single fraction [25,27]. Peptide fractionation efficiency with SCX StageTips 
was similar to Kulak et al. with 53.8% and 77.4% exclusive to 1 or 2 SCX 
fractions, respectively (Figure 2.2e) [22]. However, the HpH method gave the 
best fractionation performance with 80.1% and 94.5% of all peptides exclusive 
to 1 or 2 fractions, respectively (Figure 2.2f).  
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Figure 2.2 Fractionation efficiency varies between proteins and 
peptide separation techniques. Pie chart displaying percentage of unique 
proteins and peptides (mean ± S.D) exclusive to one (black), 2 (light grey) and 
three of more (grey) fractions for (a) SDS-PAGE (protein level), (b) GELFrEE 
(protein level), (c) SDS-PAGE (peptide level), (d) GELFrEE (peptide level), (e) 
SCX and (f) HpH. SDS-PAGE and HpH exhibited the greatest fractionation 
efficiency for protein and peptide-based separation techniques, respectively.  
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Figure 2.3 Fractionation efficiency comparison between protein based 
separation techniques. (a) Silver stained 1D SDS-PAGE of fractions 
collected on an 8% Tris-acetate GELFrEE cartridge starting with 100 ug of 
HeLa lysate. Fraction 14 was run on the same gel. (B) Gradient was slightly 
modified to allow leading dye front to be eluted in the first fraction. Fraction 1 
was discarded and fractions 2 and 3, 11 and 12, and 13 and 14 were 
combined to produce a total of 10 fractions. (C) Box-and-Whisker plot of 
median protein MW detected in each fraction for SDS-PAGE (black) and 
GELFrEE (blue). Boxes represent 75% and 25% percentiles and Whiskers 
indicate 90% and 10% percentiles. 
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2.2.3  Distribution of proteins and peptides  
Fractionation techniques which exhibit orthogonal separations are 
more efficient at maximizing MS/MS time across the entire gradient space 
[32]. Unique peptides and proteins per fraction were correlated for each 
preparative technique (Figure 2.4). For SDS-PAGE, peptides and proteins 
increased slightly with MW before declining in later fractions (higher MW) 
(Figure 2.4a). Peptides and proteins per fraction with GELFrEE decreased 
until fraction 5 before recovering (Figure 2.4b). SCX displayed a sharp 
increase in peptides/proteins detected in early fractions before plateauing 
while HpH numbers decreased only slightly with fraction number (Figure 2.4c, 
d). Retention time and peptide density plots illustrate a similar trend observed 
for peptides and proteins per fraction (Figure 2.5). For example, SDS-PAGE 
and GELFrEE exhibited higher peptide density with increasing fraction 
number (MW). Alternatively, peptide density remained even across all HpH 
fractions due to its concatenation scheme. 
 We next examined peptides: protein ratios for each technique and 
found gel-based methods had approximately one less peptide identified per 
protein compared to peptide fractionation even though gel-based approaches 
generated roughly 300K more MS2 scans (Table A2.1). As expected, in-
solution digests had the lowest peptides: protein ratio (10.1:1) but identified 
the greatest proteins/hour (1298/hour). While total unique peptides were 
indicative of proteins identified for each technique, this was not the case with 
peptide spectral matches (PSMs). For example, GELFrEE had the greatest 
number of PSMs but the fewest unique peptides and proteins. 
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Figure 2.4 Peptide and protein distribution profiles deviate for each 
separation technique. Distribution of unique peptides (right y-axis, grey) and 
proteins (left y-axis, black) identified per fraction for (a) SDS-PAGE, (b) 
GELFrEE, (c) SCX and (d) HpH. 
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Figure 2.5 Comparison of orthogonality at the peptide level between 
each fractionation technique. Peptide density distribution was assessed 
using the hexbin package in R; each hexagon represents 500 peptides with 
red indicating the highest density. (a) Orthogonality is poor at later fractions 
for both (a) SDS-PAGE and (b) GELFrEE. (c) SCX fractionation shows high 
orthogonality but high peptide density in later fractions. (d) HpH fractionation 
shows evenly distributed peptide throughout each fraction and highest 
orthogonality.  
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2.2.4  Evaluating peptide characteristics 
Examining the median sequence coverage achieved for each method 
revealed a peak in peptide density between 10% and 15% before tailing off 
(Figure 2.6a). For gel-based workflows, the median sequence coverage with 
GELFrEE (~27%) was higher than SDS-PAGE (22.6%) (Figure 2.6b). SCX 
and HpH peptide fractionation improved median sequence coverage to ~27% 
and 24.4%, respectively, over the unfractionated in-solution digest (22.8%) 
(Figure 2.6b). Combining sequence information from all methods improved 
median sequence coverage of the HeLa proteome to 38.0%. This can be 
attributed to a 48.6% increase in total unique peptides (165K) over HpH, 
which had the second highest number of unique peptides (111K) (Table 
A2.1). For comparison, Kelstrup et al. achieved a median sequence coverage 
of >40% with HeLa digests fractionated by HpH (14 fractions) using the latest 
generation Q Exactive HF [6].  
Next, we calculated the grand average of hydropathy ( GRAVY) scores 
for unique peptides detected by each workflow to determine whether any bias 
towards hydrophobic or hydrophilic species existed (Figure 2.7a). All methods 
displayed a propensity to enrich for hydrophilic peptides as indicated by 
negative GRAVY scores. Dunn’s multiple comparison, post hoc analysis 
revealed a significantly higher (P<0.001) median GRAVY score with 
unfractionated in-solution digests compared to all other techniques (Figure 
2.7b). These findings are in line with previous groups which found cellular 
digests to be primarily hydrophilic and also suggested a proportion of 
hydrophobic peptides are lost during sample handling [33,34]. 
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Figure 2.6 Different fractionation techniques provide complementary 
sequence coverage. (a) Kernel density estimation comparing percent 
sequence coverage for each technique. A slight maxima is observed near 
40% (black line) when combining sequence information from all methods. (b) 
Box-and-Whisker plots displaying median percent sequence coverage for 
individual techniques (blue). Box-and-Whisker indicates 75 and 25% 
percentiles, and 95 and 5% percentiles, respectively. On-way ANOVA was 
performed using Kruskal-Wallis test to assess differences in mean sequence 
coverage distribution between methods. Combined Data set is show in red. All 
methods were significantly different from each other (p<0.05), with the 
exception of GELFrEE and SCX. 
  
 
 
52 
 
 
 
 
 
Figure 2.7 All workflows preferentially enrich for hydrophilic peptides. 
(a) Kernel density estimation was performed using GRAVY scores from each 
method. GRAVY scores <0 indicate the presence and relative abundance of 
hydrophilic species. (b) Box-and-Whisker plot displaying mean GRAVY 
scores. Boxes represent 75% and 25% percentiles and whiskers indicate 95% 
and 5% percentiles. One-way ANOVA was performed using the Kruskal-
Wallis test to assess differences in mean GRAVY score distribution between 
methods. Combined dataset is shown in red. In-solution was significantly from 
different from all other methods (p-value <0.0001). 
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Analysis of missed cleavages revealed that a large number were 
present in most sample preparations although many (~70%) were restricted to 
one. As expected, SDS-PAGE was the highest (44.5%) which may be 
explained by poor absorption and diffusion of trypsin into the gel pieces. 
Missed cleavages with GELFrEE was relatively high (34.8%) compared to 
unfractionated in-solution samples (25.6%) even though digestion was 
performed essentially the same for both techniques. SCX fractionation 
exhibited the least missed cleavages (15.9%) followed by HpH (22.1%).  We 
also investigated peptides with missed cleavages from HpH preparations 
which contained internal lysine (K) and/or arginine (R) residues. Notably, we 
found the frequency of internal K residues to be ~2 fold higher than R even 
though their abundance in the human proteome (Uniprot) is approximately 
even (~5.8% for K and ~5.6% for R). Hence, future sample preparations may 
benefit by utilizing Trypsin and endoproteinase Lys-C (LysC) in combination to 
minimize the number of missed cleavages occurring at lysine. 
2.2.5  Sample preparation time   
Reproducibility, feasibility/cost and throughput are important 
parameters to consider when choosing a sample preparation to employ in 
bottom-up proteomics. Although it is difficult to objectively quantify these 
parameters for each technique, SCX StageTip fractionation was by far the 
most efficient and straightforward method due to the capacity to process 
samples in parallel and short elution times. HpH fraction collection was 
automated but is limited to processing one sample at a time. In addition, HpH 
requires a dedicated fractionation system as well as additional time for 
concatenation, drying and column cleaning between replicates. GELFrEE can 
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be multiplexed up to 8 samples but needs ~3 hours to run plus 
chloroform/methanol precipitation of each fraction. It also requires a dedicated 
unit and custom cartridges. SDS-PAGE, as expected, was the most labour 
intensive technique and required an additional day for de-staining. However, 
SDS-PAGE as well as SCX StageTips, were the most cost-effective and 
accessible methods. 
2.3  Discussion 
In this study, we compared the performance of several commonly used 
sample preparative techniques for bottom-up proteomics. As expected, 
fractionation yielded more protein identifications, and in most cases, greater 
sequence coverage, than unfractionated in-solution digests. Peptide-based 
fractionation outperformed gel-based workflows in terms of protein IDs and 
fractionation efficiency but not necessarily sequence coverage. However, 
differences in digestion efficiency between in-gel and in-solution preparations 
is likely a contributing factor and warrants further investigation. Interestingly, 
we did not achieve similar proteome depth with GELFrEE compared to SDS-
PAGE. This may be a consequence of the low 8% tris-acetate cartridges and 
short resolving gel (1cm) used as a prerequisite for eluting high MW proteins 
within a reasonable time frame. In addition, the GELFrEE collection chamber 
was not rinsed between cycles to maximize sample recovery. Hence, carry 
over between fractions from residual sample in the GELFrEE collection 
chamber could have led to an under representation of separation. Regardless, 
we believe that proteoforms (isoforms, PTMs and cleaved/fragmented 
proteins) migrating at different MWs are recorded as single entries during 
database searching, thereby underestimating the true fractionation efficiency 
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of SDS-PAGE and GELFrEE. For example, Titin, a 3.6 MDa protein was 
detected in low, intermediate and high MW SDS-PAGE and GELFrEE 
fractions. Nonetheless, GELFrEE remains an invaluable tool for top-down 
proteomics [35].  
Although combining multiple techniques improved protein 
identifications and sequence coverage, the additional acquisition time needed 
is not feasible for the majority of medium to large scale proteomic studies (≥1 
proteome/day of instrument time). It is doubtful that faster mass 
spectrometers with increased sensitivity and dynamic range will bypass the 
need for some form of sample fractionation to achieve maximum proteome 
coverage.  Utilizing multiple enzyme digestion strategies or iterative exclusion 
in tandem with techniques like HpH fractionation may be more appropriate for 
achieving optimal sequence coverage [7,36,37]. Additional improvements to 
protein extraction/handling, column technology and instrumentation could also 
yield increased proteome depth. In summary, the findings reported here 
illustrate the benefits and limitations of different techniques for analyzing a 
complex cellular proteome and should help aid in the design of future bottom-
up proteomics studies. Ultimately, the degree of fractionation needed is 
determined by how much data is needed to answer the biological question at 
hand.  
2.4  Experimental Methods 
2.4.1 Cell culture and protein extraction 
HeLa cells (obtained from the ATCC) were maintained in DMEM F12 
media supplemented with 10% FBS (Life Technologies). Confluent 15 cm 
plates of HeLa cells were rinsed with PBS, trypsinized and then centrifuged at 
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400 xg for 5 minutes to pellet cells. Cell pellets were re-suspended in PBS, 
pelletted again and stored at -80°C. To prepare lysates for LC-MS, frozen cell 
pellets were incubated in 8M Urea, 50 mM ammonium bicarbonate (ABC), 
10mM DTT, 2% SDS and sonicated with a probe sonicator (20 X 0.5 second 
pulses; Level 1) (ThermoFisher Scientific) to shear DNA. Lysates were 
quantified using a Pierce™ 660 nm Protein Assay (ThermoFisher Scientific) 
and stored at -80˚C until future use. 
2.4.2 Chloroform/methanol protein precipitation 
HeLa lysates were reduced in 10 mM DTT for 30 minutes and alkylated 
in 100 mM Iodoacetamide (IAA) for 30 minutes at room temperature in the 
dark. Next, lysates were precipitated in chloroform/methanol in 1.5 mL 
microfuge tubes according to Wessel and Flügge [38]. Briefly, 100 μg aliquots 
of HeLa lysates were topped up to 150 µL with 50mM ABC. To each sample, 
600 μL of cold methanol was added followed by 150 μL of chloroform and 
thorough vortexing. A volume of 450 μL of water was added before additional 
vortexing and centrifugation at 14,000 x g for 5 min. The upper 
aqueous/methanol phase was carefully removed to avoid disturbing the 
precipitated protein interphase. A second 450 μL volume of cold methanol 
was added to each sample followed by vigorous vortexing and centrifugation 
at 14, 000 x g for 5 min. Remaining chloroform/methanol was discarded and 
the precipitated protein pellet air dried in a fume hood. 
2.4.3  Unfractionated on-pellet in-solution digestion 
On-pellet protein digestion was performed using a modified protocol 
described by Duan et al. [39]. Briefly, 150 µL of 50 mM ABC (pH 8) trypsin 
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solution was added to precipitated protein pellets (1:50 ratio) and incubated 
overnight at 37°C in a water bath shaker. An additional aliquot of trypsin was 
added the next day (1:100 ratio) for ~4 hours before acidifying (pH 3-4) with 
10% formic acid (FA). Digests were centrifuged at 14,000 x g to pellet 
insoluble material before LC-MS or peptide fractionation. 
2.4.4  SDS-PAGE followed by in-gel digestion 
HeLa lysates were fractionated by SDS-PAGE as previously described 
[40]. Briefly, 100 µg of lysate was separated on a 12% acrylamide tris-glycine 
gel followed by fixing, staining with Coomassie blue and de-staining overnight 
on a horizontal shaker. Each lane was divided into 10 equal gel fractions 
which were manually processed into ~1x1 mm3 cubes using a razor blade. 
Gel pieces were reduced in 10 mM DTT for 30 minutes and alkylated in 100 
mM IAA for 30 minutes at room temperature in the dark.  After dehydration 
with ACN, gel pieces were swelled in 100 μL of 50 mM ABC (pH 8) trypsin 
solution (1:25 ratio distributed evenly across 10 fractions) and incubated 
overnight in a water bath shaker at 37°C. Peptides were extracted from gel 
pieces in the presence of a water bath sonicator by adding a small volume of 
10% FA followed by dehydration in 300 μL ACN for 10 minutes, two times. 
Samples were dried in a SpeedVac (ThermoFisher Scientific) and re-
suspended in 0.1% FA prior to LC-MS. 
2.4.5  GELFrEE fractionation followed by in-solution digestion 
HeLa lysates (100 μg/chamber) were fractionated on an 8% tris-
acetate cartridge using the GELFrEE system according to the manufacturer 
(Expedeon). Sample collection was not started until blue loading dye was 
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visible in the collection chamber after which 150-200 µL of liquid was removed 
and replaced following each time interval. Running buffer was changed every 
hour or half hour when using 50 or 100 V, respectively. Fractions 2 and 3, 11 
and 12, and 13 and 14 were concatenated to generate a total of 10 fractions 
that were processed using chloroform/methanol and in-solution digestion as 
described above. 
2.4.6  SCX peptide fractionation 
Tryptic peptides recovered from chloroform/methanol precipitated, in-
solution digests of HeLa lysate (100 µg) were fractionated using SCX 
StageTips similarly to Kulak et. al [22]. Approximately 100 µg of peptides, 
acidified with 1% TFA, were distributed evenly between four 12-plug SCX 
StageTips. In total, 10 SCX fractions were collected by eluting in 75, 100, 125, 
150, 175, 200, 225, 250 and 300 mM ammonium acetate/20% ACN solutions 
followed by a final elution with 5%mM ammonium hydroxide/80% ACN. 
Fractions eluted with identical buffers from quadruplicate StageTips were 
combined, dried in a SpeedVac, resuspended in ddH2O and dried again to 
evaporate residual ammonium acetate. All samples were resuspended in 
0.1% FA prior to LC-MS analysis. 
2.4.7 High pH reversed phase peptide fractionation 
Proteins (100 µg) obtained from chloroform/methanol precipitation were 
digested in-solution with trypsin as described above. Next, tryptic peptides 
were fractionated on a Waters XBridge BEH130 C18 5 µm 4.6 mm x 250 mm 
column connected to an Agilent 1100 HPLC system at a flow rate of 1 mL/min 
at 20°C. Buffer A (100% water) and buffer B (10% water/90% ACN) were 
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maintained at pH 10.0 by the addition of ammonium hydroxide immediately 
prior to fractionation. The gradient consisted of 5% to 35% B over 55 minutes, 
70% B over 8 min, hold at 70% B for 2 minutes, return to 5% B over 5 min and 
then hold for 15 minutes. A total of 50 fractions were collected during the first 
75 minutes of the gradient (1.5 mL per fraction) using an automated fraction 
collector. The volume of each fraction was reduced using a SpeedVac and 
every 10th fraction was concatenated. The final 10 fractions were dried 
completely using a SpeedVac and resuspended 0.1% FA prior to LC-MS. 
2.4.8  LC-MS/MS 
All fractions/digests were analyzed using an M-class nanoAcquity 
UHPLC system (Waters) connected to a Q Exactive mass spectrometer 
(ThermoFisher Scientific). Buffer A consisted of Water/0.1% FA and Buffer B 
consisted of ACN/0.1%FA. Peptides (~1 µg measured by BCA) were initially 
loaded onto an ACQUITY UPLC M-Class Symmetry C18 Trap Column, 5 µm, 
180 µm x 20 mm and trapped for 4 minutes at a flow rate of 10 µl/min at 99% 
A/1% B. Peptides were separated on an ACQUITY UPLC M-Class Peptide 
BEH C18 Column, 130 Å, 1.7 µm, 75 µm X 250 mm operating at a flow rate of 
300 nL/min at 35°C using a non-linear gradient consisting of 1-7% B over 7 
minutes, 7-19% B over 173 minutes and 19-30% B over 60 minutes before 
increasing to 95% B and washing. Settings for data acquisition on the Q 
Exactive are outlined in the appendix (Table A2.2). 
2.4.9 Data Analysis 
All raw MS files were searched in MaxQuant version 1.5.2.8 using the 
Human Uniprot database (reviewed only; updated May 2014 with 40,550 
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entries) [41,42]. Missed cleavages were set to 3 and I=L. Cysteine 
carbamidomethylation was set as a fixed modification. Oxidation (M), N-
terminal Acetylation (protein), and Deamidation (NQ) were set as a variable 
modifications (max. number of modifications per peptide = 5) and all other 
setting were left as default. Precursor mass deviation was left at 20 ppm and 
4.5 ppm for first and main search, respectively. Fragment mass deviation was 
left at 20 ppm. Protein and peptide FDR was set to 0.01 (1%) and the decoy 
database was set to revert. Match between runs was enabled where specified 
in main text. Bioinformatics analysis was performed using Perseus version 
1.5.5.3. Briefly, protein lists were loaded into Perseus and proteins identified 
by site, reverse and contaminants were removed [43]. When using the match 
between runs feature, datasets were filtered for proteins containing a 
minimum of one unique peptide in at least 2 out of 3 biological replicates. 
Kernel density estimation was performed using R statistical software version 
3.2.3. Graphpad Prism version 6.01 was used to conduct nonparametric 
Kruskal-Wallis test coupled with Dunn’s multiple comparison, along with the 
Mann-Whitney test to assess significance.  
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Chapter 3 
Proteomic Characterization of Paracrine Signals Secreted by Multipotent 
Stromal Cells that Augment Blood Glucose1 
 
3.1  Introduction 
In 2013, WHO reported that over 347 million people worldwide lived 
with diabetes, and estimated that this number will increase to 552 million by 
2030, making diabetes a worldwide epidemic [1]. The Edmonton Protocol 
provided proof-of-concept that islet transplantation can temporarily reduce 
insulin dependence in individuals with type 1 diabetes [2]. Although islet 
replacement is an attractive strategy to combat diabetes, a critical shortage of 
donor islets and eventual rejection by continuing autoimmunity prevent the 
widespread application of this approach [3]. Bone marrow (BM)-derived stem 
cell transplantation has also been reported to promote endogenous islet 
regeneration in preclinical models, and represents a promising alternative 
strategy to combat diabetes [4]. 
Human multipotent stromal cells (hMSC) have become a focal point in 
recent clinical trials for tissue repair [5]. hMSC are readily available from 
autologous or allogenic donors, they are efficiently expanded in culture and 
they home to damaged tissues to initiate innate repair mechanisms [6].  
1 This chapter contains excerpts with permission from the following paper: 
Kuljanin M, Bell GI, Sherman SE, Lajoie GA, Hess DA. (2017) “Proteomic 
Characterization Reveals Active Wnt-signaling by Human Multipotent Stromal 
Cells as a Key Regulator of Β-cell Survival and Proliferation “. Diabetologia. 
10: 1987-1998. 
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hMSC exert their therapeutic effects primarily through the secretion of trophic 
signals within damaged organs, or impact tissue repair from distant sites by 
secretion of regenerative effectors into the circulation within exosomes or 
microvessicles [7]. Exosomes harvested from hMSC contain pro-angiogenic 
proteins and promote the healing of ischemic tissue [8,9]. hMSC also secrete 
a wide variety of immunomodulatory molecules that dampen autoimmunity via 
modulation of immune cell functions [10,11]. Currently, the mechanisms 
underlying the regenerative and immunomodulatory effects of hMSC remain 
poorly understood, and better understanding of MSC protein secretion is 
required to harness the true regenerative capacity of hMSC. 
In the context of diabetes, transplanted human BM-derived hMSC have 
been shown to promote repair of pancreatic islets and renal glomeruli in non-
obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice after 
β-cell ablation [6]. Although hMSC conversion into insulin-expressing beta-like 
cells has been demonstrated after stable induction of PDX1 [12], minimally 
manipulated hMSC did not adopt a β-cell phenotype after transplantation in 
vivo. In contrast, transplanted hMSC initiated endogenous islet recovery via 
paracrine stimulation [13]. In a series of publications, we have shown that 
human BM-derived hMSC stimulated the emergence of small, recipient-
derived islet-like structures associated with the ductal epithelial niche within 7 
days of injection into streptozotocin (STZ)-treated hyperglycemic NOD/SCID 
mice [14,15]. Unfortunately, hMSC samples showed donor-dependent 
variability in the capacity to improve glycemia and prolonged expansion ex 
vivo reduced islet regenerative prowess [14]. Thus, detailed proteomic 
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analyses of the islet regenerative hMSC secretome remain the key to 
understanding which protein signals promote islet regeneration in situ. 
We compared the secretory protein profile of human BM-derived hMSC 
with or without islet regenerative capacity by performing global proteomic 
analysis of conditioned culture media (CM) after stable isotope labeling with 
amino acids in cell culture (SILAC) [16]. We hypothesized that islet 
regenerative hMSC will secrete a combination of unique protein factors that 
augment islet regeneration. In order to confirm our findings we also examined 
the effects of exogenous stimulation of Wnt signaling in hMSC for the survival 
and proliferation of human islet-derived β-cells in vitro. To our knowledge, this 
is the first proteomic study linking the human hMSC secretome profile with β-
cell regenerative function and it highlights the importance of active Wnt 
signaling in the maintenance of hMSC-induced islet regeneration. 
3.2  Results 
3.2.1  Regenerative capacity of human hMSC was donor specific 
Hyperglycemic (15–25 mmol/l), STZ-treated (35 mg/kg per day, days 
1–5) NOD/SCID mice were i.v. injected on day 10 with hMSC (5×105) [14,17], 
and blood glucose levels were monitored for 42 days. Compared with PBS-
injected control mice, hMSC samples (N=3) that showed significant reduction 
in systemic blood glucose from days 17–42 were termed hMSCR and hMSC 
samples (n=3) that did not show blood glucose reduction (>25 mmol/l) were 
termed hMSCNR (Figure 3.1a). There was a significant reduction in blood 
glucose AUC for hMSCR vs. hMSCNR samples (Figure 3.1b). Out of a total of 
18 hMSC lines tested, six (~33%) were characterized as hMSCR, four (~22%) 
demonstrated intermediate regenerative capacity and eight (~44%). were 
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characterized as hMSCNR. hMSC lines with intermediate regenerative 
capacity were not used in this study. All hMSCR and hMSCNR lines possessed 
multipotent differentiation potential into adipogenic and osteogenic lineages in 
vitro [14, 15]. Cell surface phenotype showed that both hMSCR and hMSCNR 
expressed the stromal markers CD90 and CD105 (>95%) without expression 
of the pan-leukocyte marker CD45. hMSC donor information, including age, 
sex, weight and body mass index (BMI), is shown in Figure 3.1c. 
 3.2.2 hMSCR exclusively secreted proteins associated with active Wnt 
………signaling  
We have previously shown that hMSCR demonstrated increased 
transcription of matrix metalloproteases, EGF-family ligands and downstream 
products of Wnt-signaling [15]. Here, we sought to confirm and identify 
secreted protein targets that contribute to islet regeneration by comparing the 
secretome of hMSCR and hMSCNR samples using global MS-based 
proteomics coupled with SILAC. CM was harvested from each hMSC line (24 
hrs) and analyzed in biological and technical duplicates. The total number of 
proteins detected for each hMSC sample is shown in Figure 3.2a. Proteins 
from each hMSC line were combined based on regenerative capacity and 
complete lists of secreted proteins detected exclusively in CM from hMSCR or 
hMSCNR, or proteins common to both groups, were generated (ESM Tables 
3.1–3.3). Of 4665 total proteins detected (false discovery rate 1%), 3023 
(~65%) were produced by both hMSCR and hMSCNR, 850 (~18%) were 
produced by hMSCR exclusively, while 792 (~17%) were produced by 
hMSCNR exclusively (Figure 3.2b). Gene ontology using cellular component 
analysis revealed that hMSCR CM contained qualitatively more proteins with 
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extracellular localization (21% vs. 14%), while hMSCNR CM contained more 
membrane-bound proteins (23% vs. 19%) (Figure 3.2c). Moving forward, 
protein lists were filtered to include only extracellular (secreted) and 
membrane-bound proteins, and were further analyzed for known biological 
functions and signaling family association. 
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Figure 3.1 Functional characterization of islet hMSCR and hMSCNR. (a) 
MSCs from six donors were injected into STZ-treated (35 mg/kg per day, days 
1–5) NOD/SCID mice on day 10, and blood glucose was monitored weekly 
until 42 days to segregate hMSCR (blue) vs. hMSCNR(red) samples compared 
with PBS-injected control mice (black). Blood glucose concentrations were 
lower after injection of hMSCR compared with hMSCNR samples. (b) Blood 
glucose AUC was significantly reduced with hMSCR (n = 3) (blue) vs. 
hMSCNR (n = 3) (red) samples. (c) Donor characteristics were similar between 
hMSCNR and hMSCR samples. Data are presented as mean ± SEM. 
***p < 0.001 
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Figure 3.2 Qualitative analyses of proteins exclusively secreted by 
hMSCR or hMSCNR. (a) Total proteins identified for hMSCR (blue) and 
hMSCNR (red) lines using SILAC. (b) Venn diagram showing that out of the 
4665 total proteins detected, 850 were unique to hMSCR (blue) and 792 were 
unique to hMSCNR (red). (c) hMSCR demonstrated a higher proportion of 
proteins with extracellular (secreted) localization compared with hMSCNR. (d) 
hMSCR secreted more proteins associated with the activation of Wnt signaling 
and angiogenesis. hMSCNR secreted more proteins associated with EGF, 
FGF and Notch signaling. 
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hMSCR demonstrated increased representation of secreted proteins 
associated with angiogenesis and activation of the Wnt-signaling pathway, 
while hMSCNR showed increased secretion of proteins associated with EGF, 
FGF and Notch signaling pathways (Figure 3.2d). hMSCR exclusively secreted 
several proteins associated with cell survival and growth, such as FGF7 and 
bone morphogenetic protein (BMP) 4. Pro-angiogenic factors vascular 
endothelial growth factor receptor 2 (KDR), vascular endothelial growth factor 
receptor 4 (FLT4) and regulators of angiogenesis A disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS)13 and 18 were also 
unique to the hMSCR secretome [18]. Notably, hMSCR secreted potentiators 
of Wnt signaling (spondins), ligand activators of Wnt-signaling (WNT5B) and 
downstream products of Wnt-signaling that modify the extracellular matrix 
(ECM) (Wnt-inducible signaling pathway protein 2 [WISP2/CCN5]) (Table 3.1) 
[19–21]. In contrast, proteins exclusively detected in hMSCNR CM included 
positive and negative regulators of angiogenesis (FGF receptor (FGFR) 4, 
FLT1) [18,22], and an abundance of pro-inflammatory cytokines (IL-6, IL-8) 
and C-X-C motif chemokines (CXCL2, 3, 5) (Table 3.2) [23]. Collectively, 
these findings suggested hMSCR actively secreted cell growth supportive 
factors with reduced secretion of common pro-inflammatory signals, and only 
hMSCR showed production of multiple effectors associated with active Wnt 
signaling. 
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Table 3.1 Exclusively detected proteins in CM from hMSCR. A table 
outlining highly confidence protein secreted factors that are involved in 
angiogenesis, inflammation, matrix remodeling and Wnt-signaling. 
Gene 
Symbol 
Protein Name Biological Function 
ADAMTS13 A disintegrin and metalloproteinase with 
thrombospondin motifs 13 
Matrix metalloproteinase 
ADAMTS18 A disintegrin and metalloproteinase with 
thrombospondin motifs 18 
Matrix metalloproteinase 
EGF Epidermal growth factor Regulator of cell growth, 
proliferation and differentiation 
FGF7 Fibroblast growth factor 7 Tissue repair, mitogenic cell 
survival 
FLT4 Vascular endothelial growth factor 
receptor 3 
Secretion of VEFGA/C 
IGF2 Insulin-like growth factor 2 Growth promoting hormone 
KIT Mast/stem cell growth factor receptor 
Kit 
Migration, survival and 
proliferation of stem cells 
KDR Vascular endothelial growth factor 
receptor 2 
Regulation of angiogenesis 
and vascular development 
MMP10 Stromelysin-2 Matrix metalloproteinase 
MMP12 Macrophage metalloelastase Matrix metalloproteinase 
MMP3 Stromelysin-1 Matrix metalloproteinase 
PDGFD Platelet-derived growth factor D Regulation of cell proliferation, 
migration and chemotaxis 
SPON2 Spondin 2 Activator of Wnt signaling 
TIMP4 Metalloproteinase inhibitor 4 Matrix metalloproteinase 
inhibitor 
WISP2 Wnt1-inducible-signalling pathways 
protein 2 
CCN5, regulator of cell growth 
WNT5A Protein Wnt5b Activator of Wnt signaling 
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Table 3.2 Exclusively detected proteins in CM from hMSCNR. A table 
outlining highly confidence protein secreted factors that are involved in 
angiogenesis, inflammation, matrix remodeling and Wnt-signaling 
 
Gene 
Symbol 
Protein Name Biological Function 
CXCL2 C-X-C motif chemokine 2 Inflammatory response 
CXCL3 C-X-C motif chemokine 3 Inflammatory response 
CXCL5 C-X-C motif chemokine 5 Inflammatory response 
GDF15 
Growth/differentiation factor 15 Regulator of inflammation 
and apoptosis 
FLT1 
Vascular endothelial growth factor 
receptor 1 
Negative regulator of 
vascular growth factor A 
signaling 
FGFR4 
Fibroblast growth factor receptor 4 Regulation of angiogenesis 
and vascular development 
FZD1 Frizzled-1 Wnt-signaling receptor 
FZD2 Frizzled-2 Wnt-signaling receptor 
FZD7 Frizzled-7 Wnt-signaling receptor 
IL-1β Interleukin-1 beta Inflammatory response 
IL-6 Interleukin-6 Inflammatory response 
IL-8 Interleukin-8 Inflammatory response 
MMP11 Stromelysin-3 Matrix metalloproteinase 
NOV 
Protein NOV homologue CCN3, promoter of cell 
differentiation 
TGFBR2 
Transforming growth factor beta 
receptor type-2 
Regulator of cell growth, 
proliferation and 
differentiation 
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3.2.3 Quantification of Wnt, matrix remodeling and pro-angiogenic proteins  
To quantify proteins secreted by both hMSCR and hMSCNR, 
quantitative proteomics was performed using label-free quantification [16,24] 
to identify proteins differentially secreted into serum-containing media. Lists 
were filtered to include only secreted and membrane-bound proteins, and 
1038 common proteins were quantified to generate lists of differentially 
expressed proteins (ESM Table 3.4). We did not observe any significant 
difference in the total number of proteins quantified between samples (Figure 
3.3a), and 468 proteins were differentially expressed between hMSCR vs. 
hMSCNR samples (p<0.05, Figure 3.3b). Upregulated proteins in hMSCR CM 
included matrix remodeling proteins (matrix metalloproteinase (MMP)1, 
MMP3, ADAMs and BMPs) [25,26], effectors of Wnt-signaling (WNT5A, 
secreted frizzled-related protein 1 [SFRP1]) (Figure 3.3c) [20], additional 
targets implicated in angiogenesis (angiogenin [ANG], angiopoietin 
[ANGPT]1, ANGPTL2, TGFB1, TGFB2, platelet-derived growth factor 
receptor [PDGFR] A, B) [22,27] and chemokines involved in cell recruitment 
(CXCL12) (Figure 3.3d) [21,28]. Thus, the activation of Wnt and pro-
angiogenic signaling again correlated with islet regenerative potency. 
Conversely, the negative regulator of Wnt-signaling Dickkopf-related protein 
(DKK)1 was increased ~2.5-fold in hMSCNR CM, and negative regulators of 
angiogenesis (ADAMTSs, thrombospondin [THBS] 1 and THBS2) and 
inhibitors of matrix remodeling proteins (metalloproteinase inhibitor [TIMP] 3) 
were increased in hMSCNR CM [29]. HMVECs were cultured on growth factor-
reduced Geltrex to assess the angiogenic potential of hMSC CM in vitro 
(Figure 3.3e). A significant increase in the tubule formation was observed 
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when HMVECs were cultured using CM from hMSCR compared with hMSCNR. 
Representative photomicrographs of tube formation after 24 hrs are shown in 
Figure A3.1. Finally, we identified that pro-differentiation proteins associated 
with Notch signaling were upregulated in hMSCNR (NOTCH2, JAG-1) [30], 
suggesting that inhibited Wnt and angiogenic signaling and activated Notch 
signaling was associated with diminished islet regenerative capacity. 
3.2.4 hMSCR increased expression of Wnt pathway mRNA  
To confirm the activation of Wnt-signaling in hMSCR, we assessed 
mRNA expression of 84 genes related to Wnt-pathway signal transduction, 
using three hMSCR and three hMSCNR lines performed in duplicate. 
Transcripts with differential expression greater than two fold between hMSCR 
vs. hMSCNR revealed 18 significantly changing genes (Figure 3.3f), 
normalized to the geometric mean of three housekeeping genes: ACTB, B2M 
and HPRT1, that did not show significant variation across samples. Notably, 
all differentially expressed mRNAs (18 genes) were upregulated in hMSCR, 
and no significantly changing genes were down regulated. Upregulation of 
WNT5A/B in hMSCR was confirmed at the mRNA level. Other upregulated 
mRNA in hMSCR included transcription factors (FOSL1, JUN) and receptors 
associated with Wnt-signaling (FZD5) [19,31]. Taken together, upregulation of 
Wnt-signaling at the mRNA and protein level strongly suggests active Wnt-
signaling during expansion was a unique and conserved characteristic that 
correlated with the reduction of hyperglycemia after transplantation of hMSCR 
in vivo. 
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Figure 3.3 Quantitative analyses of proteins secreted by both hMSCR 
and hMSCNR. (a) Total number of proteins quantified within all three 
hMSCR (blue), hMSCNR (red) samples and total number of quantified proteins 
(grey). (b) Representative volcano plot of differentially expressed secreted 
proteins. A change greater than twofold is represented outside the green 
boundaries. (c) hMSCR showed increased secretion of Wnt activators 
(Wnt5A), while hMSCNR showed increased secretion of Wnt inhibitors (DKK1). 
(d) hMSCR demonstrated increased secretion of pro-angiogenic proteins, 
TGFB1 and SDF-1 (CXCL12). (e) Spontaneous tubule formation of HMVECs 
on growth factor-reduced Geltrex was increased when cultured using CM 
generated from hMSCR compared with hMSCNR. (f) Quantitative PCR for Wnt-
signaling related transcripts in hMSCR compared to hMSCNR. Data are 
presented as mean ± SD. **p < 0.01 
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3.2.5 hMSC show activation of Wnt-signaling via accumulation of nuclear β-
catenin  
 Canonical Wnt-signaling converges on the actions of β-catenin, a 
transcription factor that increases the expression of downstream effectors of 
Wnt signals [32]. We mimicked Wnt-signaling in hMSCNR and hMSCR using a 
small molecule (CHIR99201) inhibitor of GSK3. GSK3 actively phosphorylates 
β-catenin, which marks it for ubiquitination and degradation. Therefore, 
inhibition of GSK3 leads to stabilization and accumulation of free β-catenin 
[19]. hMSC samples showed maximal increases in total β-catenin using 5–10  
μmol/l CHIR99201 for 24–48 h. We then used confocal microscopy to 
visualize the accumulation of nuclear β-catenin (Figure 3.4). Compared with 
DMSO control cells (Figure 3.4a), hMSCNR and hMSCR stimulated with 10 
μmol/l CHIR99201 showed increased nuclear β-catenin localization (Figure 
3.4b, c). Next, hMSCNR and hMSCR samples were analyzed in quadruplicate 
to quantify total β-catenin levels by flow cytometry (Figure 3.5d). 
Representative dot plots are shown in Figure A3.2. Compared with DMSO 
control cells, both hMSC subtypes treated with CHIR99201 showed 
significantly increased total β-catenin. Thus, inhibition of GSK3 with 
CHIR99201 mimicked activated Wnt signaling in hMSCR and hMSCNR. 
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Figure 3.4 hMSC treatment with GSK3 inhibitor induced nuclear β-
catenin localization. Representative photomicrographs showing hMSCR and 
hMSCNR stained for β-catenin (green) and DAPI (blue) after treatment with (a) 
DMSO vehicle, (b) CHIR99201 (24 h) hMSCNR, (c) CHIR99201 (24 h) hMSCR. 
White arrows indicate examined nuclei with nuclear staining and arrowheads 
indicate examined nuclei without nuclear staining. Scale bars, 50 μm. (d) 
Intracellular β-catenin was increased in both hMSCR and hMSCNR treated with 
CHIR99201 (grey bars) or DMSO control (white bars). Data are presented as 
mean ± SEM. **p < 0.01, ***p < 0.001 
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3.2.6 GSK3 inhibition in hMSCNR generates CM that improves human β-cell 
………survival in vitro  
To assess whether hMSCR CM could improve β-cell survival in vitro, 
we cultured primary human islet preparations for up to 7 days in CM from 
hMSCR and hMSCNR, and performed multiparametric flow cytometry to 
analyze β-cell survival and proliferation. Human islets were obtained through 
the Integrated Islet Distribution Program (IIDP). Compared with hMSCNR CM, 
human islets grown in hMSCR CM showed increased total number of β-cells 
(Figure 3.5a) and an increased frequency of live β-cells (Figure 3.5b) after 7 
days of culture. To further assess the influence of active Wnt-signaling on islet 
regenerative paracrine function, we also assessed whether CM generated by 
hMSCNR treated with a GSK3 inhibitor (CHIR99201) during expansion could 
promote human β-cell survival or proliferation in cultured human islets. CM 
recovered from hMSCNR cultured with vehicle control (DMSO) only (basal CM) 
was compared with CM recovered from hMSCNR treated with 10 μmol/l 
CHIR99201 (GSK3i CM) (Figure 3.5c). Five independent human islet samples 
were cultured as indicated in Figure A3.3. At each time point, human islets 
were harvested, dissociated with trypsin, and stained using Flz3 to estimate β-
cell frequency, 7AAD to determine cell viability and Annexin-V to determine 
apoptosis rates by multiparametric flow cytometry. Representative dot plots 
are shown in Figure A3.4. Compared with basal CM, human islets grown in 
CM generated by GSK3-inhibited hMSCNR showed increased total cell 
numbers (Figure 3.5d), β-cell numbers (Figure 3.5e) and the proportion of live 
(7AAD) β-cells at 7 days culture (Figure 3.5f). However, no significant 
changes in the frequency of apoptotic β-cells were observed (Figure 3.5g). 
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Figure 3.5 Culture of human islets in GSK-inhibited CM increased β-
cell number. Human islets cultured in CM generated from hMSCR showed (a) 
increased β-cell number and (b) increased proportion of live β-cells after 
7 days of culture. (c) Human islets were cultured in CM generated by 
hMSCNR treated with DMSO (basal CM) or CHIR99201 (GSK3i CM). 
Compared with human islets cultured in basal CM (red) and RPMI (blue), 
islets cultured in GSK3-inhibited CM (green) showed increased (d) cell 
number, (e) β-cell number and (f) proportion of live β-cells at day 7. (g) 
Human islets cultured in hMSCNR CM did not alter apoptotic β-cell frequency. 
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 
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To determine whether increased β-cell number was augmented by 
increased β-cell proliferation in vitro, we measured EdU incorporation in 
insulin+ β-cells. At each time point, human islets were harvested, 
permeabilized, stained for intracellular insulin and proliferation was detected 
by EdU incorporation using the Click-It system. Compared with basal CM, islet 
exposure to CM generated by GSK3-inhibited hMSCNR increased the overall 
frequency of proliferating cells (Figure 3.6a) and proportion of total 
proliferating β-cells (Figure 3.6b). Finally, islet donor variability was 
documented by donor information including age, sex, BMI and average blood 
glucose levels (Figure 3.6c). Collectively, these data suggest that CM 
generated from hMSCNR treated with CHIR99201 promoted β-cell survival and 
induced β-cell proliferation in vitro. 
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Figure 3.6 Culture of human islets in GSK-inhibited CM increased β-
cell proliferation. (a, b) Compared with human islets cultured in basal CM 
(red) and RPMI (blue), islets cultured in GSK3i CM (green) showed increased 
proportion of insulin+/EdU+ β-cells at day 3. (c) Islets were obtained through 
the IIDP from five independent donors with variable weight, BMI and average 
blood glucose (Avg.BG) values. Data are presented as mean ± SEM. 
*p < 0.05 
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3.3 Discussion 
We used comprehensive SILAC-based proteomic analyses to identify 
hMSC-secreted factors that correlated with the capacity to lower circulating 
blood glucose after transplantation into STZ-treated NOD/SCID mice. hMSCR, 
demonstrated with glucose-lowering capacity after transplantation, secreted 
proteins associated with cell growth, matrix remodeling, immunosuppressive 
and pro-angiogenic properties. In contrast, hMSCNR, which lacked islet 
regenerative functions, secreted proteins involved in the initiation of 
inflammation and the negative regulation of angiogenesis. Notably, hMSCR 
consistently demonstrated mRNA and protein expression associated with 
active Wnt-signaling, a novel signature that correlated with islet regenerative 
capacity. Inhibition of GSK3 activity with CHIR99201 mimicked Wnt-signaling 
in hMSCNR and resulted in the generation of CM that supported β-cell survival 
and proliferation within cultured human islets in vitro. Thus, we report a central 
role for Wnt-signaling in the establishment of an islet regenerative secretory 
profile in hMSCR, and improve our understanding of hMSC-secreted signals 
governing islet regeneration. We predict this data set will aid in the 
development of future therapies to augment islet regeneration during 
diabetes. 
Functional β-cells secrete pro-angiogenic proteins responsible for 
recruiting circulating or tissue resident progenitor cells to islets after damage 
[33]. However, during autoimmunity or after islet isolation and transplantation 
these critical functions are likely to be dysregulated, resulting in transient 
ischemia that significantly impairs islet function [34]. Increased production of 
potent pro-angiogenic factors, such as FGF7, PDGF and VEGFA, by hMSCR 
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underscores the functional capacity to generate a pro-angiogenic 
microenvironment. Collectively these proteins potently stimulate human islet 
vascularization in vitro [35]. To validate the functional relevance of pro-
angiogenic secretory patterns, hMSCR CM showed increased capacity to 
induce spontaneous tubule formation by HMVEC compared with hMSCNR CM. 
Interestingly, hMSCNR primarily secreted negative regulators of angiogenesis 
such as FLT1 and FGFR4, which have both been shown to inhibit the signal 
cascade mediated by VEGFA [18]. We have previously shown that 
intrapancreatic transplantation of pro-angiogenic hematopoietic progenitor 
cells induced islet revascularization and β-cell proliferation and augmented 
systemic insulin release in STZ-treated NOD/SCID mice [15]. Therefore, our 
data suggest hMSCR may also formulate a pro-angiogenic microenvironment 
to support β-cell survival and function within endogenous or transplanted 
islets. 
The prevention of pro-inflammatory states within damaged islets may 
also be relevant in the context of hMSC therapy for type 1 diabetes. The 
presence of central mediators of inflammation in CM from hMSCNR, such as 
IL-1beta, IL-6 and IL-8, suggests that hMSCNR may contribute to pro-
inflammatory cascades. In people with type 1 diabetic, β-cell destruction is 
initiated by a combination of pro-inflammatory cytokines, including IL-1beta 
and IL-6 [36], and CXCL family chemokines, leading to recruitment of immune 
effectors that mediate β-cell destruction [37]. Furthermore, high levels of IL-8 
have been linked to elevated non-essential fatty acids (NEFA), which can 
signal inflammatory cascades in the pancreas [38]. In contrast, these 
cytokines and chemokines were not secreted by hMSCR. Rather, hMSCR 
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secreted cytokines that could potentially reduce inflammation. For example, 
TGF-beta suppresses the secretion of various inflammatory 
cytokines/chemokines, and induces cytokine secretion patterns that balance 
local immunity [39]. Stromal cell-derived factor 1 (CXCL12), also upregulated 
by hMSCR, has been shown to directly promote β-cell survival through the 
activation of AKT [40]. Collectively, we propose hMSCR generate a niche with 
reduced inflammation, improving β-cell survival, while hMSCNR contribute to a 
more deleterious pro-inflammatory microenvironment. 
Inadequate β-cell mass leads to hyperglycemia in both type 1 and type 
2 diabetes. Currently, there is significant interest in restoration of β-cell mass 
through induction of endogenous regenerative mechanisms in situ using 
cellular or protein therapies. Our previous transplantation studies suggested 
that human BM-derived hMSC stimulate an islet regeneration program with 
neogenic characteristics. Mice transplanted with hMSCR, demonstrated 
improved glycemia control via the emergence of small β-cell clusters 
associated with the ductal epithelium [14]. Several identified effectors may act 
in synergy to mediate islet regenerative processes. First, hMSCR showed 
increased secretion of EGF previously shown to increase β-cell mass in 
rodents by stimulating β-cell replication [41]. However, EGF receptor signaling 
was required for expansion of murine β-cell mass in response to a high-fat 
diet, but was not crucial for neoislet formation after pancreatic ductal ligation 
[42]. Second, the CCN family of extracellular matrix-associated, heparin-
binding proteins has been shown to modulate cell growth and repair in many 
tissues by increasing the bioavailability of BMPs, VEGF, Wnt and TGF ligands 
[43]. More specifically, connective tissue growth factor (CTGF) or CCN2 has 
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been widely studied during β-cell development [44]. Within our data set, 
hMSCR exclusively secreted CCN5). Previously, we have identified WISP1 
(encoding CCN4) and WISP2 (encoding CCN5) mRNA as being upregulated 
in hMSCR [15]. Importantly, CCN4 and CCN5 secretion is directly linked to 
active Wnt-signaling. CCN5 also represents a link between insulin and IGF-I 
regulation in islet function, and CCN5 over expression leads to increased islet 
cell growth in vitro [45]. Interestingly, hMSCNR exclusively secreted 
nephroblastoma overexpressed protein or NOV isoform (CCN3), which has 
been shown to impair β-cell proliferation and inhibit glucose-stimulated insulin 
secretion in vitro [44]. Thus, we predict modification of the ECM via Wnt-
inducible CCN protein regulation is a critical step in islet regenerative 
processes. 
One of the key differences between hMSCR and hMSCNR was the 
activation of Wnt-signaling. Wnt-signaling is highly conserved in primitive 
hMSC and is involved in multiple developmental processes, including cell 
proliferation, growth and fate determination. Aly and colleagues have shown 
that delivery of WNT3A and R-spondin to cultured islets increased the 
proliferation of adult human β-cells [46]. Our data suggests that hMSCR 
propagate Wnt-signaling primarily by autocrine secretion of WNT5A/B ligands 
with potential regulation by SFRP1. In contrast, hMSCNR expressed proteins 
that inhibit Wnt-signaling, namely DKK1 and DKK3. Although more research 
is required to determine potential effects of WNT5 signaling on human β-cells, 
it is clear that hMSCR maintain active canonical Wnt-signaling and increase 
secretion of downstream effectors that promote β-cell regeneration. By 
inhibiting GSK3 activity using CHIR99201, we have shown that the activation 
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of canonical Wnt pathway signals in hMSCNR can mimic Wnt-signaling 
allowing accumulation of nuclear β-catenin. Human pancreatic islets grown in 
media conditioned by hMSCNR treated with CHIR99201 showed increased β-
cell survival and proliferation during 7 days of culture. Manipulation of Wnt-
signaling through the inhibition of GSK3 has been previously suggested to 
directly increase β-cell proliferation. One study treated diabetic neonates with 
LiCl, a known inhibitor of GSK3, and doubled β-cell mass in rat models of 
diabetes [47]. Others have inhibited GSK3 using small molecules to regulate 
islet cell survival and proliferation in vitro [48]. Although, the mechanisms by 
which inhibition of GSK3 affects β-cell survival and proliferation in vivo is still 
unclear, our results suggest that activation of Wnt-signaling in pancreas-
resident stromal cells may have practical application in β-cell regenerative 
therapies. Nonetheless, activation of Wnt-signaling during hMSC culture 
increased the regenerative capacity of hMSCNR by altering downstream 
secretory patterns. 
In summary, our data outlines several dynamic and complementary 
pathways that formulate a regenerative microenvironment applicable to the 
development of islet expansion therapies for diabetes using hMSC or their 
secretory products. The proteomic data reported in this study will be used in 
future studies to characterize functional mechanisms relevant to islet 
regeneration, or as screening technology to select hMSC subpopulations that 
possess augmented capacity to regenerate islets in situ. 
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3.4  Experimental Methods 
3.4.1 Transplantation of human derived hMSC  
Human BM was obtained from healthy donors after informed consent 
at the London Health Sciences Centre (London, ON, Canada). All studies 
were approved by the Human Research Ethics Board at Western University 
(REB#12934, 12252E). The hyperglycemia-lowering capacity of six hMSC 
samples was assessed after tail vein injection of 500,000 cells into STZ-
treated NOD/SCID mice as previously described [14]. Blood glucose 
concentrations were monitored weekly for 42 days and samples were 
segregated into regenerative (hMSCR) or non-regenerative (hMSCNR) based 
on the ability to reduce blood glucose compared with PBS-injected control 
mice. 
 3.4.2 hMSC culture and SILAC labeling  
hMSC were expanded in AmnioMax media (Invitrogen). At passage 3, 
hMSC were switched to custom AmnioMax that contained no l-arginine or l-
lysine. Heavy [13C6, 
15N4] l-arginine and [
13C6, 
15N2] l-lysine were added into 
SILAC media at 87.8 mg/l and 52.2 mg/l, respectively (Silantes). Excess 
unlabelled l-proline was added to prevent conversion of heavy arginine into 
heavy proline [49]. hMSC were grown in SILAC media for 9 days to achieve 
>95% label incorporation. 
 3.4.3 Generation of labeled CM and proteomic workflows  
After 9 days of labeling in SILAC media, hMSC were washed twice with 
PBS to remove residual growth factors and replated in basal AmnioMaxTM 
without supplement to collected proteins secreted by labeled hMSC for 24h. 
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Media conditioned by hMSC was collected, filtered and centrifuged at 450 x g 
to remove any cellular debris. Cell viability was assayed using trypan blue and 
>95% viability was used as a standard cut-off for secretome analyses. CM 
was generated in biological and technical duplicate for a total of 6 individual 
hMSC lines and was concentrated using 3 kDa molecular weight cut-off filter 
units (Millipore). Pelletted cells were harvested and lysed to determine 
isotopic label incorporation. Concentrated CM was lyophilized overnight and 
re-suspended in 8M urea, 50 mM ammonium bicarbonate, 10 mM 
dithiothreitol and 2% SDS solution prior to protein quantitation and 
fractionation. Protein concentration was measured using the Pierce 660 nm 
protein assay (ThermoFisher Scientific). 
3.4.4 SDS-PAGE Fractionation and mass spectrometry  
Protein samples generated from hMSC CM were subjected to 1D SDS-
PAGE fractionation using in-house made 12% gels in technical duplicate. 
Briefly, 150 µg of total protein was loaded onto each gel generating 10 
fractions. Each band was subsequently digested using an in-gel protocol with 
trypsin (Promega), as previously described. Fractions were quantified using 
the BCA assay (ThermoFisher Scientific) and approximately 1 µg of material 
was injected per fraction. Each fraction was injected and separated using a 
nanoAcquity system (Waters) on a 25 cm long x 75 µm inner diameter C18 
column (Waters), maintained at 35oC. All samples were trapped for 5 min at 
99% H2O, 1% acetonitrile, and separated using a 5.0% to 37.5% acetonitrile 
gradient over 80 min, followed by 95% acetonitrile over 5 min, at a flow rate of 
300 nL/min. Mass spectrometry was performed using a Q Exactive 
(ThermoFisher Scientific). Full MS parameters are outlined in Table A3.1. 
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 3.4.5 Proteomic data analysis  
Qualitative data analysis was performed using PEAKS 7.5 software 
(Bioinformatics Solutions Inc.). Briefly, raw data files were refined using 
correct precursor mass only and de novo sequencing was performed using 
the following parameters: parent mass tolerance 20 ppm; fragment ion 
tolerance 0.05 Da; enzyme was set to trypsin; fixed modifications, 
carbamidomethylation; and variable modifications included: deamidation 
(NQ), oxidation (M), +10 Da on arginine and +8 Da on lysine for SILAC 
labeling. Data were searched against the Uniprot human sequence database 
(updated May 2014, 20178 entries). Quantitative data analysis was performed 
using MaxQuant version 1.5.2.8 30. All parameters were set to as described 
above. Match between runs was enabled and all other parameters left at 
default. Data was analyzed using label free quantitation (LFQ) as described 
previously 30. Bioinformatic analysis was performed using Perseus version 
1.5.0.8. Briefly, protein lists were loaded into Perseus. Proteins identified by 
site, reverse and contaminants were removed manually 20. Gene annotation 
was performed with the online software tool PANTHER version 9.0. 
3.4.6 HMVEC tubule forming assay  
To assess CM influence on endothelial cell function in vitro, 120,000 
human microvascular endothelial cells (HMVECs) were cultured on growth 
factor-reduced Geltrex (Life Technologies) in endothelial basal media (EBM-2; 
Lonza) conditioned by hMSCR and hMSCNR for 24 h. As a positive control, 
HMVECs were also grown in Geltrex bathed in complete endothelial growth 
medium (EGM-2 = EBM-2 + 5% FBS + IGF, basic fibroblast growth factor 
[FGF], EGF, vascular endothelial growth factor [VEGF]). Tube formation was 
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quantified by counting the number of complete tubule branches in four fields 
of view using ImageJ software (NIH). 
 3.4.7 qRT-PCR of the Wnt-signaling pathway 
RNA was purified in duplicate from three regenerative and three non-
regenerative hMSC cell lines using the PerfectPureTM RNA Cultured Cell Kit 
according to the manufacturer instructions (5PRIME).  RNA quality and 
quantity was assessed using NanoDrop.  Subsequently, cDNA was 
synthesized using the High Capacity cDNA Reverse Transcription Kit with 
RNase inhibitor (Invitrogen).  Real-time PCR was performed using SYBR® 
Green along with the human WNT-Signaling Pathway PCR Array, which 
contained 84 genes related to Wnt signal transduction using the 384 well 
formats (Qiagen).  Samples were incubated at 50oC for 2 minutes followed by 
10 min at 95oC. DNA was amplified at 95oC for 15 s followed by 1 min at 60oC 
for 40 cycles, using the Bio-Rad CFX384 Real-Time PCR Detection System 
(Bio-Rad).  All samples were analyzed using the RT2 Profiler PCR Array Data 
Analysis version 3.5 online (Qiagen).  Samples were normalized using the 
geometric mean of three housekeeping genes.  
3.4.8 Confocal microscopy for total β-catenin 
hMSC were cultured in 6-well plates on glass cover slips and treated 
using the following concentrations of GSK3 inhibitor CHIR99021 (EMD 
Millipore): DMSO (vehicle control), (250 nM, 500 nM, 1 μM, 5 μM, 10 μM) for 
6, 12, 24, and 48 hrs in AmnioMaxTM media + supplement.  hMSC were fixed 
in 10% formalin (Sigma), permeabilized in 1% triton X-100 and treated with 
goat block.  Cells were incubated with rabbit anti-human β-catenin antibody 
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(1/200) (Abcam) and detected with goat anti-rabbit fluorescein antibody 
(Vector Laboratories).  The cover slips were mounted using Vectashield with 
DAPI.  Confocal microscopy was performed at the London Regional Confocal 
Microscopy Core Facility (London, ON) using the FV1000 microscope 
(Olympus).  
3.4.9 Flow cytometry for total β-catenin 
hMSC were treated for 24 h with 10 μM of CHIR99021 inhibitor or 
DMSO (control).  Cells were harvested and fixed using 10% formalin and 
permeabilized using Saponin buffer as indicated by manufacturer’s 
instructions (Life Technologies).  FITC conjugated β-catenin antibody was 
diluted into the cell suspension according to the manufacturer’s instruction 
(EBioscience).  Samples containing isotype controls for the primary antibody 
were used.  All flow cytometry data were collected at the London Regional 
Flow Cytometry Facility (London, ON) using an LSR II flow cytometer 
(Beckton Dickenson) and analysis was performed using FACSDIVA software 
(BD Biosciences).  Geometric mean fluorescent intensities (gMFI) were 
reported compared to isotype control. 
3.4.10 Human islet culture with MSC CM  
Human islets from five donors were obtained from the Integrated Islet 
Distribution Program (IIDP). Upon arrival, 200 islet equivalents were plated in 
RPMI media without serum (Invitrogen). hMSC CM was collected after 24 h 
from hMSC treated with DMSO (basal CM) or with 10 μmol/l of CHIR99021 
(GSK3i CM). CM was concentrated using 3 kDa molecular mass cut-off filters, 
and ~1.0 μg/μl total protein was added to human islet culture for 1, 3 or 7 days 
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(Figure A3.2). After islet harvest and dissociation, β-cell content was 
estimated using FluoZin-3 (Flz3) (ThermoFisher Scientific) and apoptosis was 
quantified using 7AAD and Annexin-V. To detect islet cell proliferation, 500 
nmol/l of 5-ethynyl-2′-deoxyuridine (EdU) was added to islet culture 24 h prior 
to harvest. Islets were fixed and permeabilized using 10% formalin and 
saponin buffer, stained for insulin using a PE-conjugated insulin antibody 
(R&D Systems), and nuclear EdU incorporation was detected using the Click-
It flow cytometry assay (Life Technologies). Flow cytometry data were 
analyzed using FloJo software (Treestar). 
3.4.11 Statistical analysis  
Statistical analysis was performed using GraphPad Prism version 6.01 
(GraphPad) by ANOVA with Tukey’s post hoc test or by multiple t tests. Data 
are expressed as means (S.E.M). 
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Chapter 4 
Predicting the Therapeutic Potential of Human Multipotent Stromal Cells 
Using Quantitative Proteomics1 
 
4.1  Introduction 
 Multipotent stromal cells (MSC) have been described as one of the 
most versatile cell types for use in regenerative medicine applications. Since 
their initial discovery in bone marrow, MSC have been identified and isolated 
from several adult and fetal tissues [1]. The use of donor-matched MSC or 
autologous MSC greatly increases therapeutic potential in the clinical setting, 
bypassing host-versus-graft disease requirement for long-term 
imunnosupression that normally arise during cell based therapies [2]. In 
addition, MSC have the capacity to respond to injury, infection or diseases in 
all vascularized tissues within the body [3]. MSC harvested from multiple 
anatomical locations are equivalent in terms of surface marker expression and 
differentiation potential [4]. However, MSC harvested from different sites may 
express very different genes, which may have an impact on their function as 
well as clinical relevance in cellular therapies [5]. For example, MSC 
harvested from amniotic fluid have been shown to have neonatal defense 
properties while MSC harvested from bone marrow play functional roles in 
blood and bone formation [6].  
1 This chapter contains excerpts with permission from the following paper: 
Kuljanin M, Bell GI, Hess DA. Lajoie GA. (2017) “Predicting the Therapeutic 
Potential of Human Multipotent Stromal Cells Conditioned Media using 
Quantitative Proteomics”. (In preparation) 
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One of the most useful properties that MSC possess is ample secretion of 
various regenerative cytokines and immunomodulatory factors. MSC secrete 
a wide variety of growth factors and cytokines/chemokines that can induce 
cell proliferation and angiogenesis [7]. It has been well documented that MSC 
secrete pro-angiogenic cytokines, such as HGF, EGF, and VEGF, that 
increase fibroblast, epithelial and endothelial cell division as well as 
chemokines, such as stromal derived factor-1 (SDF-1 or CXCL12), that 
increase accessory cell recruitment to sites of injury [8]. MSC have also been 
shown to secrete a wide variety of extracellular vesicles to package peptides, 
proteins, membrane lipids and nucleic acids, that impact regenerative 
processes at distant sites via the blood stream [9,10]. In addition to having 
pro-angiogenic effects, MSC have also been implemented in anti-
inflammatory, immunomodulatory, anti-apoptotic, anti-microbial and most 
recently β-cell regeneration applications [7,11,12]. 
Although MSC have been safely and successfully used in many clinical 
applications, direct characterization of trophic factors secreted by MSC is still 
lacking and could lead to optimization of their therapeutic potential [13]. The 
therapeutic potential of each MSC line isolated is directly related to what they 
secrete and how much of each factor they secrete. For example, the vascular 
regenerative capacity of BM-derived MSC can be enriched by subset 
selection based on high aldehyde dehydrogenase activity [14]. In addition, the 
heterogeneous nature of MSC populations isolated from different donors, and 
expanded in culture, has been shown to impact β-cell regenerative potential 
using in vivo mouse models [15]. Interestingly, the β-cell therapeutic potential 
of MSC has also been shown to diminish with age, or with prolonged passage 
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in culture [16]. Both of the above mentioned studies relied on lengthy in vivo 
evaluations to characterize MSC that have angiogenic and β-cell regenerative 
properties. This process is inherently ineffective at screening a large number 
of donor derived MSC lines for therapeutic efficacy relevant to cellular 
therapies. Therefore, thorough examination of protein secretion by MSC using 
high throughput technologies are needed to improve existing therapies, to 
tailoring each MSC line isolated for a specific function. 
Extensive proteomic characterization of human MSC (hMSC) that 
possess the ability to decrease blood glucose levels in hyperglycemia mouse 
models have revealed key protein signature that could be used for future 
screening techniques [17]. These include: the increased secretion of pro-
angiogenic, cell growth supportive factors and reduced secretion of common 
pro-inflammatory signals that were found highly expressed in non-
regenerative hMSC. However, due to the relatively small sample sized used, 
more in depth analysis is required to determine a protein signature that can be 
used to predict which hMSC lines possess the ability to initiate islet 
regeneration after transplantation into streptozotocin (STZ)-treated mice in 
vivo. 
Herein, we present a quantitative proteomic approach that can be used 
to predict the therapeutic potential of hMSC lines in terms of angiogenesis 
and β-cell regeneration inducing capacity (Figure 4.1). By using previously 
characterized hMSC lines, we were able to develop a surrogate assay using 
human islets to assess the β-cell regenerative effects of hMSC conditioned 
media (CM) in vitro. Quantitative label-free proteomics was used to generate 
a training data set. Next, using machine learning algorithms, we are able to 
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determine an unbiased protein signature of islet regenerative hMSC samples 
that are in turn quantitatively validated by using targeted proteomics. In 
addition, the secreted proteins from 16 uncharacterized cells lines were tested 
against this protein signature to predict the therapeutic potential of each 
hMSC line. Lastly, results are were validated using the aforementioned in vitro 
co-culture human islet assay coupled with multiparametric flow cytometry as 
well as quantitative recovery from hyperglycemia in STZ-treated mice. For the 
first time, we describe a protein signature that can be used to screen hMSC 
lines selected for use in β-cell regenerative applications. 
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Figure 4.1 Predictive assay workflow. hMSC lines previously 
characterized were used to recapitulate angiogenic or β-cell regenerative 
potential using in vitro models. Label-free quantitative proteomics was 
performed on secreted proteins from 10 different hMSC lines to build a 
training data set. Protein signatures were obtained using machine learning 
and validated with targeted proteomics. The predictive power of the assay 
was tested using 10 previously uncharacterized hMSC lines and their 
regenerative properties were validated using proteomics and in vitro / in vivo 
models. 
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4.2 Results 
4.2.1 Angiogenic capacity of hMSC CM 
To determine the angiogenic potential of hMSC CM, spontaneous 
tubular formation was assessed in vitro using human microvascular 
endothelial cells (HMVEC). HMVEC were cultured on growth factor reduced 
GeltrexTM bathed in endothelial basal media (EBM) without growth factors, 
endothelial growth media (EGM) supplemented with bFGF, EGF, IGF, VEGF 
or ~ 50 µg of secreted protein from hMSC CM for 20 hours. The total number 
of tubes formed was numerated and angiogenic capacity was quantified 
(Figure 4.2a-d). In total, 10 different hMSC CM samples, generated by 10 
different hMSC lines, were evaluated for the capacity to increase tubule 
formation in biological triplicate. A significant increase in the tubule formation 
was observed for three out of 10 hMSC lines. hMSC lines that possessed 
significant tubule formation capacity compared to EBM were grouped and 
deemed angiogenic and those that failed to augment tubule formation 
grouped and deemed non-angiogenic (Figure 4.2e). Collectively, angiogenic 
hMSC showed significantly increased number of tubules formed compared to 
non-angiogenic hMSC (Figure 4.2f, ***p<0.001). Quantitative label-free 
proteomics was used to determine relative expression levels of all proteins 
identified in hMSC CM, in biological triplicate. In addition, quantitative 
assessment of the proteins was used to identify signatures that could be 
implemented in predicting the angiogenic potential of hMSC CM.  
In total ~ 2500 proteins were identified and gene ontology cellular component 
(GOCC) analysis was used to determine proteins that were associated with 
extracellular localization (752). Protein lists were further filtered to only include 
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proteins that were quantified in > 6 out of 10 hMSC lines, and missing values 
were imputated [18,19]. Protein lists were cross-compared using Gene Set 
Enrichment Analysis (GSEA) to hallmark gene sets for angiogenesis and in 
total 32 proteins were selected for subsequent analysis [20]. In addition, the 
two groups were compared using hierarchical clustering with Euclidean 
distances in Perseus, with z-scoring to determine directional changes in 
protein abundances (Figure 4.2g) [21]. Unfortunately, protein changes were 
very heterogeneous between samples and showed no distinct correlations 
that could be used to predict angiogenic potential of hMSC CM. However, the 
top two and bottom two hMSC CM could be predicted using the expression 
levels of four proteins. The top two angiogenic hMSC lines were predictable 
by high relative abundance of two potent pro-angiogenic proteins, stem cell 
factor (KITLG) and angiogenin (ANG), while the least angiogenic hMSC lines 
showed low relative abundance. Conversely, platelet factor 4 variant (PF4V1) 
and vascular endothelial factor C (VEGFC) were highly expressed in the least 
angiogenic hMSC lines. In summary, these data suggested that proteomic 
assessment of angiogenic capacity could not be reliably achieved for each 
sample using the current screening strategy. However, the angiogenic 
potential of the top 20% and the bottom 20% of hMSC samples could be 
predicted by the relative expression levels of four angiogenic proteins.  
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Figure 4.2 Angiogenic potential of hMSC CM. (a) HMVEC were grown on 
growth factor reduced Matrigel and spontaneous tubular formation was 
assessed using (a) EGM, (b) EBM, (c-d) CM from hMSC samples. (e) 
Average number of tubules formed was quantified In triplicate and three 
hMSC lines showed significantly increased tubular formation compared to 
EBM control. (f) hMSC lines were grouped and angiogenic hMSC (red) 
showed significantly higher number of tubules formed compared to non-
angiogenic hMSC. (g) Label-free quantitative proteomic clustering using 
Euclidean distances and z-scoring did not show a distinct angiogenic protein 
secretion pattern that could be used to predict angiogenic potential of hMSC. 
Data is represented as mean ± S.E.M. (*p<0.05, ***p<0.001). 
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4.2.2 β-cell regenerative capacity of hMSC CM 
 We have previously shown that hMSCs can be used to initiate 
regeneration of endogenous β-cells after transplantation into STZ-treated 
NOD/SCID mice. However, hMSC represented a heterogeneous population 
and the extent of regenerative capacity was cell line specific [15]. In addition, 
hMSC that possessed the capacity to induce islet regeneration after 
transplantation were rare, with only ~10-20% of hMSC samples able to 
reverse established hyperglycemia after transplantation. To determine 
whether hMSC possessed β-cell regenerative capacity, a lengthy 42 day in 
vivo experiment needed to be performed, making it too inefficient to be used 
as a screening modality. Similar to the angiogenesis screen performed above, 
we sought to identify a quantitative proteomic signature that could be used to 
predict β-cell regenerative capacity using hMSC CM. A training data set was 
constructed using two known regenerative hMSC lines and two non-
regenerative hMSCs lines that were previously characterized using the in vivo 
transplantation model [15]. In addition, 6 previously uncharacterized hMSC 
lines were added to the training data set, for a total of 10 hMSC lines. To 
group hMSC lines, human islet culture assays were performed using CM to 
assess which hMSC lines could improve β-cell survival in vitro after 7 days of 
culture, using multiparametric flow cytometry for beta cell survival and 
proliferation (Figure 4.3a-b). CM from two islet regenerative hMSC lines 
showed significantly higher total live β-cell numbers compared to CM 
generated from the two known non-regenerative hMSC lines, as previously 
shown (Figure 4.3c) [17]. The remaining hMSC lines were used for test 
validation and none of the samples showed significant improvement over 
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negative controls (RPMI) and were thus classified as non-regenerative. When 
grouped, regenerative hMSC showed a significant increase in the total 
number of viable β-cells compared to non-regenerative hMSC (Figure 4.3d), 
therefore validating our in vitro functional assay. 
Quantitative proteomics was used to determine what factors could best 
identify and place unknown hMSC lines into either regenerative or non-
regenerative classes. Unbiased mining and protein marker selection of label-
free quantitative proteomic data was achieved using the R package 
“geNetClassifier support vector machine (SVM)” [22]. Data mining was 
performed using the training data set mentioned above, where two 
regenerative lines and 8 non-regenerative lines were used to train the SVM. 
The posterior probability of each gene was assessed and, in total, 20 genes 
that met a threshold of 0.90 could be used to reliably segregate the two 
classes (Figure 4.3e). A full list of all proteins and their corresponding 
posterior probabilities can be found in Table A4.1. The top 10 proteins, which 
included: six inflammatory markers, one Wnt-signaling protein and three 
proteases, were chosen to perform further prospective validation. 
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Figure 4.3 Predictive protein signatures for β-cell regenerative hMSC. 
(a) Multiparametric flow analysis of human islets cultured for 7 days bathed in 
hMSC CM. Assessment of β-cell content was achieved with FluoZin-3. (b) 
Survival rate of β-cell was assessed by looking at the frequency of 7AAD and 
Annexin-V. (c) Total live β-cell number was used to assess regenerative 
potential of two regenerative and two non-regenerative hMSC lines. 
Regenerative hMSC lines showed significantly increased total live β-cell 
numbers compared to RPMI. Non-regenerative hMSC lines were not 
significantly different from RPMI. Six additional hMSC lines were 
characterized as non-regenerative. (d) Regenerative hMSC lines were 
grouped and showed significantly increased live β-cell numbers compared to 
non-regenerative hMSC lines. (e) Unbiased machine learning was performed 
using label free quantitative values and 20 proteins could be used accurately 
segregate regenerative and non-regenerative hMSC lines. Data is 
represented as mean ± S.E.M. **p<0.01, ***p<0.001.  
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4.2.3 Validation of regenerative signature using targeted proteomics 
  Proteins obtained from the SVM suggested that regenerative hMSC 
lines secreted three proteins in significantly higher abundance than non-
regenerative hMSC, while 7 proteins were secreted in significantly lower 
abundance compared to non-regenerative hMSC. To confirm these findings, 
label-free quantitation (LFQ) for each of the top 10 proteins was assessed 
across classes (Figure 4.4a). Indeed, the three proteins chosen by SVM 
showed elevated relative expression levels in regenerative hMSC ranging 
from 16-32-fold higher compared to non-regenerative hMSC. In contrast, the 7 
proteins chosen as highly expressed in non-regenerative hMSC showed 
relative expression levels in non-regenerative hMSC ranging from 4-32-fold 
higher compared to regenerative hMSC. These results confirmed that the 
classification performed by the SVM algorithm was accurate. 
 To further quantify the relative abundance of the candidate proteins 
obtained from SVM, parallel reaction monitoring (PRM) was performed using 
an in-house made, stable isotope labeled (SIL) peptide spike-in (glu-1-
fibrinopeptide B: EGVNDNEEGFFSAR) that was purified using HPLC (>95%) 
. Endogenous light peptide levels were first assessed in hMSC CM and were 
determined to be below the detection limit. Next, a five point standard curve, 
spanning 3 orders of magnitude (50amol-50fmol), was constructed using the 
ratio of light to heavy peptides within the hMSC CM to account for matrix 
effects (Figure 4.4b) [23]. To assess the relative abundance of each protein, 
three highly abundant peptides were chosen per target (where applicable) 
(Table A4.2), and five transitions were used for total area integrations in 
Skyline [24]. Each sample was spiked with 1fmol/uL of SIL peptide and 1 µg 
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of total protein was injected onto the column and analyzed by PRM-LC-MSMS 
in duplicate. The total integrated fragment area for each target was 
normalized to the spike-in SIL peptide, and the relative abundance (fmol) for 
each target was determined using a standard curve (Figure 4.4c). Proteins 
ranged from ~ 0.20-18 fmol and could be reliably quantified using the targeted 
parameters. Proteins that were classified as overexpressed by the SVM in 
regenerative hMSC were once again confirmed using our PRM approach. 
Proteins such as SFRP1 were found to be 7.7 fold higher in regenerative 
hMSC, while classifiers of non-regenerative hMSC, such as CXCL6, were 
found to be 17.5-fold lower in regenerative hMSC. In addition, the inter-
coefficient of variance (CV) for each protein target was assessed (Figure 
4.4d-e). In general, CV was found to be very low (<20%) for the majority of 
hMSC samples tested. One cell line showed consistently high CV for each 
protein investigated and was removed from further analysis. Samples that did 
not meet CV standards were not used in averaging in assigning relative 
abundance cut-offs. 
 
 
 
 
 
 
 
 
  
 
 
116 
 
 
 
Figure 4.4 Quantitative validation of regenerative hMSC protein 
signature. (a) Label-free quantitative values for the top 10 proteins identified 
by the SVM as regenerative discriminators. (b) A 5-point standard curve was 
constructed using light and heavy isotope labeled peptide spanning 3 orders 
of magnitude. (c) The relative abundance (fmol) of each protein selected by 
the SVM was assessed using PRM and the generated standard curve. 
Concentrations ranged from 0.2-18 fmol. The inter-coefficient of variance was 
assessed for each targeted protein, as shown for (d) SFRP1 and (e) CXCL6. 
Samples with consistently high CV (>20%) were discarded in subsequent 
analysis. Data is represented as mean ± S.D. 
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4.2.4 Characterization of unknown hMSC lines using proteomic classifier 
 To determine if accurate assessment of unknown hMSC lines could be 
achieved using the top 10 proteins within the classifier, 10 unknown hMSC 
lines were grown in biological triplicate, and CM was collected after 24 hours 
of culture. Concentrated CM was first assessed using label-free quantitative 
proteomics, representing the test data set. Each protein target in the training 
data set was quantified and relative label-free expression levels were 
compared. Relative expression levels from the training data set were used to 
create cut-off that must be met by unknown samples to be classified as 
regenerative or non-regenerative. For example, the relative expression levels 
of proteins that were highly expressed, such as SFRP1 minus the standard 
error of the mean (S.E.M) was used to determine what the lowest value an 
unknown hMSC line must have to be considered regenerative (Figure 4.5a-b). 
In this fashion, a score system could be constructed. Samples that reached 
set cut-offs that were representative of a regenerative samples (shaded area) 
received a score of +1 and those that did not received a score of -1. The sum 
of the score was used to assign an unknown sample into either the 
regenerative or non-regenerative cohorts. Unknown hMSC samples that 
achieved a score of ≥6 were termed as regenerative and samples that 
achieved a combined score of ≤5 were termed as non-regenerative (Table 
4.1). In total one unknown hMSC line was determined to be regenerative with 
a score of 8, the remaining unknown hMSC lines were determine to be non-
regenerative (ranging from -5 to -10). In addition, quantitative validation of 
candidate proteins obtained from the SVM was performed using PRM as 
mentioned above (Figure 4.5c). In general the relative abundance of each 
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protein correlated well with the LFQ expression levels reported earlier. 
However, noticeable variability was associated with some proteins, such as 
CCL2, suggesting that it was a poor candidate for targeted proteomic 
applications. The hMSC line that was classified as regenerative by LFQ 
scoring also met many of the cut-off assigned by using the relative abundance 
quantification obtained from the training data set.  
 To assess the efficiency of our scoring metrics, all LFQ data obtained 
from the unknown samples was tested against the SVM created using the 
training data set. Each sample was tested against the SVM and the probability 
of assigning each unknown cell line to either regenerative or non-regenerative 
class was calculated (Table 4.2). Using this approach, we obtained a call rate 
accuracy of 100%, meaning that all unknown cell lines could be assigned with 
confidence to one category or the other. Again, only one uncharacterized 
hMSC line could be assigned to the regenerative class with a 97.6% 
probability. The remaining hMSC lines were assigned to the non-regenerative 
class ranging from 77.5%-93% probabilities. 
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Figure 4.5 Quantitative proteomic assessments of unknown hMSC 
lines. (a-b) Label-free quantitation for the top 10 proteins identified by the 
SVM as regenerative discriminators was used to assess scoring of each 
unknown hMSC cell lines. Training data set cut-offs were shown in the 
shaded area. For each protein, samples that met cut-offs (were within the 
shaded area) received a score of +1, those that did not meet the cut-offs 
received a score of -1. (c) The abundance of each protein target was also 
assessed using targeted proteomics and a standard curve generated using 
SIL peptide. Abundance cut off for regenerative samples are shown in shaded 
area. Data is represented as mean. 
 
 
120 
 
Table 4.1 Score metric for regenerative capacity of unknown hMSC lines. A table outlining the score system used to 
place each unknown hMSC line based on the relative expression level of each protein obtained from the SVM. 
Cell Line NPTX1 CXCL8 SERPING1 IL6 SFRP1 MMP1 CXCL5 CCL2 CXCL6 GDF15 Total Score Class 
BM34 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -10 NR 
BM67 1 -1 -1 -1 -1 1 -1 -1 -1 -1 -8 NR 
BM71 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -10 NR 
BM73 1 1 -1 1 -1 1 1 1 1 1 8 R 
BM75 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -10 NR 
BM77 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -9 NR 
BM82 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -10 NR 
BM83 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -9 NR 
BM86 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -10 NR 
BM89 1 1 -1 -1 -1 1 1 -1 1 -1 -5 NR 
* Regenerative score ≥6, non-regenerative score ≤5. 
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Table 4.2 Support vector machine scoring metric for regenerative 
capacity of unknown hMSC lines. A table outlining the posterior probability 
of each unknown hMSC line being assigned to a regenerate or non-
regenerative class. 
 
Cell Line Probability R Probability NR Class 
BM34 
0.191 0.809 NR 
BM67 
0.255 0.775 NR 
BM71 
0.07 0.93 NR 
BM73 
0.976 0.024 R 
BM75 
0.107 0.893 NR 
BM77 
0.093 0.907 NR 
BM82 
0.183 0.817 NR 
BM83 
0.128 0.872 NR 
BM86 
0.159 0.841 NR 
BM89 
0.163 0.837 NR 
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4.2.5 Biological validation of unknown hMSC lines  
Validation of each of the uncharacterized cell lines was performed 
using the human islet culture with CM in vitro screen described above. The 
total live β-cell number was once again used to determine which hMSC lines 
had the ability to increase β-cell survival. We found that only one out of 10 
uncharacterized hMSC cell lines had significantly increased total number of 
live β-cell compared to our negative control, and that the remaining hMSC 
samples were not statistically different from control (Figure 4.6a). Again, these 
results highlight the predictive power of the quantitative screen. To further 
validate and β-cell regenerative potential of our unknown cell lines assigned 
by our system, one non-regenerative hMSC lines was assessed by 
transplantation in vivo. STZ-treated (35 mg/kg/day, days 1-5), hyperglycemic 
(15-25mmol/l) NOD/SCID mice were intravenously (IV) injected on day 10 
with BM-derived hMSC (5.0x 105 cells), and blood glucose levels were 
monitored for 42 days (Figure 4.6b). Compared with PBS-injected control 
mice (n=3) that remained severely hyperglycemic (>25mmol/l), mice 
transplanted with the non-regenerative hMSC line (n=3) remained severely 
hyperglycemic and showed no improvement compared to PBS-injected mice 
over the 42 day time course (Figure 4.6c). Thus, the predictive proteomic 
screen presented here efficiently identified both regenerative and non-
regenerative hMSC validated by both in vitro and in vivo functional testing. 
Lastly, to demonstrate the potential utility of the screen, donor information, 
including age, sex, weight and BMI, was correlated with islet regenerative 
classification to determine whether any general trends could be observed with 
patient characteristics. In total, 10 female and 10 male donors were used in 
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our studies that ranged in age from 21-66 years (Figure 4.6d). Surprisingly, no 
direct correlation between the regenerative capacity of the hMSC and the age 
of the donor could be determined. Conversely, when donor BMI was 
considered, there was an apparent trend between BMI and islet regenerative 
classification, with 15/17 non-regenerative lines had BMI>25 and 7/7 hMSC 
donors with BMI>30 were classified as non-regenerative (Figure 4.6e). In 
contrast all hMSC lines (3/3) classified as regenerative were within healthy 
BMI range (18-24.9).   
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Figure 4.6 Biological validation of the predictive assay. (a) 
Multiparametric flow analysis of human islets cultured for 7 days bathed in 
hMSC CM. (b) hMSC from one non-regenerative and one regenerative line 
was transplanted into STZ-treated (35 mg/kg per day, days 1–5) NOD/SCID 
mice on day 10, and blood glucose was monitored weekly until 42 days 
compared with PBS-injected control mice. Blood glucose concentrations 
remained equal compared to PBS-injected mice. (c) Blood glucose AUC was 
not significantly reduced with non-regenerative hMSC (n = 3) compared to 
PBS-controls (n = 3). (d) No correlation with donor age was observed for islet 
regenerative potential. (e) All hMSC line classified as regenerative were 
obtained from donors that had healthy BMI, while the majority (15/17) of non-
regenerative hMSC samples were from donors with BMI > 25. Data is 
represented as mean ± S.E.M. (*p<0.05). 
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4.3 Discussion 
 Our study demonstrates that CM derived from hMSC can be used to 
predict the therapeutic potential for the paracrine induction of regeneration by 
corresponding hMSC lines. Importantly, using a quantitative proteomics 
approach, we showed that each hMSC line could be efficiently placed into a 
regenerative or non-regenerative class based on hMSC secretory profiling. 
Employing the current proteomics strategy, the angiogenic potential of the top 
20% and the bottom 20% of hMSC samples could be predicted by the relative 
expression levels of four angiogenic proteins. In addition, using machine 
learning algorithms, an unbiased protein signature of β-cell regenerative 
hMSC could be efficiently determined. Impressively, a panel of 10 proteins 
and their expression levels within hMSC CM could reliably predict the β-cell 
regenerative potential of 16 uncharacterized hMSC samples. Further 
validation using targeted proteomics confirmed our findings providing a high 
throughput assay that could be used to efficiently screen up to 10 
uncharacterized hMSC lines within 24hours. Lastly, using patient information 
including donor age or BMI for 20 screened hMSC samples; we identify a 
trend correlating BMI to β-cell regenerative capacity, which could be used as 
a prescreening approach, in conjunction with our targeted proteomics 
approach, to identify the most regenerative hMSC lines selected for clinical 
applications. 
 Protein signatures were used to predict the angiogenic potential of 
uncharacterized hMSC samples relied on the ability to distinguish two 
different classifications, hMSC that possessed angiogenic capacity and those 
that did not. In an attempt to determine the pro-angiogenic classification of 
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hMSC samples, HMVEC tubule forming assays were performed, and perhaps 
were not a reliable predictor of paracrine hMSC CM pro-angiogenic functions. 
Tubule forming assays are commonly used as a surrogate assay for vessel 
formation in vitro but may not necessarily the best predictors of angiogenic 
potential  in vivo [25]. In addition to tube forming assays, directed in vivo 
angiogenesis assays (DIVAA) are commonly performed to assess angiogenic 
capacity [26]. We have used DIVAA inserts to assess angiogenic induction by 
hMSC CM and has provided evidence for secretome variability between 
hMSC samples [14]. However, DIVAA was not used as a screening modality 
in the current study but could represent a possible solution to the poor 
assignment of angiogenic versus non-angiogenic hMSC. Nonetheless, the 
use of two potent angiogenic proteins, kit ligand (or SCF) and angiogenin [27] 
could be used as potential prescreening tools, to asses hMSC lines with 
promise towards angiogenesis secretory patterns. In combination, 
prescreening hMSC CM to determine which hMSC lines possessed the 
highest levels of angiogenic factors, in combination with DIVAA could 
potentially improve the accuracy of characterization with unknown hMSC 
lines. 
 Combining previously characterized hMSC lines, a surrogate in vitro 
human islet survival assay, and our high-throughput proteomic screening 
techniques, we successfully demonstrate that hMSC CM could be used to 
determine a subset of 10 secretory proteins that predict β-cell regenerative 
capacity by hMSC. Within this list of proteins, we identified neuronal pentraxin 
1 (NPTX1) to be highly upregulated in β-cell regenerative hMSC. NPTX1  
decreases apoptotic and oxidative stress pathways shown previously to 
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impair insulin secretion and β-cell failure using rat models [28]. These results 
could be predicted with the islet survival culture assay, and hMSC lines 
classified as regenerative consistently showed increased β-cell survival 
compared to non-regenerative hMSC. In addition, expression of SFRP1, a 
Wnt-signaling modulator, was consistently upregulated in β-cell regenerative 
hMSC. Wnt-signaling has been previously characterized as an important 
pathway modulating β-cell functions including cell proliferation and survival 
[17,29,30]. Lastly, the expression of matrix metalloproteinase 1 (MMP1) was 
also found to be consistently upregulated in islet regenerative hMSC. 
Although matrix metalloproteinases (MMPs) have not been thoroughly studied 
in the context of diabetes and β-cells,  evidence has suggested that MMPs 
are important in modulating inflammation and innate immunity (reviewed in 
[31]). Thus β-cell regenerative hMSC lines secreted several proteins 
consistent with the modulation of β-cell survival, proliferation and innate 
immunity. 
 hMSC samples characterized as non-regenerative represented 85% of 
samples screened, and showed elevated levels of 5 pro-inflammatory 
markers. Firstly, upregulated secretion of C-X-C motif chemokine 8 
(CXCL8/IL8) and 6 (CXCL6) has been linked to increased inflammatory 
responses within islets that can lead to down regulation of pancreas-specific 
transcription factors and upregulation of pancreatic progenitor cell specific 
factors, suggesting transformation of mature β-cells towards a more immature 
endocrine cell phenotype, a phenomenon referred to as dedifferentiation [32]. 
Secondly, upregulated of interleukin 6 (IL6) within β-cells has been shown to 
decrease GLUT2-expression, implicated in the loss of glucose sensing ability, 
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as well as increased T-cell responses and reduced regulatory T-cell function 
[33]. Thirdly, C-C motif chemokine ligand 2 (CCL2) is involved in the 
recruitment of inflammatory monocytes towards islet or β-cell populations [34]. 
In addition, CCL2 plays a critical role in the clinical outcome of islet 
transplantation in patients with type one diabetes (T1D) by increasing 
macrophage recruitment, increasing destruction of β-cells and negatively 
impacting long-lasting insulin independence [35]. Finally, the increased serum 
expression of CXCL5 is linked to obesity and the onset of type two diabetes 
(T2D) by impairing insulin secretion in response to glucose stimulation [36]. 
Taken together, these data suggested that non-regenerative hMSC establish 
a pro-inflammatory microenvironment not permissive of β-cell regeneration in 
murine models In vivo. 
 Recently, growth differentiated factor 15 (GDF15) has been described 
as a novel marker of conditions associated with T2D. A commonly used 
glucose-lowering drug metformin is used to alleviate complications associated 
with T2D, and the concentration of GDF15 can be used as a biomarker that 
directly correlates with dosage amount and duration of metformin [37]. In 
addition, levels of GDF15 serum concentrations have been used as a 
valuable clinical marker for predicting transitions in albuminuria stages in 
patients with T2D [38], as well as cardiovascular risk in newly diagnosed T2D 
[39] and most recently involvement in body weight management [40,41]. 
Lastly, GDF15 can be accurately used to predict future insulin resistance and 
impaired glucose control in obese non-diabetic individuals [42].   
There are two possible reasons for the elevated levels of GDF15 
observed in non-regenerative hMSC. Firstly, in agreement with the pro-
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inflammatory microenvironment established by non-regenerative hMSC, 
GDF15 represented yet another protein responsible for mediating chronic islet 
inflammation [43]. Secondly, elevated levels of GDF15 in non-regenerative 
hMSC could be directly correlated to the BMI of the donors that the cell lines 
were derived from. As mentioned previously, (>88%) of the non-regenerative 
hMSC lines were derived from donors that had BMIs > 25. Increased BMI is 
correlated with increased inflammation as well as increased risk of diabetes 
[44]. Patients at risk or with long-term exposure to T2D related inflammation 
may have altered hMSC function [45]. Specifically, in mouse models of T2D, 
the therapeutic potential of endogenous bone marrow-derived MSC was 
impaired [46]. Also, hMSC derived from patients with T2D showed gene 
expression profiles that were significantly different in terms of cytokine 
secretion, immunomodulatory ability, suggesting states of “disease memory” 
within hMSC samples [47]. Taking all these considerations together, hMSC 
derived from patients that are outside of the healthy BMI range, or are 
considered ‘pre-diabetic’ can generate altered secretory profiles that warrant 
further investigation in eventual disease progression. 
In summary, our proteomic analyses of hMSC CM revealed that the 
most and least angiogenic hMSC lines could be predicted by using the 
expression values of four angiogenesis modulating proteins. In addition, our 
analysis demonstrated the rarity of finding a hMSC with islet regenerative 
capacity without prior ex vivo manipulations. Also, for the first time, 
quantitative proteomic analysis has determined an hMSC sample-specific 
protein secretion signature that can be used, in a high-throughput fashion, to 
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pre-determine the β-cell regenerative potential of previously uncharacterized 
hMSC lines.  
4.4  Experimental Methods 
4.4.1 Generation of CM for co-culture and proteomic analysis  
After 4 days of culture (~80% confluency), hMSC were washed twice 
with PBS to remove residual growth factors and replated in basal 
AmnioMaxTM without supplement to collected proteins secreted hMSC for 24 
hrs. Media conditioned by hMSC was collected, filtered and centrifuged at 450 
x g to remove any cellular debris. Cell viability was assayed using trypan blue 
and >95% viability was used as a standard cut-off for co-culture and 
secretome analyses. CM was generated in triplicate for a total of 20 individual 
MSC lines and was concentrated using 3 kDa molecular weight cut-off filter 
units (Millipore). For co-culture assays, CM was quantified and the protein 
amount was normalized (~50 µg total). For proteomic analysis, Concentrated 
CM was lyophilized overnight and re-suspended in 8M urea, 50 mM 
ammonium bicarbonate, 10 mM dithiothreitol and 2% SDS solution prior to 
protein quantitation. Protein concentration was measured using the Pierce 
660nm protein assay (ThermoFisher Scientific). 
4.4.2 HMVEC tubule forming assay  
To assess CM influence on endothelial cell function in vitro, 120,000 
human microvascular endothelial cells (HMVECs) were cultured on growth 
factor-reduced Geltrex (Life Technologies) in endothelial basal media (EBM-2; 
Lonza) conditioned by hMSC CM for 20 hrs. As a positive control, HMVECs 
were also grown in Geltrex bathed in complete endothelial growth medium 
(EGM-2 = EBM-2 + 5% FBS + IGF, basic fibroblast growth factor [FGF], EGF, 
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vascular endothelial growth factor [VEGF]). Tube formation was quantified by 
counting the number of complete tubule branches in four fields of view using 
ImageJ software (NIH). 
4.4.3 Human islet culture with hMSC CM  
Human islets from 6 donors were obtained from the Integrated Islet 
Distribution Program (IIDP). Upon arrival, 200 islet equivalents were plated in 
RPMI media without serum (Invitrogen). CM was concentrated using 3 kDa 
molecular mass cut-off filters, and ~50 μg total protein was added to human 
islet culture for 7 days. After islet harvest and dissociation, β-cell content was 
estimated using FluoZin-3 (Flz3) (ThermoFisher Scientific) and apoptosis was 
quantified using 7AAD and Annexin-V. Flow cytometry data were analyzed 
using FloJo software (Treestar). 
4.4.4  Chloroform/Methanol Precipitation and Protein Digestion 
  Protein extracts from hMSC CM samples were reduced in 10 mM DTT 
for 30 min and alkylated with 100 mM iodoacetamide (IAA) for 30 min at room 
temperature in the dark. Next, to facilitate the removal of incompatible 
detergents, reducing and alkylating reagents, the proteins were precipitated 
using chloroform/methanol according to the Wessel and Flügge protocol [48].  
Briefly, 30 μg of protein extracted from each sample was diluted to a total 
volume of 150 μL with 50 mM ammonium bicarbonate (ABC), and 600 μL of 
ice cold methanol was added to each sample, followed by 150 μL of 
chloroform, with thorough vortexing.  450 μL of ice-cold DIH2O was added 
before additional vortexing and centrifugation at 14,000 x g for 5 min at room 
temperature.  The upper/aqueous methanol phase was removed and 450 μL 
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of ice-cold methanol was added to each sample, followed by vigorous 
vortexing and centrifugation at 14,000 x g for 5 min.  The remaining 
chloroform/methanol was discarded and the precipitated protein pellet was air 
dried before protein digestion.   
For on-pellet protein digestion, 100 μL of 50 mM ABC (pH 8.0) with LysC 
(Wako) (1:100) solution was added to each precipitated sample and incubated 
in a ThermoMixer at 37°C for 4 hrs at 1000 RPM, followed by trypsin/LysC 
(1:50 ratio of enzyme: sample) (Promega) solution was added to each 
precipitated sample and incubated in a water bath shaker at 37°C overnight at 
400 RPM. The next day, an additional aliquot of trypsin (1:100 ratio) was 
added for ~ 4 hrs, prior to acidifying with 10% formic acid (FA) (pH 3-4). The 
peptide concentrations were estimated using a Pierce BCA assay 
(ThermoFisher Scientific). 
4.4.5  Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
 Approximately 1 μg of each sample was injected onto a Waters M-
Class nanoAcquity HPLC system (Waters) coupled to an ESI ion-trap/Orbitrap 
mass spectrometer (Q Exactive Plus).  Buffer A consisted of mass spec. 
grade water/0.1% FA and Buffer B consisted of ACN/0.1% FA.  All samples 
were trapped for 5 min at a flow rate of 5 μL/min using 99% Buffer A and 1% 
Buffer B on a Symmetry BEH C18 Trapping Column (5 μm, 180 μm x 20 mm, 
Waters). Peptides were separated using a Peptide BEH C18 Column (130 Å, 
1.7 μm, 75 μm x 250 mm) operating at a flow rate of 300 nL/min at 35°C 
(Waters).  Samples were separated using a non-linear gradient consisting of 
1-7% Buffer B over 1 min, 7-23% Buffer B over 135 min and 23-35% Buffer B 
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over 45 min, before increasing to 98% Buffer B and washing. Settings for data 
acquisition on the Q Exactive Plus for both LFQ and PRM are outlined in 
Table A4.3. 
4.4.6 Label-free proteomic data analysis 
All MS raw files were searched in MaxQuant version 1.5.8.30 using the 
Human Uniprot database (updated May 2015 with 20, 264 entries) [49,50]. 
For all database searches, missed cleavages were set to 3, cysteine 
carbamidomethylation was set as a fixed modification and Oxidation (M), N-
terminal Acetylation (protein) and Deamidation (NQ) were set as a variable 
modifications (max. number of modifications per peptide = 5). Precursor mass 
deviation was left at 20 ppm and 4.5 ppm for first and main search, 
respectively. Fragment mass deviation was left at 20 ppm. Protein and 
peptide FDR was left to 0.01 (1%) and decoy database was set to revert. 
Match between runs was enabled and all other parameters left at default. 
Bioinformatics analysis was performed using Perseus version 1.5.8.5. Briefly, 
protein lists were loaded into Perseus and proteins identified by site reverse 
and contaminants were removed. When using the match between runs 
feature, datasets were filtered for proteins containing a minimum of 1 unique 
peptide in at least two of three biological replicates, as well as 6 out of 10 
different hMSC lines.  
4.4.7 Support vector machine learning 
Data mining and protein marker selection of label-free quantitative 
proteomic data was achieved using the R package “geNetClassifier support 
vector machine (SVM)”. Briefly, a text document was constructed that 
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included all secreted proteins identified within the initial training data set. In 
additions, classification (regenerative versus non-regenerative) was assigned 
using human islet co-culture assays mentioned above. The posterior 
probability, or the predictive power, of each protein within the data set was 
determined and exported. Proteins that achieved a posterior probability of 
>0.90 were further evaluated. Uncharacterized hMSC lines were assessed 
against the classifier in the same manor. LFQ data for each uncharacterized 
hMSC line was imported into the SVM constructed from the training data set, 
and the probability of assigning each cell line was determined. 
4.4.8 Peptide Synthesis 
 Solid phase peptide synthesis was achieved using the 96-well format 
on the MultiPep RS (Intavis). Peptides were synthesized using fmoc-
chemistry on heavy (13C15N) labeled arginine preloaded chlorotrityl chloride 
resin (Cambridge Isotopes). Crude peptides were purified using an Agilent 
1100 pump systems on a C18 column. Peptide purify was assessed using LC-
MSMS. 
4.4.9 Targeted proteomic data analysis 
 Parallel reaction monitors (PRM) data sets were analyzed using 
Skyline V3.7.0.11317. A spectral library was constructed from combining 
data-dependent acquisition runs using each cell line. Protein lists were filtered 
to only include proteins that had posterior probabilities of >0.80. In addition, 
missed cleavages were set to zero, and peptide length was limited to 16 
amino acids. Peptides were chosen for targeting by order of pick intensity, 
meaning the three most abundant peptides for each target were measured for 
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a total of 28 targets corresponding to 208 peptides. A scheduled list was 
exported using a retention time window of ±10 min. For each PRM sample, 20 
µg of peptide was lyophilized and resuspended in 1 fmol/uL solution of “heavy 
gfp”. PRM raw files were processed using skyline and total fragment area, 
which corresponded to the 5 most intense fragment ions (not including y1), 
were chosen for automatic integration. The total integrated fragment area of 
each peptide was determined and the ratio of target: heavy gfp was used to 
determine the relative abundance of each protein using a standard curve.   
4.4.10   Transplantation of hMSC  
  Human BM was obtained from healthy donors after informed consent 
at the London Health Sciences Centre (London, ON, Canada). All studies 
were approved by the Human Research Ethics Board at Western University 
(REB# 12934, 12252E). The hyperglycemia-lowering capacity of one non-
regenerative hMSC cell line classified using the SVM was assessed after tail 
vein injection of 500,000 cells into STZ-treated NOD/SCID mice as previously 
described [15]. Blood glucose concentrations were monitored weekly for 42 
days and samples were segregated into regenerative or non-regenerative 
hMSC based on the ability to reduce blood glucose compared with PBS-
injected control mice. 
4.4.11   Statistical analysis  
  Statistical analysis was performed using GraphPad Prism version 
6.01 (GraphPad) by ANOVA with Tukey’s post hoc test or by multiple t tests. 
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Chapter 5 
Wnt-Activated hMSC Conditioned Media Mediates Islet Cell 
Regeneration in vivo1 
 
5.1  Introduction 
Both type 1 (T1D) and type 2 diabetes (T2D) are characterized by a 
deficiency in insulin due to β-cell failure. Therefore curative strategies for 
diabetes treatment must begin with renewal of functional β-cell mass [1]. Even 
with modern exogenous insulin therapy, dysregulated glucose homeostasis 
results in devastating complications, and current therapeutic approaches to 
replace lost β-cells have included whole pancreas transplantation or 
intraportal delivery of isolated islets [2].  Unfortunately, implementation of 
these replacement strategies is limited due to an extreme shortage of donor 
tissue, and therapy is associated with eventual graft failure despite chronic 
imunnosupression [3,4]. 
In recent years, considerable progress has been made in the 
development of strategies to replace β-cell mass via ex vivo production of 
insulin-secreting, beta-like cells from pluripotent stem cells. Human embryonic 
stem cells (hESC) possess the potential to generate an unlimited number of 
β-cells for diabetes therapy [5].  
 
1 This chapter contains excerpts with permission from the following paper: 
Kuljanin M, Elgamal RM, Bell GI, Lajoie GA, Hess DA. (2017) “Wnt-pathway 
stimulated hMSC-secreted effectors mediate islet cell regeneration “. Cell 
Stem Cell. (Submitted, November 2017) 
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However, hESC must be guided through various stages of development to 
form pancreatic endoderm and then endocrine precursors that ultimately 
acquire the ability to release insulin after pro-longed residence in vivo [6]. 
Recently, functionally matured beta-like cells have been generated in vitro 
through strict differentiation regimes to produce cells that secrete insulin in 
response to elevated glucose, and can revert hyperglycemia after 
implantation into STZ-treated NOD/SCID mice [7,8]. Like hESC, human 
induced pluripotent stem cells (iPSC) have also been used to generate insulin 
secreting cells. Most recently, the direct differentiation of multiple iPSC lines 
using small molecules, has been shown to produce insulin secreting cells that 
co-express PDX1 and NKX6.1 at varying frequencies [9,10]. Although the 
aforementioned studies represent impressive advances in the field of β-cell 
replacement, the cells generated secreted insulin at variable efficiencies and 
a deeper understanding of the genetic programs that govern β-cell genesis is 
still required to efficiently produce fully differentiated, glucose-responsive β-
cells. 
β-cell replacement can also be achieved by regeneration of β-cells 
within the pancreas itself. Interestingly, patients with long-standing T1D 
(Joslin Medalists) have preserved C-peptide production after >50 years of 
diabetes [11]. This has lead to the notion that recovery of β-cell function in situ 
represents a feasible strategy for T1D treatment. Furthermore, recent 
evidence has shown that regulation of β-cell mass is more dynamic than 
previously understood. Human β-cells are capable of undergoing massive 
replication during obesity and pregnancy [12]. Two mechanisms controlling β-
cell regeneration have been proposed. The first, suggests pre-existing β-cells 
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can undergo proliferation to generate greater β-cell mass [13,14]. The second 
suggests that β-cell regeneration is initiated from within islets or the ductal 
epithelial niche through the activation of facultative endocrine precursors via 
β-cell neogenesis [15–17]. In addition, α-β-cell conversion can occur in human 
islets [18], and recapitulates a developmental pattern elegantly demonstrated 
in lineage-tracing studies in mice [19]. Importantly, α-β-cell transition is 
accompanied by epithelial to mesenchymal transition (EMT) in the ductal 
epithelium, which subsequently convert to endocrine cell types that expand to 
generate new islets through a neogenic cascade. Currently, the specific 
stimuli that control these multi-factorial regenerative processes are unknown 
and remain the key to harnessing β-cell neogenesis in situ as a therapeutic 
option for T1D. 
In a series of publications, elucidating the mechanisms of islet 
regeneration stimulated by the transplantation of human bone marrow-derived 
stem cells into STZ-treated mice, we have show that human multipotent 
stromal cells (hMSC) stimulate the emergence of small, recipient-derived islet-
like structures associated with the ductal epithelial niche, [20–22]. Detailed 
proteomic analysis of secretory factors deposited into the regenerative niche 
have revealed Wnt-signaling to be an important pathway in hMSC regulation 
of this secretory pattern [23].  Indeed, activation of Wnt-signaling resulted in 
the production of a conditioned media (CM) cocktail that increased the 
proliferation rate of adult human β-cells and more than doubled the β-cell 
mass in rodent models [24,25]. Collectively, these findings suggested that 
activation of endogenous islet regenerative mechanisms could be achieved 
via protein-based therapies derived from hMSC. 
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The use of protein factors or media conditioned by hMSC to treat 
diabetes has recently gained traction. Multiple intravenous injections of CM in 
experimental T2D rats effectively reduced systemic blood glucose levels by 
stimulating the proliferation of residual β-cells [26]. In addition, Gao et. al. 
demonstrated the CM could initiate recovery of T1D mice through the 
activation of pAKT pathways, and successfully demonstrated that harvested 
islets bathed in CM can undergo β-cell proliferation in vitro [27]. Both studies 
used intravenous-injection as their mode of delivery and did not investigate 
whether direct delivery to the pancreas would increase the therapeutic effect 
of the CM. Other modes of delivery have been investigated. Intraperitoneal 
and intra-ductal injection of periostin, a protein produced by pancreatic stellate 
cells and found in high levels in hMSC CM, resulted in an increased number 
of islets and augmented glucose homeostasis in vivo [28]. 
Herein, we investigate the direct delivery of hMSC CM into the 
pancreas of STZ-treated mice and show for the first time that islet 
regeneration is efficient and robust after CM delivery. The regenerative 
response could be modulated by protein dose and activation of Wnt-signaling 
in vitro augmented the regenerative potency of CM generated. We also show 
that the regenerative mechanism for the restoration of glucose homeostasis 
involved the paracrine activation of multiple regenerative pathways consistent 
with ductal tree associated α to beta-like cell neogenesis followed by β-cell 
replication and functional maturation. Finally, key effectors secreted during 
Wnt-pathway stimulation were identified using quantitative proteomics and 
provided a list of potential targets for further investigation. 
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5.2 Results 
5.2.1 Intrapancreatic hMSC injection induced emergence of single insulin+ 
………cells 
STZ-treated (35 mg/kg/day, days 1-5) and hyperglycemic (15-25 
mmol/l) NOD/SCID mice were intrapancreatically (iPan) injected on day 10 
with BM-derived hMSC (5.0x 105 cells), and blood glucose levels were 
monitored for 42 days (Figure 5.1a). Compared with PBS-injected control 
mice (n=6) that remained severely hyperglycemic (>25 mmol/l), hMSC 
injection (N=3, n=8) led to slightly reduced systemic glycemia from days 28-42 
(Figure 5.1b). Although blood glucose stabilized after hMSC transplantation, 
glucose levels plateaued at 22.5±2.5 mmol/l (Figure 5.1b) indicating 
transplantation did not significantly reduce established hyperglycemia (AUC) 
over the full time course (Figure 5.1c). To better characterize endogenous 
mechanisms by which transplanted hMSC showed improved glycemia, the 
pancreas of transplanted mice were stained for murine insulin and analyzed 
for islet number (Figure 5.1d), islet size (Figure 5.1e) and β-cell mass (Figure 
5.1f). Although histological sections at day 42 did not reveal any differences in 
islet number or structure between PBS (Figure 5.2a) or hMSC (Figure 5.2b) 
transplanted mice, we observed a trend towards increased islet size and total 
β-cell mass, but these differences were not significant by students T-test. 
However, all mice transplanted with hMSC showed the emergence of single 
insulin+ cells at early (D14) time points (Figure 5.2c, d). To rule out whether 
hMSC were differentiating into insulin+ cells, human cell engraftment (HLA) 
and co-expression of insulin was assessed. Mice transplanted with hMSC 
show high levels of engraftment at day 14 (Figure 5.2e), which was 
diminished by day 42 (Figure 5.2f). Although hMSC never co-expressed 
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insulin, hMSC were commonly found adjacent to single murine insulin+ cells, 
suggesting that endogenous regenerative mechanisms were activated in a 
paracrine fashion. Thus, iPan transplantation of hMSC seemed to induce 
regenerative effects consistent with the activation of putative islet neogenic 
mechanisms.  
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Figure 5.1  Intrapancreatic delivery of ex vivo expanded hMSC cells 
does not augment the recovery of blood glucose in STZ-treated 
NOD/SCID mice. (a) hMSC were expanded ex vivo and transplanted (5.0 
x105 cells) directly into the pancreas and systemic blood glucose was 
monitored for 42 days. (b) Compared with PBS injected controls, mice 
transplanted with hMSC showed a slight reduction in blood glucose at D28-
D42. (c) Total AUC after 42 days was not significantly different from PBS. 
Mice injected with hMSC did not show a significant increase in (d) number of 
islets/mm2 (e) or average islet size and β-cell mass (f). Data is represented as 
mean ± S.E.M. 
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Figure 5.2  Intrapancreatic transplanted hMSC are present in the 
pancreas at D42 and give rise to single insulin positive murine cells. 
Representative photomicrographs of insulin+ islets at D42 injected with (a) 
PBS and (b) hMSC. (c) Mice injected with hMSC give rise to single insulin+ 
cells (arrow heads), not observed in PBS controls. (d) Magnified view of box 
found in (c). (d) Transplantation of hMSC resulted in consistent and high-
frequency cell engraftment in the mouse pancreas at D14. (e) At D42 human 
HLA  A,B,C+ (arrows) surrounding murine cells that do not co-express insulin 
are present (arrow heads). Scale bars= 200 µm. 
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5.2.2 Intrapancreatic hMSC CM injection reduced hyperglycemia  
hMSC were grown to ~80% confluency and switched to serum free 
media for 24 hours when CM was collected, concentrated and quantified. 
Hyperglycemic (15-25 mmol/l), STZ-treated NOD/SCID mice were iPan 
injected on day 10 with hMSC CM with either 4 µg or 8 µg of total protein (in 
20 µl) and blood glucose levels were monitored for 42 days (Figure 5.3a). 
Normoglycemic control mice were injected with citric acid buffer (CAB) instead 
of STZ from days 1-5, or STZ-treated mice were injected with basal media 
concentrated without conditioning (unconditioned media). Compared to mice 
injected with unconditioned media (n=11) that remained severely 
hyperglycemic or mice injected with the lower dose of 4 µg hMSC CM (n=7), 
mice injected with higher dose of 8 µg CM (n=7) showed significantly 
improved systemic glycemia as early as 4 days post injection (Figure 5.3b). 
Overall, injection of 8 µg CM significantly reduced AUC for systemic blood 
glucose levels over the full 42 days (Figure 5.3c). At day 42, serum insulin 
levels were quantified. STZ-injected, media control mice, or mice injected with 
4 µg CM showed ≈5-fold reduced serum insulin concentrations compared to 
CAB controls (Figure 5.3d). However, mice transplanted with 8 µg CM 
showed significantly increased serum insulin compared to mice injected with 
unconditioned media or 4 µg CM. Residual insulin levels within concentrated 
basal CM samples were below the detectable limit of the assay (<0.0025 
ng/ml). 
Glucose tolerance was also performed at day 42 to assess whether 
transplanted mice could respond to a glucose challenge. Compared with 
CAB-injected mice that were normoglycemic (4.4±1.0 mmol/l) and showed 
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strong biphasic glucose reduction, while mice injected with unconditioned 
media or 4 µg CM showed little response to glucose bolus and prolonged 
hyperglycemia that never returned to starting concentrations (Figure 5.3e). In 
contrast, mice injected with 8 µg CM showed glucose levels that peaked at 30 
min (22.7±2.5 mmol/l) and eventually returned back down to initial 
concentration (13.5±2.3 mmol/l) at 90 minutes. The AUC for mice injected 
with 8 µg CM was significantly lower than both mice injected with 
unconditioned media or mice injected with 4 µg CM (Figure 5.3f). In addition, 
the weight of each mouse was monitored for the full 42 days to ensure weight 
loss did not contribute to glucose readings (Figure 5.3g). There was no 
significant reduction in weight for any of the treated mouse groups. Taken 
together, mice transplanted with hMSC CM demonstrated significant recovery 
of endocrine function and improved glycemia was observed in a 
concentration-dependent manor. 
5.2.3 Active Wnt-signaling generated CM with augmented glucose lowering 
capacity  
We have previously shown that active Wnt-signaling is an important 
component of the islet regenerative niche established by hMSC, and 
activation of Wnt-signaling using GSK-inhibition during hMSC CM generation 
increased cultured human β-cell survival and proliferation in vitro [23]. To 
determine how modulation of Wnt-signaling during hMSC CM generation 
would impact systemic blood glucose levels after iPan injection of CM, we 
sought to activate and inhibit Wnt-signaling using small molecules 
(CHIR99201 and IWR-1) respectively [29,30]. To determine the optimal 
concentration for Wnt-pathway activation, qPCR was performed on two 
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downstream Wnt-signaling genes, BCL9 (Figure 5.4a) and MYC (Figure 5.4b). 
A significant (>2 fold) increase was observed in both genes upon treatment of 
hMSC with 10 µM of CHIR99201. In addition, we also quantified total β-
catenin levels, the master regulator of Wnt-signaling pathway [31], by flow 
cytometry. Treatment with 10 µM of CHIR99201 increased β-catenin protein 
levels ~1.9 fold (Figure 5.4c). The optimal concentration for inhibition of Wnt-
signaling with IWR-1 was determined using the same approach. Treatment of 
hMSC with 20 µM of IWR-1 showed a significant (>two fold) decrease in both 
BCL9 (Figure 5.4d) and MYC (Figure 5.4e). Treatment with 20 µM of IWR-1 
also decreased β-catenin protein levels by ~1.5 fold (Figure 5.4f). 
To generate Wnt-activated (WNT+) or inhibited (WNT-) media, hMSC 
were grown to ~80% confluency, switched to serum free media and cultured 
with 10 µM CHIR99201 or 20 µM of IWR-1, for 24 hours. CM was collected 
and concentrated as described above and hyperglycemic mice were injected 
with WNT+ CM (20 µl) at either ~4 or ~8 µg total protein or ~8 µg WNT- CM. 
Compared to mice injected with unconditioned media, mice injected with 4µg 
WNT+ CM (13.5±1.6 mmol/l) or 8 µg WNT+ CM (8.3±1.1mmol/l) showed 
significantly reduced systemic glycemia post injection (Figure 5.3h). In 
contrast, 8 µg WNT- CM did not significantly reduce systemic glycemia post 
injection (29.7±2.2 mmol/l)). Overall, injection of either 4 or 8 µg WNT+ CM 
significantly reduced the AUC for blood glucose levels over the full 42 days 
compared to media controls and 8 µg WNT- CM (Figure 5.3i). The total 
recovery was not significantly different between 4 and 8 µg WNT+ CM over 
the full time course (p=0.10), but was found to be significantly different at day 
42. Mice injected with 4 or 8 µg WNT+ CM showed significantly increased 
 153 
 
serum insulin levels at day 42, compared to unconditioned media controls 
(3.2-fold and 4.7-fold increase, respectively), while WNT- CM did not alter 
serum insulin (Figure 5.3j). Most notably, mice injected with 8 µg WNT+ CM 
had circulating serum insulin levels equivalent to CAB controls (0.485 ng/ml). 
Again, residual insulin levels within concentrated CM were below the 
detectable limit of the assay (<0.0025 ng/ml). Finally glucose tolerance was 
also performed at day 42 to assess response to a glucose challenge. Mice 
injected with 4 µg WNT+ CM showed blood glucose levels that peaked at 15 
min (22.7±3.1 mmol/l) and gradually decreased to (15.3±2.2 mmol/l) (Figure 
5.3k). Furthermore, mice injected with 8 µg WNT+ CM showed blood glucose 
levels that spiked at 10 min (22.3±1.5 mmol/l) and rapidly returning back down 
to initial conditions (11.5±2.1 mmol/l). In contrast, mice injected with 8 µg 
WNT- CM showed blood glucose levels that spiked at 30 min to maximal 
levels (>33 mmol/l) remained high (26.2±4.5 mmol/l) for 120 minutes. The 
AUC for mice that were injected with 4 or 8µg of WNT+ CM were significantly 
lower compared to unconditioned controls or 8 µg of WNT- CM injected mice 
(Figure 5.3l). A ratio of the starting weight (D0) and the final weight (D42) 
showed that there was no significant reduction in weight (Figure 5.3m). Taken 
together, mice that were injected with 4 µg WNT+ CM demonstrated 
significant, although partial, recovery of endocrine function in response to 
glucose challenge, while mice that were injected with 8 µg WNT+ CM 
demonstrated full recovery of endocrine function. Thus activation of Wnt-
signaling during CM generation augmented glucose control, and inhibition of 
Wnt-signaling reversed this beneficial effect.  
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Figure 5.3  Intrapancreatic-injection of Wnt-activated hMSC CM 
improved glucose control. (a) hMSC CM was generated for 24h, 
concentrated (40X), and iPan-injected at 4 µg or 8 µg total protein. (b-f) Mice 
injected with 8 µg hMSC CM showed reduced blood glucose, increased 
serum insulin, and improved glucose tolerance compared to mice injected 
with 4 µg hMSC CM or unconditioned media. (g) Mouse weight was not 
changed by injection of hMSC CM. (h-l) Mice injected with 4 µg or 8 µg WNT+ 
CM showed reduced blood glucose, increased serum insulin, and improved 
glucose tolerance compared to mice injected with 8 µg WNT- CM or 
unconditioned media. (m) Mouse weight was not changed by injection of 
WNT+ or WNT- CM. Data is represented as mean ± S.E.M. (*p<0.05, 
**p<0.01, ***p<0.001). 
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Figure 5.4  hMSC show robustly stimulation and inhibition of Wnt-
signaling by CHIR99201 and IWR-1, respectfully. hMSC stimulated with 
CHIR99201 at (0.1, 0.5, 1, 5 and 10 µM) show increased transcript expression 
of downstream products of Wnt-signaling (a) BCL9 and (b) MYC. (c) hMSC 
stimulated with CHIR99201 also show increased expression of β-catenin at 
the protein level. hMSC inhibited with IWR-1 at (0.5, 1, 5, 10 and 20 µM) show 
decreased expression of downstream products of Wnt-signaling (d) BCL9 and 
(e) MYC. (f) hMSC inhibited with IWR-1 also show decreased expression of β-
catenin at the protein level. Transcript data was normalized to housekeep 
gene (ACTB). Data is represented as mean ± S.D. (*p<0.05, ***p<0.01, 
***p<0.001). 
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5.2.4 hMSC CM loses glucose lowering capacity after heat denaturing 
Wnt-activated CM was generated and concentrated as described 
above and CM was denatured via heating at 90oC for 20 min. After heating, 
mice were injected with an equivalent dose (4 µg) of denatured CM (dWNT+) 
(n=3) and compared to 4 µg of WNT+ CM. Overall, transplantation of 4µg 
WNT+ CM significantly reduced systemic blood glucose levels over the full 42 
days compared to media controls and injection of 4 µg dWNT+ CM did not 
reduce blood glucose levels (Figure 5.5a). AUC measurements confirmed a 
significant reduction in hyperglycemia (Figure 5.5b). In addition, serum insulin 
concentrations in mice injected with dWNT+ CM were 6.8-fold lower than 
WNT+ CM (data not shown). To determine what factors in the CM were 
degraded during heating, native PAGE was performed to confirm proteins 
present in the CM were fully denatured (Figure 5.5c). Proteins within the 
dWNT+ CM migrated differently on native PAGE due to disruption of the 
overall charge state [32], and serum albumin shifted (lane 2), along with other 
faint bands, signifying denaturation of proteins has occurred. 
Generation of CM was achieved using MWCO filters (3 kDa) that are 
also known to concentrate extracellular vesicles containing protein, long-non-
coding RNA and micro-RNAs [33]. To investigate residual RNA content within 
dWNT+ CM samples, RNA integrity analysis was performed using picoRNA 
chip technology (Figure 5.5d-e). Upon heating, there was a drastic decrease 
in the total RNA content observed in the CM. However, the quality of the RNA, 
interpreted by using the RNA Integrity Number (RIN), was extremely low in 
both the WNT+ (1.9) and the dWNT+ (1.0) CM, suggesting that residual RNA 
in the CM was severely degraded during collection and concentration of the 
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media without RNase inhibition (Figure 5.5f) [34] . In summary, heating CM 
reversed the blood glucose lowering capacity through denaturing of proteins 
within the CM. Although the effect of residual miRNA was not directly 
investigated, only 6.1-12.2 pg of mostly degraded RNA was injected into each 
mouse, making the glucose lowering contribution of RNA within the CM 
samples highly unlikely. 
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Figure 5.5  Islet Regenerative CM loses capacity to lower blood 
glucose levels after heating. (a) hMSC CM generated by stimulation with 10 
µM of CHIR99201 was heated to 90oC for 20 min and injected into STZ-
treated NOD/SCID mouse. Glucose lowering capacity was abrogated upon 
denaturation of the components in the CM. (b) Blood glucose concentrations 
were significantly higher after injection of denatured CM compared to native 
CM. (c) WNT+ CM was assessed using Native PAGE to determine if proteins 
were denatured. Lane 1 contains native CM, while lane 2 is heated to 90oC. 
(d-e) PicoRNA analysis revealed that RNA content was severely degraded 
during CM generation and concentration. (f) Total amount of RNA injected per 
condition. 
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5.2.5 Islet regeneration resulted in increased β-cell mass  
To characterize the mechanisms and dynamics by which injection of 
hMSC CM augmented islet regeneration, pancreata of injected mice 
euthanized at day 11 (D11), 14 (D14) and 42 (D42), were first stained for 
murine insulin (Figure 5.6a-c). As a general observation, the number of islets, 
mean islet size and total β-cell mass were increased over time in each 
condition tested (D11-D42). Compared to mice injected with unconditioned 
media, mice that received 8 µg hMSC CM had significantly increased islet 
number (Figure 5.6d), islet size (Figure 5.6e), and total β-cell mass (Figure 
5.6f) at each time point tested. Importantly, mice that received 4 µg hMSC CM 
also showed significantly increased islet size compared to unconditioned 
controls at D42. In addition, the increase in both islet number and islet size 
after WNT+ CM injection occurred within 4 days after transplantation 
(between D10-D14), eventually plateauing between D14-D42. Mice injected 
with 4 µg or 8 µg WNT+ CM also demonstrated significantly increased islet 
number (Figure 5.6g), islet size (Figure 5.6h), and total β-cell mass (Figure 
5.6i). Interestingly, 4 µg WNT+ CM showed islet regenerative capacity similar 
to 8 µg hMSC CM. In contrast, when Wnt-signaling was inhibited during CM 
generation, islet number, islet size and β-cell mass were similar to media 
controls (Figure 5.6g-i). As an overall indication of endocrine recovery, 
transplantation of 8 µg hMSC CM or 8 µg WNT+ CM maximally increased β-
cell mass (Figure 5.6f,i), and the kinetics of β-cell mass increased steadily 
over time. Finally, injection of 8 µg WNT+ CM initiated islet regeneration 
within one day post-injection and β-cell mass continued to increase over 42 
days. Overall, these data confirm that hMSC CM can stimulate the recovery of 
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β-cell mass and that active Wnt-signaling during CM generation is an 
important contributor for β-cell recovery.  
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Figure 5.6  Intrapancreatic-injection of Wnt-activated hMSC CM 
increased islet number, size, and β-cell mass. (a-c) Representative 
photomicrographs of insulin expression in islets at days 11, 14 and 42 in mice 
injected with unconditioned media, or 8 µg hMSC CM, or 8 µg WNT+ CM. (d-
f) Mice injected with 8 µg hMSC CM showed increased islet number, islet 
size, and β-cell mass compared to mice injected with 4 µg hMSC CM or 
unconditioned media. (g-i) Mice injected with 4 µg or 8 µg WNT+ CM showed 
increased islet number, islet size, and β-cell mass compared to mice injected 
with 8 µg WNT- CM or unconditioned media. Data is represented as mean ± 
S.E.M. (*p<0.05, **p<0.01, ***p<0.001). 
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5.2.6 Regenerated islets showed increased vascularization 
 Immunofluorescent staining for murine insulin in combination with vWF 
or CD31, to mark larger vessels, and intra-islet capillaries respectively, was 
used to investigate islet vascularization at D42 (Figure A5.1a-f). Because we 
observed differences in islet size between treatments, total CD31+ vessels 
and capillaries within islets were normalized to islet area. Compared with 
unconditioned media injected controls, mice that were injected with 8 µg 
hMSC CM or 4/8 µg WNT+ CM showed significantly increased vWF+ vessels 
associated with islets (Figure A5.1g) and total CD31+ cells found within islets 
(Figure A5.1h-i). Notably, these cohorts showed no difference in vessel 
density compared to CAB injected mice, suggesting newly formed islet were 
highly vascularized. Injection of WNT- CM showed vessel densities equivalent 
to unconditioned media control injected mice. Thus, transplantation of hMSC 
CM promoted re-vascularization of regenerated islets, thereby improving 
insulin release into circulation. 
5.2.7 Regenerative CM increased islet association with the ductal epithelium 
 Transplantation of hMSC has been shown to increase the number of 
islets associated with the ductal epithelium, suggesting developmental islet 
neogenesis was activated [21,22]. To investigate whether islet formation was 
initiated in ductal regions after hMSC CM injection, co-staining for insulin and 
ck19, to mark ductal epithelial cells, was performed at each time points 
(Figure 5.7a-c). As a general observation, the ductal association of islet 
clusters decreased over time under each condition tested. Interestingly, 
unconditioned media injected mice showed increased ductal associated islets 
at early time points (40%), suggesting that STZ-treatment alone stimulated 
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endogenous islet regeneration in the ductal epithelial niche. Mice that 
received 8µg hMSC CM showed significantly increased ductal association at 
early and late time points (D11 and D42) (Figure 5.7d). However, activation of 
Wnt-signaling during CM generation significantly increased ductal association 
for 4 µg or 8 µg WNT+ CM injected mice at each time point tested (Figure 
5.7e). Finally, injection of WNT- CM showed ductal association of islets similar 
to unconditioned media injected mice across each time point. These data 
suggested the ductal epithelial niche as a site for hMSC CM-mediated islet 
regeneration. 
5.2.8 Regenerative CM stimulated β-cell proliferation 
To further investigate the mechanisms of islet expansion induced after 
CM injection, we analyzed EdU incorporation into proliferating β-cell within 
islets labeled for 24 hours prior to euthanasia at D11, D14 and D42 (Figure 
5.8a-c). As a general observation, the frequency of islets that contained 
proliferating β-cells were decreased over time under each condition tested 
(D11-D42). In mice injected with unconditioned media, proliferating insulin+ β-
cells were extremely rare, with approximately 1 in 5 islets containing a 
proliferating β-cell, indicating a slow turnover of β-cells after STZ-treatment. 
Mice that received 8 µg hMSC CM showed proliferation rates that were more 
than 2-fold higher compared 8 µg hMSC CM and unconditioned media at D14 
(Figure 5.8d). Mice that received WNT+ (either 4 or 8 µg) CM showed 
significantly higher proliferation rates at D11, D14 and D42 (Figure 5.8e). In all 
conditions that showed significantly increased proliferation rates at D14, the 
frequency of proliferating islets was maintained at D42, suggesting that 
restoration of basal proliferative levels was achieved. These data suggest that 
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hMSC CM induced β-cell proliferation leading to increased β-cell mass. In 
addition, Wnt-pathway activation during CM generation increased the 
frequency of proliferating β-cells maximally within 1 day post-injection. 
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Figure 5.7  Intrapancreatic-injection of Wnt-activated hMSC CM 
increased islet ductal association. (a-c) Representative photomicrographs 
of ck19+ cells (arrows) associated with islets at day 11, 14, and 42 in mice 
injected with unconditioned media, or 8 µg hMSC CM, or 8 µg WNT+ CM. (d) 
Mice injected with 8 µg hMSC CM showed an increased frequency of islets 
associated with ducts compared to mice injected with 4µg hMSC CM or 
unconditioned media. (e) Mice injected with 4 µg or 8 µg WNT+ CM showed 
an increased frequency of islets associated with ducts compared to mice 
injected with 8 µg WNT- CM or unconditioned media. Scale bar=200µm. Data 
is represented as mean ± S.E.M. (*p<0.05, **p<0.01, ***p<0.001).  
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Figure 5.8  Intrapancreatic-injection of Wnt-Activated hMSC CM 
increased β-cell proliferation. (a-c) Representative photomicrographs of 
EdU+ β-cells (arrows) within islets at day 11, 14, and 42 in mice injected with 
unconditioned media, or 8 µg hMSC CM, or 8 µg WNT+ CM. (d) Mice injected 
with 8 µg hMSC CM showed an increased number of proliferating islets 
compared to mice injected with 4 µg hMSC CM or unconditioned media at late 
time points. (e) Mice injected with 4 µg or 8 µg WNT+ CM showed an 
increased number of proliferating islets at all time points compared to mice 
injected with 8 µg WNT- CM or unconditioned media. Scale bar=200µm. Data 
is represented as mean ± S.E.M. (*p<0.05, **p<0.01, ***p<0.001). 
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5.2.9 hMSC CM induce α-β-cell conversion and maturation of new β-cells 
The homeodomain transcription factor NKX2.2 is required for cell fate 
decisions in pancreatic islets and has been implicated in the prevention of α-
β-cell reprogramming [35]. In addition, NKX6.1 expression has been show to 
be vital in the final stages of β-cell differentiation and maturation [9,10]. 
Therefore, to further characterize the mechanism of islet formation after 
injection of hMSC CM, we investigated the presence of both NKX2.2 and 
NKX6.1 in newly formed islets at D11, D14 and D42. Representative 
photomicrographs show that nuclear localization of NKX2.2 (Figure A5.2a-c) 
was present in similar frequencies (~80%) across all conditions tested at all 
time points, including CAB injected mice (Figure A5.2d-e). Interestingly, the 
expression of NKX6.1 varied drastically between conditions but not between 
different time points (Figure 5.9a-c). Compared to unconditioned media 
injected mice, mice injected with 8 µg of hMSC CM and 4 or 8 µg WNT+ CM 
showed significantly higher frequencies of nuclear localization of NKX6.1 at 
D14-D42 (Figure 5.9d-e). Mice that were injected with 4 µg of hMSC CM or 
WNT- CM did not show significantly increased NKX6.1 expression. It has 
been estimated that adult mice contain approximately 60% β-cells in their 
islets, and in turn have about 60% expression of NKX6.1 [36]. Mice that were 
CAB injected had an expression of ~ 58%, supporting this hypothesis. Taken 
together, these data suggest that hMSC CM is capable of inducing both β-cell 
regeneration and maturation. 
In addition, hMSC CM has the ability to initiate conversion of α-cells to 
β-cells. Therefore, to characterize these mechanisms, the total number of 
glucagon+ cells was investigated (Figure 5.10a-c). The total number of 
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glucagon+ cells was found to be elevated in each condition at early time 
points. However, only mice injected with 8 µg hMSC CM or WNT+ CM 
showed significantly reduced levels of glucagon+ cells by D14-42 that 
eventually returned to physiological level (Figure 5.10d-e). More importantly, 
the misexpression of mature β-cell marker NKX6.1 was observed in 
significantly higher frequencies at early time points. Mice that were injected 
with 8 µg hMSC CM or WNT+ CM showed significantly higher misexpression 
glucagon+ cells at early time points that decreased over time compared to 
unconditioned media injected mice (Figure 5.10f-g). Interestingly, this 
decrease directly correlated with the total decrease in glucagon+ cells. Thus 
hMSC CM has the ability to induce α-β-cell conversion to increase total β-cell 
mass. Finally, confocal z-stacking was used to confirm these findings and 
illustrated the presence of glucagon+ cells, glucagon+ NKX6.1+ cells, insulin+ 
NKX6.1+ cells and finally insulin+ glucagon+ cells (Figure 5.11a-c). 
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Figure 5.9  Intrapancreatic-injection of Wnt-activated hMSC CM 
increased β-cell maturation. (a-c) Representative photomicrographs of 
NKX6.1+ cells within islets at day 11, 14, and 42 in mice injected with 
unconditioned media, or 8 µg hMSC CM, or 8 µg WNT+ CM. (d) Mice injected 
with 8 µg hMSC CM showed an increased frequency of NKX6.1+ cells per islet 
compared to mice injected with 4 µg hMSC CM or unconditioned media. (e) 
Mice injected with 4 µg or 8 µg WNT+ CM showed an increased frequency of 
NKX6.1+ cells per islet compared to mice injected with 8 µg WNT- CM or 
unconditioned media. Scale bar=200µm. Data is represented as mean ± 
S.E.M. (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 5.10  Intrapancreatic-injection of Wnt-activated hMSC CM 
increased α-β-cell conversion. (a-c) Representative photomicrographs of 
glucagon+ NKX6.1+ cells within islets at day 11, 14, and 42 in mice injected 
with unconditioned media, or 8 µg hMSC CM, or 8 µg WNT+ CM. (d-e) Mice 
injected with 8 µg hMSC CM showed a decreased frequency of glucagon+ and 
glucagon+ NKX6.1+ cells per islet compared to mice injected with 4 µg hMSC 
CM or unconditioned media. (f-g) Mice injected with 4 µg or 8 µg WNT+ CM 
showed an increased decreased frequency of glucagon+ and glucagon+ 
NKX6.1+ cells per islet compared to mice injected with 8 µg WNT- CM or 
unconditioned media. Scale bar=200µm. Data is represented as mean ± 
S.E.M. (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 5.11  Intrapancreatic-injection of Wnt-activated hMSC CM 
displays α-β-cell transition. (a) [(1), (2), (3)] Represent individual cells that 
co-express nuclear transcription factor Nkx6.1 and cytosolic hormone, 
glucagon . (Right) Z-stack showing NKX6.1+ nuclei surrounded by glucagon. 
(b) [(4), (5), (6)] represent individual cells that co-express nuclear transcription 
factor NKX6.1 and cytosolic hormone, insulin. (Right) Z-stack showing 
NKX6.1+ nuclei surrounded by insulin. (c) [(7), (8), (9)] represent individual 
cells that co-express cytosolic hormones insulin and glucagon. (Right) Z-stack 
showing insulin and glucagon co-staining (magenta). Z-stack reconstructions 
were created from a tissue depth of 20 µm. 
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5.2.10    Proteomic analyses of WNT+ CM identified pro-islet regenerative    ..   
...proteins 
  To identify proteins secreted by hMSC and associated with increased 
β-cell mass, we performed global quantitative proteomic analysis on hMSC 
CM generated under untreated conditions (hMSC CM), Wnt-activated 
conditions (WNT+) and Wnt-inhibited conditions (WNT-), in biological triplicate 
(Figure 5.12a). Protein lists were filtered to include only those identified in at 
least two biological replicates in a single condition and missing values were 
imputated using a normal distribution [37]. Gene ontology using cellular 
component (GOCC) analysis was used to filter proteins to only include 
extracellular proteins. In total 434 proteins were found to be secreted in hMSC 
CM (ESM Table 5.1).  Label-free quantitation was used to investigate what 
proteins were differentially expressed upon treatment of hMSC by CHIR99201 
(WNT+) or IWR-1 (WNT-). Investigation of proteins differentially expressed 
compared to WNT+ CM were highlighted (Figure 5.12b) (Table A5.1). 
Proteins that were upregulated in WNT+ CM included those associated with 
regulation of Wnt-signaling such as LRP1, and WNT5A. Conversely, negative 
regulators of Wnt-signaling, such as DKK1-3, were observed in decreased 
amounts in WNT+ CM, confirming robust Wnt-activation occurred during CM 
generation. Down-regulated proteins also included biomarkers of pancreatic 
cancer (VNN1) [38], negative regulators of insulin secretion (CFD) [39], as 
well as connective-tissue growth factor (CTGF), which has been shown 
previously to be a regulator of β-cell regeneration [40–42]. Of most 
importance, we observed upregulation of key β-cell pro-survival and 
proliferative proteins, such as IGF-1, TGFβ2 and LIF, in WNT+ CM [43–45].  
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Many proteins were not differentially expressed between the three conditions, 
and included extracellular matrix scaffolding proteins, and angiogenic factors 
such as angiopoietin like protein 2 (ANGPTL2) and VEGFA. 
To determine whether murine islets could receive the signals found in 
WNT+ CM, we probed murine islets for receptors corresponding to TGFB2, 
IGF1 and LIF (Figure 5.12c-e). Murine islets showed robust signals for both 
TGFβR2 and LIFR, and modest expression of IGFR1. Nonetheless, these 
findings confirmed that murine islets could putatively respond to these β-cell 
survival and proliferative ques generated by hMSC CM. Next, we sought to 
investigate whether culturing of human-derived islets using recombinant 
proteins for TGFβ2, IGF-1 and LIF could increase survival and proliferation in 
vitro compared to full hMSC CM. Human islets were obtained from the IIDP 
and cultured for three days in hMSC CM (hMSC CM, WNT+ CM and WNT- 
CM), along with each recombinant ligand alone, or in combination. 
Concentration ranges of each ligand were determined by using the average 
total detector intensity (raw intensity) across all three conditions (data not 
shown) [46]. Each ligand was matched to the average concentration found in 
the hMSC CM and β-cell survival and proliferation was assessed using 
multiparametric flow cytometry. Although we did not observe any differences 
in the proliferation rates of human β-cells after three-days of culture, a 
significant increase in the frequency of live β-cells (Figure 5.12f) and total live 
β-cells (Figure 5.12g) was observed for the WNT+ CM conditions and for 
TGFβ2, IGF-1 and LIF used in combination. Interestingly, ligands in 
combination achieved β-cell survival rates equivalent to WNT+ CM. 
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Figure 5.12   Proteomic analyses of WNT+ CM identified pro-islet 
regenerative proteins. (a) Quantitative proteomic of secreted proteins found 
in hMSC CM, WNT+ and WNT- CM. Total quantified proteins were filtered 
using GOCC to only include extracellular proteins. (b) Scatter plot showing the 
fold change of WNT+CM compared to hMSC CM and WNT- CM. Significantly 
changing proteins are highlighted. Representative photomicrographs of (c) 
TGFβR2, (d) IGFR1 and (e) LIFR on murine islets. (f) WNT+ CM and 
recombinant proteins used in combination show increases in total live β-cell 
numbers, while (g) only recombinant proteins used in combination show 
increases in live β-cell frequency. Data is represented as mean ± S.E.M. 
(*p<0.05). 
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5.3  Discussion 
Our study demonstrates that secreted products contained in hMSC CM 
can stimulate endogenous islet regeneration without cell transfer. Importantly, 
regenerated β-cells were functionally mature, and secreted insulin in response 
to elevated blood glucose to reverse chemically-induced hyperglycemia in 
vivo. In addition, the extent glucose control was dependent on the 
concentration of secreted proteins delivered to the pancreas, and stimulation 
of Wnt-signaling during CM generation augmented regenerative capacity. 
Impressively, mice injected with Wnt-activated hMSC CM showed full 
recovery of endocrine function, resulting from increased β-cell mass and 
accelerated β-cell maturation via α-β-cell conversion accompanied by 
increased β-cell proliferation. Misexpression of NKX6.1 within glucagon+ cells 
suggested that hMSC CM stimulated initial conversion of α-cells into β-like 
cells, and these mechanisms occurred within a four day therapeutic window 
after a single dose hMSC CM. Finally, using quantitative proteomic screening 
techniques, we were able to identify a subset of 3 proteins, IGF-1, TGF-β2 
and LIF, upregulated during CM generation, that directly stimulated β-cell 
survival and proliferation using human islet preparations, suggesting that  
targeted protein based therapies may be developed to restore β-cell mass in 
patients with diabetes. 
Although administration of hMSC directly into the pancreas had 
minimal effect on overall hyperglycemic recovery, the emergence of single 
insulin+ cells found adjacent to the ductal epithelium at early time points 
suggested that hMSC were capable of initiating -cell neogenesis in situ. 
Thus, poor hMSC survival in the pancreas after injection, alteration in the 
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secretory profile of cells in vivo and insufficient accumulation of regenerative 
factors resulted in a truncated or partial regenerative response in vivo. After 
transplantation, hMSC are met with a harsh environment coupled with 
activation of detachment-induced apoptotic signals and inadequate adhesion 
caused by a lack of matrix supports [47] , that may drastically limit hMSC 
engraftment and function within the injured pancreas [48]. Indeed, detection of 
viable hMSC by HLA-A, B, C-expression was drastically reduced at the site of 
injection between days 14 and 42. However, direct administration of hMSC 
CM, is not limited by the same complications associated with cellular transfer, 
we were able to demonstrate the immediate emergence of functional islets as 
early as one day after a single CM injection. Interestingly, an increase in islet 
number was observed when sufficient total protein was administered, and 
appeared to plateau at approximately four days post transplantation only 
when delivered at a lower dose of 4 µg hMSC CM. In contrast, this plateau 
was not observed for mice that received 8 µg hMSC CM, or when CM was 
generated under Wnt-pathway stimulated conditions suggesting that CM-
delivery triggered endogenous regenerative programs, partially dependent on 
protein concentration. In addition, a single dose of 4 µg WNT+ CM sequential 
increases in islet size, islet number and β-cell mass suggesting protein 
content was also important for the extent of islet regeneration observed. 
Finally, a single injection of 12 µg WNT+ CM was also investigated and 
showed no difference over 8 µg WNT+ CM, suggesting maximum therapeutic 
recovery was achieved. Further insights on how to extend this therapeutic 
window could lead to improved protein based therapies designed to stimulate 
β-cell regeneration. 
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Exploring the components within the hMSC CM that stimulate 
endogenous regeneration also suggested protein as opposed to 
microvessicles-encapsulated miRNA, as the major signaling moiety 
contributing to islet regeneration. However, CM generation and concentration 
process will collect content within the microvessicle fraction, and miRNA 
content analyses as well as metabolite profiling within hMSC-secreted fraction 
may represent an additional avenue for future investigation for potential islet 
regenerative stimuli. Recently, gamma-amiobutryic acid (GABA) has been 
shown to induce islet hyperplasia in STZ-treated mouse models [18,49]. 
Although the impact of GABA was also not assessed herein, hMSC possess 
the ability to produce GABA [50], that may  contribute to the therapeutic effect. 
However, in experiments performed by the Collombat group administration of 
GABA was >1 month in duration before islet hyperplasia was observed. In 
contrast, in our experimental design, mice only received a single dose of CM 
and responded with new islet formation within 4 days, making it unlikely that 
GABA could be solely responsible for β-cell mass recovery. In addition, the 
involvement of miRNA in the regulation of β-cell function during islet 
development had been documented [51]. Therefore, hMSC may influence 
cellular processes through extracellular vesicles shuttling miRNA [52]. 
Microarray analysis on harvested extracellular vesicles from hMSC has 
reveled high expression of miR-21, miR-146a, and miR-181, linked to 
downstream products important in immune response [53], but did not identify 
any miRNA directly implicated in insulin homeostasis. Nonetheless, only a 
small amount of already degraded RNA was injected in the current study, 
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making it improbable that miRNA was the main contributor to islet 
regeneration.  
The endogenous mechanisms underlining the induction of β-cell 
regeneration by hMSC CM were multi-factorial. Increased ductal association 
with newly formed islets suggests the ductal epithelial niche as a potential 
source of β-cell renewal. In vitro cultivation of ductal tissue preparations has 
provided evidence that ductal cells can be directed to differentiate into 
glucose responsive -cells [54,55]. However, we did not observe direct 
evidence for ck19+ ductal epithelial conversion to cells that expressed 
endocrine specific genes, such as NKX2.2, or insulin or glucagon. However, 
we observed increased representation of ck19+ cells within islets suggesting 
the involvement of the epithelial niche as a site of active regeneration. In 
addition, periductal vimentin+ cell hyperplasia was associated with the 
emergence of glucagon+ cell clusters as early as one day post-
transplantation. Activation of β-cell proliferation was also predominant at early 
time points in mice that received Wnt-activated CM. Wnt-ligands have been 
well documented to play a key role in initiating β-cell proliferation both in vitro 
and vivo [23,24]. However, the short burst of -cell proliferation in our study 
suggested that alternative mechanisms of β-cell conversion were likely to 
account for the large increases in β-cell mass observed.  
Although lineage tracing needs to be performed to conclusively 
demonstrate endocrine cell conversion, several observations support  to -
cell conversion as the primary mechanism for the recovery of -cell mass after 
CM injection. First, as β-cell mass gradually increased with time after WNT+ 
CM injection, the frequency of glucagon+ cells was diminished. Second, using 
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NKX6.1 as a marker of functionally matured -cells, WNT+ CM accelerated 
the maturation of β-cells as early as 24 hours post injection. While the 
expression of endocrine marker NKX2.2 remained constant across all time 
points and conditions, the frequency of NKX6.1+ cells / islet was significantly 
increased in mice that received WNT+ CM, but failed to reach the 60% 
benchmark observed in healthy, CAB-treated islets. The outcome of this was 
confirmed in glucose tolerance tests, where the recovery from hyperglycemia 
after glucose bolus was present but delayed compared to CAB controls. Third, 
glucagon+ cell that expressed NKX6.1 were consistently detected at early time 
points under conditions that induced regeneration of β-cells. Indeed, the 
expression of mature β-cell transcription factor NKX6.1 was detected in ~50% 
of glucagon+ cells at day 11 in mice treated with WNT+ CM. As expected the 
frequency of Glucagon+ / NKX6.1+ cells decreased with time post-CM 
injection. Finally, presence of islet cells that expressed both glucagon and 
insulin further supports the hypothesis that hMSC CM efficiently induced α-β-
cell conversion [19,56].  
Combining quantitative proteomic analysis comparing the secreted 
protein composition of various hMSC treatments, human islet co-culture 
experiments and multiparametric flow cytometer analysis, we identified a 
shortlist of proteins (IGF-1, TGFβ2, LIF) within hMSC CM as our top secreted 
candidates to modulate β-cell survival and proliferation in vitro. As proof of 
concept, these recombinant proteins were equivalent, if not better than Wnt-
activated CM at preserving β-cell survival. The effective range of each ligand 
was determined using the average detector intensity to equally compare back 
to CM. Therefore, further optimization is needed to determine the optimal 
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concentration needed elicit islet regeneration. Proteins known to negatively 
alter the secretion of insulin (CFD, VNN1) were found in hMSC CM that 
decreased during Wnt-activation.  Importantly, deleterious proteins are 
present in all hMSC CM, potentially decreasing the therapeutic effects. 
Nonetheless, we provide a list of protein targets that can be used to design 
protein-based strategies to stimulate endogenous islet regeneration that offer 
one step closer towards a potential peptide treatment for diabetes. 
In summary, our analyses of hMSC CM directly injected into STZ-
treated hyperglycemic mice  demonstrates that: (1) hMSC CM can induce 
endogenous regeneration of murine islet without transferring cells; (2) newly 
formed islets are mature and functional; (3) regeneration of β-cell mass is 
multi-factorial involving both β-cell maturation and proliferation; (4) 
regenerating β-cells are primarily derived from α-β-cell conversion; and lastly 
(5) hMSC CM contains pro-β-cell effectors that can potentially be 
administered in combination to reduce hyperglycemia. Based on these 
findings, we believe that injection of Wnt-pathway stimulated hMSC-derived 
CM or peptide effectors represents a promising approach as a novel therapy 
for T1D. 
 
5.4 Experimental Methods 
 
5.4.1 Animal Maintenance and Manipulations 
Mouse protocols were reviewed and approved by the Institutional 
Ethical committee at the University of Western Ontario and all colonies were 
maintained following Canadian animal research guidelines. NOD/SCID mice 
obtained from Jackson Laboratories were housed and used according to the 
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guidelines of the Animal Use Protocol (AUB#2015-033). To induce 
hyperglycemia, STZ (Sigma) was dissolved in 0.1M sodium citrate buffer 
(CAB) (pH 4.5), and 5 doses (Days 1-5) were administered intraperitoneally 
(35 mg/kg/day) within 15 minutes of dissolving. Hyperglycemia progression 
(>15 mmol/l) was assessed by monitoring the blood glucose levels of mice on 
transplant day (day 10). For intrapancreatic (iPan) injections, mice were 
anesthetized; the pancreas and spleen exposed; cells (5e5) or CM (~4 or 8 
µg) was microinjected (20 µl) into the splenic portion of the pancreas. 
Negative control mice were injected with unconditioned basal media that was 
used to collect secreted hMSC proteins. Positive control mice received CAB 
instead of STZ for five days. In addition CAB mice were intrapancreatically 
injected with unconditioned basal media on day 10. To assess cell 
proliferation, mice were intraperitoneally injected (100 ul) with EdU (2 ug/ul) 
24 hrs prior to sacrifice. Cells that had incorporated EdU were detected by 
immunohistochemistry (ThermoFisher Scientific). 
5.4.2 Human Subjects 
Human bone marrow was obtained from healthy donors after informed 
consent at the London Health Science Centre (London, ON, Canada). All 
studies were approved by the Human Research Ethics board at the University 
of Western Ontario (REB#12934, 12252E). Human pancreatic islets were 
provided by the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) funded Integrated Islet Distribution Program (IIDP) at the 
City of Hope (California, USA), NIH Grant # 2UC4DK098085-02. 
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5.4.3 Generation of hMSC CM for injection and proteomics 
After 4 days of culture (~80% confluency), hMSC were washed twice 
with PBS to remove residual growth factors and replated in basal 
AmnioMaxTM without supplement to collected proteins secreted hMSC for 24 
hrs. Media conditioned by hMSC was collected, filtered and centrifuged at 450 
x g to remove any cellular debris. Cell viability was assayed using trypan blue 
and >95% viability was used as a standard cut-off for co-culture and 
secretome analyses. CM was generated fresh and concentrated the morning 
of each in vivo experiment. For proteomics CM was generated in triplicate and 
all CM was concentrated using 3 kDa molecular weight cut-off filter units 
(Millipore). For in vivo assays, CM was quantified and the protein amount was 
normalized to either 0.2 or 0.4 µg/uL. For proteomic analysis, concentrated 
CM was lyophilized overnight and re-suspended in 8M urea, 50mM 
ammonium bicarbonate, 10mM dithiothreitol and 2% SDS solution prior to 
protein quantitation. Protein concentration was measured using the Pierce 
660 nm protein assay (ThermoFisher Scientific) or by NanoDrop (A280). For 
Wnt-modulated hMSC CM, cells were treated with 10 µM of CHIR99201 or 20 
µM of IWR-1 for 24 hrs during media generation. 
5.4.4 Glucose Tolerance Test 
  For challenge purposes, mice were fasted for 4-6hrs and were injected 
intraperitoneally with glucose (2.0 g/kg). Blood glucose levels were measured 
at the indicated times points for 2 hrs using a FreeStyle Lite glucometer 
(Abbott). 
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5.4.5 Serum insulin and glucagon ELISA 
 On day 42, after cervical dislocation, blood was collected from the left 
ventricle from serum insulin and glucagon quantification by ELISA. 
Approximately 25 ul of serum was used to assay circulating insulin by ultra-
sensitive ELISA according to manufacturer’s specifications (Alpco). 
Approximately 50 ul of serum was used to assay circulating glucagon levels 
according to manufacturer’s specifications (Alpco). Each mouse was 
measured in duplicate. 
5.4.5 RNA isolation, qPCR and integrity analysis 
RNA was purified in triplicate from CHIR99201 or IWR-1 treated hMSC 
cell using the RNeasyTM RNA extraction kit according to the manufacturer 
instructions (Qiagen).  RNA quality and quantity was assessed using 
NanoDrop.  Subsequently, cDNA was synthesized using the High Capacity 
cDNA Reverse Transcription Kit with RNase inhibitor (Invitrogen).  Real-time 
PCR was performed using SYBR® Green along with BCL9 and c-MYC 
primers (Genecopoeia).  Samples were incubated at 50oC for 2 minutes 
followed by 10min at 95oC. DNA was amplified at 95oC for 15 s followed by 1 
min at 60oC for 40 cycles, using the Bio-Rad CFX384 Real-Time PCR 
Detection System (Bio-Rad). Samples were normalized using the geometric 
mean of three housekeeping genes. For RNA integrity, 4 uL of extracted RNA 
analyzed using the Agilent RNA 6000 pico kit coupled to the 2100 bioanalyzer 
system (Agilent). Total chromatographic area integration was performed using 
the 2100 Expert software package. 
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5.4.6 Immunohistochemistry and Immunofluorescent analysis 
 Pancreata were frozen in optimal cutting temperature media and 
sectioned at 10 µm such that each slide contained 3 sections each 150µm 
apart. Sections were fixed in 10% buffered formalin and blocked with mouse 
serum, incubated with mouse insulin antibody (1/1000) and were detected 
with peroxidase-labeled rabbit anti-mouse antibody and DAB (Vector). Size 
and number of islets were quantified by using light microscopy and analyzing 
four areas (1 mm2) selected at random per section for a total of three 
sections/mouse. β-cell mass was calculated by β-cell area/(total area-β-cell 
area)x pancreas weight. Frozen pancreas sections were also stained for 
Immunofluorescent analysis to detect murine insulin, glucagon, human cell 
engraftment (HLA), blood vessel density (vWF, CD31), proliferation (EdU), 
islet transcription factors (NKX2.2, 6.1), ductal association (ck19), and 
vimentin. Concentration and manufacture information for all antibodies used 
for immunofluorescent analysis are found in Table A5.2 
5.4.7 Quantification of islet blood vessel density 
 Von Willebrand factor (vWF) and CD31 were used to detected large 
vessels and small capillaries respectively. Briefly, intra-islet blood vessel 
densities were quantified by counting vWF+ vessels/ islet by randomly 
selecting four islets/section for three section/mouse. In addition the total 
numbers of CD31+ cells were counted for within the total insulin area for each 
islet and the number of CD31+ cells was normalized by using the area of each 
islet. 
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5.4.8 Quantification of proliferating cells and ductal association 
 EdU+ cells were detected using the Click-iTTM EdU imaging kit 
(Invitrogen) and co-stained for insulin to identify proliferating β-cells and every 
islet in three sections for each mouse was used from quantification. Islets that 
contained ≥1 proliferating β-cell were counted and divided by the total number 
of β-cells per mouse. Cytokeratin-19 (ck19) was used to label ductal 
structures within the pancreas. Each islet in three pancreatic sections per 
mouse was designated as not associated with, or in direct contact with, ck19+ 
ducts. 
5.4.9 Quantification of transcription factor expression 
 Pan-endocrine marker NKX2.2 and β-cell specific NKX6.1 were used to 
assess β-cell maturity. Each marker was co-stained with insulin to determine 
the total frequency within 12 islets per section per mouse. The total frequency 
of each transcription factor was calculated by counting the total number of 
NKX2.2 or 6.1 positive nuclei/ the total number of nuclei per islet. 
5.4.10   Quantification of glucagon+ cells with NKX6.1 
    Glucagon was co-stained with NKX6.1 and insulin as just described. 
The frequency of glucagon positive cells was calculated by counting the total 
number of glucagon+ cells/ the total number of cells per islet for 12 islets per 
section per mouse. The frequency of glucagon+ cells expression NKX 6.1 was 
calculated by counting the total number of glucagon+ cells NNK6.1+ cells/ total 
number of NKX6.1+ cells per islet for 12 islets per section per mouse. 
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5.4.11   Confocal Microscopy 
  Immunohistochemistry was performed on 20 µm pancreas 
cryosections for confocal imaging. Tissue was fixed with 10% buffered 
formalin for 20 min and permeabilized with 1% Triton X-100 for 10 min. Prior 
to incubation with antibodies, tissue samples were blocked in 10% heat 
inactivated FBS for 90 min. Tissue samples were incubated with the following 
primary antibodies for 60 min at room temperature: mouse monoclonal anti-
glucagon, rabbit monoclonal anti-insulin, and goat polyclonal Nkx6.1. Tissue 
samples were washed 2 times with PBS prior to incubation with the following 
secondary antibodies for 30 min at room temperature: hose anti-mouse IgG 
fluorescein, goat anti-rabbit IgG AlexaFluor 647 and bovine anti-goat IgG 
AlexaFluor 594 . Tissue samples were washed 2 times with PBS and 
incubated for 5 min with DAPI. Images were acquired using the LSM 510 
confocal laser scanning microscope (Zeiss) running Zeiss ZEN 2009 imaging 
software (Zeiss). Images were captured using a 20x objective lens. Z-stack 
optimization was performed using Zeiss Zen 2009 imaging software to 
determine optimal slice thickness and Z-projections were constructed and 
analyzed using ImageJ software (NIH). 
5.4.12   Chloroform/methanol precipitation and protein digestion 
  Protein extracts from hMSC CM samples were reduced in 10 mM 
DTT for 30 min and alkylated with 100 mM iodoacetamide (IAA) for 30 min at 
room temperature in the dark. Next, to facilitate the removal of incompatible 
detergents, reducing and alkylating reagents, the proteins were precipitated 
using chloroform/methanol.  Briefly, 25 μg of protein extracted from each 
sample was diluted to a total volume of 150 μL with 50 mM ammonium 
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bicarbonate (ABC), and 600 μL of ice cold methanol was added to each 
sample, followed by 150 μL of chloroform, with thorough vortexing.  450 μL of 
ice-cold DIH2O was added before additional vortexing and centrifugation at 
14,000 x g for 5 min at room temperature.  The upper/aqueous methanol 
phase was removed and 450 μL of ice-cold methanol was added to each 
sample, followed by vigorous vortexing and centrifugation at 14,000 x g for 5 
min.  The remaining chloroform/methanol was discarded and the precipitated 
protein pellet was air dried before protein digestion.  For on-pellet protein 
digestion, 100 μL of 50 mM ABC (pH 8.0) with LysC (Wako) (1:100) solution 
was added to each precipitated sample and incubated in a ThermoMixer at 
37°C for 4 hrs at 1000 RPM, followed by trypsin/LysC (1:50 ratio of enzyme: 
sample) (Promega) solution was added to each precipitated sample and 
incubated in a water bath shaker at 37°C overnight at 400 RPM. The next 
day, an additional aliquot of trypsin (1:100 ratio) was added for ~ 4 hrs, prior 
to acidifying with 10% formic acid (FA) (pH 3-4). The peptide concentrations 
were estimated using a Pierce BCA assay (ThermoFisher Scientific). 
5.4.13   Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
   Approximately 1 μg of each sample was injected onto a Waters M-
Class nanoAcquity HPLC system (Waters) coupled to an ESI ion-trap/Orbitrap 
mass spectrometer (Q Exactive Plus).  Buffer A consisted of mass spec. 
grade water/0.1% FA and Buffer B consisted of ACN/0.1% FA.  All samples 
were trapped for 5 min at a flow rate of 5 μL/min using 99% Buffer A and 1% 
Buffer B on a Symmetry BEH C18 Trapping Column (5 μm, 180 μm x 20 mm, 
Waters). Peptides were separated using a Peptide BEH C18 Column (130 Å, 
1.7 μm, 75 μm x 250 mm) operating at a flow rate of 300 nL/min at 35°C 
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(Waters).  Samples were separated using a non-linear gradient consisting of 
1-7% Buffer B over 1 min, 7-23% Buffer B over 135 min and 23-35% Buffer B 
over 45 min, before increasing to 98% Buffer B and washing. Settings for data 
acquisition on the Q Exactive Plus are outlined in Table A4.3. 
5.4.14   Label-free proteomic data analysis 
  All MS raw files were searched in MaxQuant version 1.5.8.30 using 
the Human Uniprot database (updated May 2015 with 20, 264 entries). For all 
database searches, missed cleavages were set to 3, cysteine 
carbamidomethylation was set as a fixed modification and Oxidation (M), N-
terminal Acetylation (protein) and Deamidation (NQ) were set as a variable 
modifications (max. number of modifications per peptide = 5). Precursor mass 
deviation was left at 20 ppm and 4.5 ppm for first and main search, 
respectively. Fragment mass deviation was left at 20 ppm. Protein and 
peptide FDR was left to 0.01 (1%) and decoy database was set to revert. 
Match between runs was enabled and all other parameters left at default. 
Bioinformatics analysis was performed using Perseus version 1.5.8.5. Briefly, 
protein lists were loaded into Perseus and proteins identified by site reverse 
and contaminants were removed. When using the match between runs 
feature, datasets were filtered for proteins containing a minimum of 1 unique 
peptide in at least two of three biological replicates.  
5.4.15   Human islet culture with hMSC CM and recombinant ligands 
  Human islets from 4 donors were obtained from the Integrated Islet 
Distribution Program (IIDP). Upon arrival, 200 islet equivalents were plated in 
RPMI media without serum (Invitrogen). CM was concentrated using 3 kDa 
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molecular mass cut-off filters, and ~50 μg total protein was added to human 
islet culture for 7 days. After islet harvest and dissociation, β-cell content was 
estimated using FluoZin-3 (Flz3) (ThermoFisher Scientific) and apoptosis was 
quantified using 7AAD and Annexin-V. Recombinant proteins were added at 
concentrations estimated by proteomics. Flow cytometry data were analyzed 
using FloJo software (Treestar). 
5.4.16   Cell Counts 
  Quantitative analyses were performed by manually counting of cells 
and nuclei on immunostained section of the mouse pancreas in a blinded 
fashion. Specifically, every tenth section was counted and photographs were 
taken at random by three different people. For islet size and beta cell mass 
quantification, colorimetric insulin was used to define regions on interest. 
Circumferences and area calculation were made by using AxioVision 
microscope software 
5.4.17   Statistical analysis 
  All values are represented as mean ±S.E.M, unless otherwise stated 
in the figure legend, and were considered significant if p<0.05 using ANOVA 
with Tukey’s post hoc test. Data were analyzed using Prism software 
(Graphpad Version 6.01). Proteomic data analysis was conducted using build 
in multiple sample t-tests using Perseus. Fold changes were considered 
significant if they were >2-fold higher and p<0.05 using Permutation based 
FDR test. 
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Chapter 6 
Discussion 
 
6.1 Summary 
 Proteomic characterization by mass spectrometry has emerged as one 
of the most powerful tools for studying biological systems. Large-scale 
analysis of complex biological systems has been obscured by an increase in 
available proteomic techniques. Central to the success of applying proteomic 
characterizations to investigate both qualitative and quantitative changes is 
inherent in method selection. Due to the complex nature of the human 
proteome, both in terms of protein number as well as dynamic concentration 
range, fractionation is often needed to maximize visibility.  However, choosing 
the appropriate fractionation strategies to answer the biological questions at 
hand are not always apparent. To this end, the work in this thesis has 
provided insight into method selection as well highlights trade-offs, such as 
cost and time, which need to be considered when performing large-scale 
mass spectrometry based proteomics (Chapter 2) [1]. Ultimately, all 
fractionation techniques offer investigators a deeper view into biological 
systems. When combined with the analysis of human multipotent stromal cells 
(hMSC) to probe for novel secreted proteins, we discovered an 
unprecedented number of growth factors which serve as signals for 
endogenous regeneration of β-cell mass (Chapter 3) [2]. In doing so, we 
established the concept that Wnt-signaling was essential for optimized islet 
regeneration, based on protein expression levels observed in hMSC that 
possessed the ability to augment blood glucose using in vivo models. In 
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addition, we recognized the clinical applicability of determining protein 
signatures that could be used to screen hMSC that possessed the ability to 
induce islet regeneration. Therefore, a robust quantitative proteomics method 
was developed to predict, or screen, hMSC that could be used in downstream 
clinical applications for β-cell regeneration (Chapter 4). The adapted 
quantitative method not only proved that a protein signature obtained from 
hMSC conditioned media (CM) could be used to reliably characterize many 
hMSC lines in a high throughput fashion, but it also highlighted the rarity of 
identifying hMSC lines that possessed regenerative potential. To circumvent 
this challenge, we applied concepts borrowed from earlier proteomic analyses 
(Chapter 3) to increase the regenerative potential of hMSC that were 
classified as non-regenerative by activating Wnt-signaling during expansion 
(Chapter 5). Applying these methodologies, we proved that Wnt-activation 
during CM generation reliably increased the regenerative potential of non-
regenerative hMSC and potently initiated regeneration of β-cell mass through 
previously undocumented mechanisms. Taken together, these observations 
into hMSC trophic factors that mediate β-cell regeneration will aid in the 
development of potential cell, protein or drug therapies for the treatment of 
diabetes. 
6.2  A new model for hMSC regulated β-cell regeneration 
 Research focused on recovery of β-cell mass has mostly been 
achieved using transplantation of pre-differentiated β-like cells from 
pluripotent stem cells or by the induction of endogenous islet regenerative 
programs after intravenous infusion of hMSC [3–5]. Although, both methods 
have shown tremendous promise, recoveries achieved by these methods 
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have been suboptimal and further understanding of relevant mechanisms is 
required to harness the potential of these cell types for islet regenerative 
applications. Parallel to this need, is to cultivate the ability to induce islet 
regeneration without transplantation of foreign cells potentially rejected by the 
immune system. Currently, there are only a few examples of stimulated 
endogenous recoveries achieved by delivery of proteins or metabolites [6–8] . 
However, many of these studies struggle to produce potential targets that 
contribute to regeneration as well as detailed understanding of regenerative 
mechanisms. As we have shown in this thesis, the compilation of signals 
secreted by hMSC can be used to induce regeneration in mice, without the 
transfer of cells, and ultimately coordinate in order to promote two critical 
events in β-cell neogenesis: (1) initiating conversion of α-cells to β-like cells, 
and (2) promoting the survival and proliferation of newly formed β-cells.  In 
hMSC CM, the specific factors upregulated during Wnt-activation, in addition 
to other supportive factors constitutively present in hMSC CM, have been 
characterized as playing a central role in homeostatic regulation of pancreatic  
6.2.1 Insulin like growth factors (IGFs) and β-cell mass 
 Many protein-based studies have been conducted to identify factors 
important in regeneration of β-cell mass. As part of our own efforts to 
characterize signals secreted by islet regenerative hMSC (Chapter 3), we 
identified a number of components belonging to the insulin like growth factor 
(IGF) family, mainly IGF1 and IGF2 [2]. Interestingly, the expression of IGF2 
was only found in measurable quantities in hMSC lines that possessed the 
ability to augment hyperglycemia recovery after transplantation. IGF2 has 
many important roles in maintaining “stemness” of multiple cell types including 
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hMSC [9]. Of particular interest, IGF2 has been show to regulate β-cell mass 
both in development and the adult pancreas [10]. Using spontaneous models 
of type 2 diabetes (T2D), defective IGF2 production within the embryonic 
pancreas was directly responsible for anomalies in β-cell mass [11]. In the 
adult pancreas, using IGF2 knockout mice, Modi et. al. showed that adult β-
cells actively secreted IGF2 to regulate β-cell mass after pancreatic damage 
and during pregnancy [12]. Additionally, the re-expression of IGF2 in adult 
mice increased endogenous β-cell regeneration after STZ-damage in vivo 
[13]. High levels of IGF2 produced by hMSC could act on endogenous β-cells 
to increase proliferation and maintenance. In contrast, IGF1 protein was not 
differentially expressed by regenerative and non-regenerative hMSC. 
However, after Wnt-activation, the secreted levels of IGF1 were also 
significantly increased (Chapter 4). IGF1 can also influence β-cell mass using 
similar mechanisms discussed for IGF2, but also has been implicated in the 
regulation of β-cell apoptosis [14]. These results can be directly observed in 
human co-culture assay in which exposure of human islets to recombinant 
human IGF1 promoted the survival of β-cells over 7 days (Figure 5.10). 
Conversely, IGF1 does not participate in controlling β-cell development, but 
has been directly linked to defective glucose stimulated insulin secretion and 
impaired glucose tolerance [15]. Lastly, distribution of IGF1 within pancreatic 
biopsies harvested from T2D patients showed significantly reduced levels, 
again cementing an important role for IGF1 in maintaining both β-cell mass 
and regulation of insulin secretion [16]. Finally, the expression of IGF1 has 
been shown to protect β-cells against apoptosis, by an autocrine loop 
established by glucagon-like peptide 1 (GLP1) [17]. 
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6.2.2 Transforming growth factor β and β-cell mass 
 Further proteomic analysis of secreted growth factors derived from 
hMSC revealed the presence of multiple members belonging to the 
transforming growth factor β (TGFβ) superfamily (Chapter 3) [2]. In particular 
two TGFβ family members, TGFβ1 and TGFβi were upregulated in hMSC that 
possessed the ability to reduce hyperglycemia after transplantation (Figure 
3.3). Exogenous administration of TGFβi to islets in vitro, or over expression 
of TGFβi in mice, both resulted in increased β-cell proliferation rates and 
better glucose tolerance, suggesting TGFβi was necessary for islet 
regeneration and function [18]. On the other hand, the role of TGFβ1 in islet 
function is less clear with conflicting results suggesting it may act both as a 
negative or positive regulator of β-cell genesis. Inhibition of TGFβ1 signaling 
after partial pancreatectomy significantly decreased β-cell mass recovery 
resulting directly from increased β-cell apoptosis[19]. Similarly, independent 
reports also suggested that inhibition of TGFβ1 reduced β-cell proliferation by 
interfering with cell cycle check points [20,21]. TGFβ1 involvement in the 
mechanisms elicited by hMSC was not further investigated and could be of 
future interest. The proteomic data obtained after activation of Wnt-signaling 
could offer some insight into unanswered questions regarding TGFβ 
involvement. Upon Wnt-activation, the secreted levels of TGFβ1 were found 
to be equivalent across all conditions. However, TGFβ2 protein levels in Wnt-
activated CM were more than 4-fold higher compared to untreated CM or 
Wnt-inhibited CM. Human islet co-cultures exposed to recombinant human 
TGFβ2 showed significantly increased survival rates compared to islets 
exposed to untreated or Wnt-inhibited media (Figure 5.10). Recently, TGFβ2 
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signaling was reported to be involved in β-cell proliferation under increased 
inflammation and increased β-cell workloads [22]. We believe this is strong 
evidence that TGFβ pathway plays an important role in inducing or 
maintaining the islet regenerative niche created by hMSC.  
6.2.3 Wnt-signals formulate a regenerative niche 
 Throughout this thesis, much focus has been put on characterization of 
Wnt-signaling, both in terms of hMSC secretory profiles in relation to β-cell 
biology. Wnt-signaling plays a vital role in regulating proliferation and 
differentiation of hMSC [23]. Although not investigated, multiple studies have 
suggested that the inhibition or low levels of Wnt-signaling could be 
responsible for cell senescence [24]. Indeed, studies previously conducted by 
our lab have suggested, at the transcriptional level, that Wnt-signaling was 
important in maintaining regenerative capacity as cells were passaged in 
culture [25]. Preliminary unpublished proteomic investigation confirmed these 
results as inhibitors of Wnt-signaling were increased at later passages. Within 
the data set presented in Chapter 3, low levels of Wnt-signaling in non-
regenerative hMSC may predict premature hMSC senescence. In addition, 
the establishment of a deleterious pro-inflammatory microenvironment by non-
regenerative hMSC (Chapter 4) may be potentially be linked to senescence-
associated secretory phenotypes [26]. Thus, we used the activation of Wnt-
signaling during hMSC culture to increase the therapeutic potential of non-
regenerative hMSC CM (Chapter 5). Further proteomic characterization of the 
secretory changes upon Wnt-activation have also reveled decreased levels of 
pro-inflammatory cytokines (Table 5.1). This would suggest that a prevention 
of hMSC senescence was potentially involved in decreasing a deleterious 
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secretory microenvironment contributed by non-regenerative hMSC, although 
further investigations are needed to confirm these findings. If the niche 
established by hMSC could be further optimized to exclude these deleterious 
proteins, and translated in vivo via delivery of CM, the therapeutic potential on 
β-cell regenerative pathways could be greatly increased. Overall these 
observations combine to highlight that multiple factors secreted by hMSC both 
in vitro and in vivo need to work in synergy to optimize β-cell proliferation and 
survival within newly formed islets (Figure 6.1). 
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Figure 6.1  New model for hMSC induced β-cell regeneration. A 
schematic of potential ligands secreted by hMSC that act synergistically to 
activate neogenic mechanisms and convert residual α-cells into β-like cells 
and finally into fully functional β-cells. 
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6.3 α-to-β-cell conversion 
 The islets of Langerhans are multi-cellular structures that regulate 
glucose metabolism within the body [27]. During type 1 diabetes (T1D) the 
destruction of β-cells by the immune systems occurs through auto-antibodies 
against specific epitomes only found on β-cells [28]. However, other cells 
types within the islets, such as α-cells, remain largely unaffected. Recent, 
genetic analyses of endocrine cells within the islet reveal a high degree of 
cellular plasticity (reviewed in [29]). An overwhelming amount of recent 
evidence in animal models has emerged suggesting α-cells can be converted 
into functional β-cells and represent a means to increase β-cell mass after 
islet damage [30]. Epigenomic analysis of human islets also supports the 
hypothesis that α-to-β-cell conversion is also possible [31]. Lineage-tracing 
experiments using chemically induced β-cell damage have demonstrated that 
a large fraction of regenerated β-cells were derived from α-cells [32]. These 
findings represent previously unexplored avenues for β-cell regeneration. With 
this in mind, most efforts to direct α-β-cell conversion have relied on genetic 
manipulation of transcription factors found within α-cells, such as Pax-4 [33–
35]. Only recently, has work been performed to determine exogenous factors 
that can initiate conversion of α-β-cells. As mentioned previously, the long-
term administration of GABA has been well characterized in the recovery of β-
cell mass via the conversion of α-cells [36]. In addition, the use of small 
molecule compounds can initiate similar processes and increase β-cell mass 
[37]. Within this thesis, for the first time we provide evidence that the secretory 
products generated during hMSC culture can be harnessed to initiate 
regeneration of β-cell mass via the conversion of α-cells that survive STZ-
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treatment (Chapter 5). In addition, using proteomic techniques we have 
provided a list of potential factors that could mediate initiation of conversion. 
Although these findings still premature, we feel these data may be extended 
to the potential development of new therapies for the treatment of diabetes. 
6.4 Clinical Applications  
 The findings presented in this thesis provide substantial pre-clinical 
justification for further investigation of islet regenerative strategies using 
hMSC as well as their secretory products for the treatment of diabetes. The 
clinical feasibility of using hMSC transfer to treat diabetes have been 
previously investigated (reviewed in [38]), but the advantages of transferring 
protein cocktails generated from hMSC, rather than hMSC themselves has 
been presented here for the first time. One of the biggest advantages of using 
protein cocktails over cells is that autologous sources are not required. As we 
have exemplified in Chapter 4, the rarity of acquiring islet regenerative hMSC 
represented a potential setback for clinical applications. In addition, donor-
specific characteristics should be taken into account, such as BMI, to 
maximize therapeutic potential of transplanting cell lines also hinder 
progression towards clinic. Preliminary data not presented here, has shown 
that injection of regenerative hMSC CM has increased β-cell regenerative 
potential compared to non-regenerative hMSC and did not need additional 
manipulation, such as Wnt-activation. However, because regenerative hMSC 
lines are less accessible, we presented an alternative approach to increase 
the potency of any bone marrow derived hMSC lines, through the activation of 
Wnt-signaling (Chapter 5). The scalability of hMSC culture has already been 
proven using batch culture systems [39]. In theory, generation of hMSC CM in 
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large quantities, using xeno-free serum-free approaches, can be achieved by 
applying these methodologies. Therefore it is realistic to predict that many 
diabetic patients could be treated using hMSC CM. However, certain 
considerations that were not investigated within this thesis must be taken into 
account. 
6.4.1 Directed delivery of hMSC CM 
 One avenue that needs to be addressed before injection of hMSC CM 
can become a potential treatment for T1D patients is how to deliver CM using 
a clinically applicable modality. It has been largely accepted that one of the 
main factors reducing the regenerative efficacy of hMSC after transplantation, 
at least in mouse models, is that cells often get trapped in the lungs and are 
not directly targeted to the site of tissue damage [40]. As we have also shown 
in Chapter 5, transplanted cell do not survive long when directly delivered to 
pancreas. Also, delivery of hMSC CM intravenously would hypothetically 
encounter similar problems. Trophic factors responsible for initiating 
endogenous recovery may never make it to the site of injury and those that do 
may not be found within concentrations needed for regeneration. Although not 
presented in this thesis, preliminary assessment of hMSC CM delivered 
intravenously was attempted. Initial results were promising in which mice that 
were injected with Wnt-activated CM showed signs of recovery that quickly 
dissipated and never reached levels observed with direct delivery into the 
pancreas. Importantly, 12.5X more CM was needed to elicit fractional results. 
One of the major hurdles met with injection of hMSC CM into the pancreas is 
that it is very invasive and as the data presented in this thesis suggests, 
multiple injection of CM directly to the site of injury could potentially increase 
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recovery. In addition, only very small volumes (20 µL in mice) were used to 
delivery CM, limiting the dose available for delivery. Others have delivered 
proteins factor throughout the pancreas using the common bile duct [7]. 
Although this is still an invasive procedure it could offer a larger volume range 
for CM delivery. Another potential solution to increase the therapeutic effects 
of CM could include a combination of delivery systems. Initial delivery directly 
into the pancreas could be superseded with infusion of CM, either once or 
multiple times, intravenously. Finding the least invasive way, while retaining 
the therapeutic benefits of the CM-injection would be the first step towards 
commercialization of CM based therapies for diabetes. 
6.4.2 Autoimmunity after regeneration 
One major concern that all therapies aimed at increasing β-cell mass 
face is the concomitant destruction of newly formed islets by the immune 
system that have retained memory of β-cell antigens. In addition, dealing with 
potential insulin resistance and co-morbidities common in T2D may also 
represent a hurdle to therapeutic application. Although not investigated, 
multiple solutions to this problem might already exist in the current study. 
Firstly, the autoimmune-mediated β-cell loss is a slow progressing condition 
[41]. Therefore, regeneration of newly formed β-cells could occur at a faster 
rate than destruction if an attempt to curb ongoing autoimmunity can be 
established. This is exemplified in the data presented in this thesis by 
highlighting the very fast therapeutic response to CM injection with significant 
recovery of β-cell function observed within 1-4 days of CM-injection. Therefore 
if multiple rounds of CM delivery prove feasible, the eventual deletion of β-cell 
mass by the immune system could be combated. Secondly, since the 
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mechanisms responsible for restoring β-cell mass are via α-cell conversion, 
newly formed β-cells could contain surface antigens that are specific to α-
cells, rendering them undetected by immune surveillance. Complete profiling 
for surface antigens that are known to be involved in β-cell destruction, such 
as zinc transporter 8, could be conducted to determine if newly formed β-cells 
have autoantibody antigens [42]. Lastly, a combinatorial approach that 
involves immunosuppressive treatment with regeneration mediated by hMSC 
CM could be a viable strategy. Screening hMSC lines that possess a high 
degree of immuno-suppressive secreted ligands, using the proteomic 
techniques developed in Chapter 4 could represent one approach that would 
allow mix-and-matching of targeted CMs, with islet regenerative and 
immunosuppressive capacity that someday may be possible to achieve both 
regeneration and induce immune tolerance. 
6.5 Future Directions 
Despite the extensive analysis of growth factors secreted by islet 
regenerative hMSC (Chapter 3) and growth factors upregulated during Wnt-
activation (Chapter 5), relatively few of those that were identified have yet to 
be characterized in islet culture assays or in vivo. For example, we identified 
members of the IGF and TGFβ families, found in regenerative and Wnt-
activated CM, have only been shown briefly in this thesis to enhance survival 
of human islet in vitro. When used in combination, these ligands performed 
equivalently, if not better, than CM generated from hMSC. While these ligands 
were investigated, their optimal dose was not determined and would require 
additional in vitro characterization using the methods described in this thesis 
(Chapter 3 and 5). In addition, direct delivery of each ligand or in combination 
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need to be performed using in vivo mouse models to determine whether they 
can induce endogenous islet regeneration. Using any of these approaches, 
growth factors identified in islet regenerative hMSC could be studied in the 
context of β-cell regeneration. 
 While both islet regenerative and non-regenerative hMSC were 
investigated in this thesis, it is clear that the majority of samples received for 
clinical application may not be useful for islet regeneration. Although 
successful, our screening approaches aimed at identify secreted proteins that 
could predict the islet regenerative potential of hMSC could be improved by 
acquiring more samples. Since the majority of samples used in this assay 
were classified as non-regenerative, more samples that are regenerative are 
needed to better assign classes using the support vector machine algorithm. 
In particular, one of the purposed future directions should include further 
characterization of donor BMI and regenerative capacity. As it has been 
presented in this thesis, the donor BMI was correlative with islet regenerative 
capacity. Obtaining more samples from donors in health <25 BMI ranges 
could further strength this observation and allow for further optimization of the 
predictive assay. In theory, donor BMI information could be used as a 
prerequisite for assessing regenerative capacity in conjunction with the 
quantitative proteomic assays developed in Chapter 4. As mentioned 
previously, one major question left to answer if hMSC CM is to be used as a 
therapeutic, is whether endogenous regeneration can occur in the face of 
autoimmunity. Thus, to answer some of these questions hMSC CM injection 
needs to be performed using NOD mice. NOD mice develop diabetes 
spontaneously with many similarities to human autoimmune T1D [43]. A 
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promising feature of the methodologies presented here is that CM used to 
induce endogenous regeneration may simultaneously contain a wide variety 
of effectors known to regulate and often suppress immune responses [2]. 
Nonetheless, transplantation of hMSC CM into NOD mice may induce islet 
regeneration and/or delay insulitis progression by modulating regulatory T-cell 
functions [44]. Finally, the transplantation of bone marrow derived hMSC into 
patients with new onset T1D has been shown to preserve β-cell function for 
up to 2 years, [45]. Therefore, combining the immunomodulatory properties 
inherent to hMSC, as well as the β-cell regenerative properties shown here 
within hMSC CM, represents an extremely attractive option for the potential 
development of a cell-free regenerative treatment designed to tip the balance 
in favor of islet regeneration versus autoimmune destruction.  
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Appendix I 
 
Supporting datasets for proteomic characterization of conditioned 
media generated from human multipotent stromal cells (hMSC). 
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Table A2.1 Proteomic performance across different fractionation 
workflows. The total number of converted MSMS scans, unique peptides, 
unique proteins and average number of proteins identified per hour for: in-
solution, SDS-PAGE, GELFrEE, SCX, HpH and all data sets combined. 
 
 
 
Method In-solution SDS-PAGE GELFrEE SCX HpH Comb. 
MS/MS 
Scans 
318K 2.96M 2.90M 2.55M 2.68M 11.4M 
PSMs 182K 557K 830K 769K 653K 2.97M 
Unique 
Peptides 
52.5K 85.9K 71.7K 104K 111K 165K 
Proteins 5189 6959 5919 7655 8470 8710 
Pep/Pro Ratio 10.1 12.3 12.1 13.5 13.1 18.9 
Gradient 
Time a 
4.0h 40h 40h 40h 40h 492h 
Proteins/hr b 1298 173 148 191 212 n/a 
a Total amount of time per LC MS gradient excluding washing and 
equilibration 
b Average proteins per hour identified for one biological replicate 
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Table A2.2 Acquisition parameters for the Q Exactive. Overview of the 
parameters used for data acquisition on a Q Exactive for large scale sample 
preparation. 
 
Parameter Q Exactive 
Mass Range (m/z) 400-1500 
Isolation Window (m/z) 1.2 
MS resolution 70K @ 200m/z 
MSMS Resolution 17.5K 
MS Injection Time (ms) 250 
MSn Injection Time (ms) 64 
AGC Target (MS) 3E6 
AGC Target (MSn) 2E5 
Preview Scan n/a 
Threshold (counts) 3.1E4 
Minimum AGC Target 2.0E3 
Data Dependent Acquisition Top12 
Dynamic Exclusion (s) 30 
Exclusion Mass Width (m/z) n/a 
Exclude Isotopes/ Monoisotopic 
precursor Selection 
Enabled 
Fragmentation Type HCD 
Normalized Collision Energy 25 
Lock Mass (445.120025m/z) Best 
Charge State Rejection Unassigned, +1, 7,>8 
Default Charge State +2 
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Table A3.1 Acquisition parameters for the Q Exactive. Overview of the 
parameters used for data acquisition on a Q Exactive for secreted proteins 
from hMSC. 
 
Parameter Q Exactive 
Mass Range (m/z) 400-1450 
Isolation Window (m/z) 2.0 
MS resolution 70K @ 200m/z 
MSMS Resolution 17.5K 
MS Injection Time (ms) 250 
MSn Injection Time (ms) 120 
AGC Target (MS) 1E6 
AGC Target (MSn) 2E5 
Preview Scan n/a 
Threshold (counts) 5.0E4 
Minimum AGC Target 6.0E3 
Data Dependent Acquisition Top15 
Dynamic Exclusion (s) 30 
Exclusion Mass Width (m/z) n/a 
Exclude Isotopes/ Monoisotopic 
precursor Selection 
Enabled 
Fragmentation Type HCD 
Normalized Collision Energy 25 
Lock Mass (445.120025m/z) Best 
Charge State Rejection Unassigned, +1,>8 
Default Charge State +2 
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Table A4.1 Posterior probabilities generated using SVM. Posterior 
probability of each protein used to identify a protein signature that could 
segregate regenerative and non-regenerative hMSC. 
 
Accession Number Gene Name 
Posterior 
Probability 
Direction 
Q15818 NPTX1 1 DOWN 
P12111 COL6A3 1 UP 
P01210 PENK 1 UP 
P10145 CXCL8 0.99989 UP 
P05155 SERPING1 0.99989 UP 
P05231 IL6 0.99928 UP 
Q8N474 SFRP1 0.99713 DOWN 
P03956 MMP1 0.98958 DOWN 
P42830 CXCL5 0.98215 UP 
P13500 CCL2 0.97828 UP 
P10915 HAPLN1 0.97428 UP 
P80162 CXCL6 0.97341 UP 
Q99988 GDF15 0.96315 UP 
Q05707 COL14A1 0.95743 DOWN 
P41271 NBL1 0.95535 UP 
P36222 CHI3L1 0.94348 UP 
P23142 FBLN1 0.91515 DOWN 
P35556 FBN2 0.91069 DOWN 
P05120 SERPINB2 0.90423 UP 
P35318 ADM 0.90229 UP 
P31947 SFN 0.8768 UP 
Q00888 PSG4 0.87446 UP 
Q9NZU1 FLRT1 0.86897 DOWN 
P26583 HMGB2 0.86321 DOWN 
Q71DI3 HIST2H3A 0.81959 DOWN 
P09341 CXCL1 0.81228 UP 
P20742 PZP 0.80745 DOWN 
P43121 MCAM 0.8029 UP 
Q9BUD6 SPON2 0.77233 DOWN 
Q9H5V8 CDCP1 0.6761 UP 
P19876 CXCL3 0.65295 UP 
O00622 CYR61 0.56003 UP 
P10451 SPP1 0.53353 UP 
O60565 GREM1 0.51981 DOWN 
P11464 PSG1 0.50732 UP 
P12107 COL11A1 0.50057 DOWN 
O75094 SLIT3 0.4996 UP 
P00749 PLAU 0.45896 UP 
P0C0L4 C4A 0.45695 DOWN 
P58215 LOXL3 0.40034 DOWN 
Q04756 HGFAC 0.39176 UP 
P30533 LRPAP1 0.383 UP 
Q14515 SPARCL1 0.37279 DOWN 
O94907 DKK1 0.34996 UP 
P05156 CFI 0.34264 UP 
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P55268 LAMB2 0.34133 UP 
Q16352 INA 0.33821 DOWN 
P01185 AVP 0.33801 DOWN 
Q8IW75 SERPINA12 0.33079 UP 
P69905 HBA1 0.32042 UP 
P02790 HPX 0.31057 DOWN 
P39060 COL18A1 0.30654 DOWN 
Q99470 SDF2 0.29463 UP 
P35443 THBS4 0.29269 DOWN 
P07093 SERPINE2 0.27079 DOWN 
Q13219 PAPPA 0.23725 UP 
P21583 KITLG 0.2343 DOWN 
P24043 LAMA2 0.23247 UP 
P62328 TMSB4X 0.23026 UP 
O94813 SLIT2 0.22586 DOWN 
P62805 HIST1H4A 0.22213 DOWN 
P26927 MST1 0.2178 DOWN 
P02751 FN1 0.21377 DOWN 
Q13753 LAMC2 0.20698 UP 
P19320 VCAM1 0.20395 UP 
Q8TB73 NDNF 0.20354 DOWN 
P14618 PKM 0.20082 DOWN 
P01040 CSTA 0.19951 UP 
Q99880 HIST1H2BL 0.19624 DOWN 
Q9BX67 JAM3 0.18673 UP 
P12643 BMP2 0.17129 UP 
P04114 APOB 0.16782 DOWN 
P02753 RBP4 0.16063 DOWN 
Q02388 COL7A1 0.15448 UP 
P47929 LGALS7 0.15433 UP 
A8K2U0 A2ML1 0.1476 UP 
Q99985 SEMA3C 0.14525 UP 
P05089 ARG1 0.13376 UP 
P03952 KLKB1 0.13201 DOWN 
Q13361 MFAP5 0.13088 DOWN 
P48307 TFPI2 0.12743 UP 
Q06828 FMOD 0.12607 DOWN 
P22692 IGFBP4 0.123 UP 
P0DML3 CSH2 0.11377 DOWN 
P05090 APOD 0.10707 UP 
Q15063 POSTN 0.106 UP 
Q9BZM5 ULBP2 0.103 UP 
Q8IX30 SCUBE3 0.096418 DOWN 
Q14574 DSC3 0.094911 UP 
P18065 IGFBP2 0.093993 UP 
P00750 PLAT 0.093536 UP 
P55145 MANF 0.088626 UP 
Q6UXH1 CRELD2 0.08812 UP 
P48594 SERPINB4 0.087681 UP 
Q07092 COL16A1 0.084733 DOWN 
P55001 MFAP2 0.083819 DOWN 
Q8WZ42 TTN 0.082636 DOWN 
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Table A4.2 Proteins and peptides used for targeted proteomics. The 
proteins and peptides chosen for parallel reaction monitoring (PRM) based on 
the list obtained from the SVM. 
 
Protein Peptide 
Precursor 
m/z 
Precursor 
Charge 
MMP1 
IENYTPDLPR 609.3117 2 
MIAHDFPGIGHK 441.5607 3 
VDAVFMK 405.2149 2 
SFRP1 
FYTKPPQCVDIPADLR 640.661 3 
MVLPNLLEHETMAEVK 618.6548 3 
WLCEAVR 467.2342 2 
NPTX1 
FQLTFPLR 511.2951 2 
TNYMYAK 445.7075 2 
LPFVINDGK 501.7846 2 
IL6 
YILDGISALR 560.8217 2 
FESSEEQAR 541.7411 2 
VLIQFLQK 494.8131 2 
CXCL5 
CVCLQTTQGVHPK 509.9184 3 
MISNLQVFAIGPQCSK 896.9579 2 
EICLDPEAPFLK 716.3631 2 
CXCL6 
LQVFPAGPQCSK 666.3425 2 
VEVVASLK 422.7606 2 
QVCLDPEAPFLK 708.8632 2 
GDF15 
ILTPEVR 414.2529 2 
AALPEGLPEASR 605.825 2 
LKPDTVPAPCCVPASYNPMVLIQK 900.1304 3 
CCL2 
 
EICADPK 416.6971 2 
WVQDSMDHLDK 458.5433 3 
 
CXCL8 
VIESGPHCANTEIIVK 589.6147 3 
ELCLDPK 437.7206 2 
ENWVQR 416.209 2 
SERPING1 
LLDSLPSDTR 558.7984 2 
VPMMNSK 403.6989 2 
FQPTLLTLPR 593.3531 2 
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Table A4.3 Acquisition parameters for the Q Exactive Plus. Overview of 
the parameters used for data acquisition on a Q Exactive Plus for label-free 
and targeted proteomics. 
 
Parameter Q Exactive Plus PRM 
Mass Range (m/z) 400-1500 395-1500 
Isolation Window (m/z) 2.0 1.2 
MS resolution 70K @ 200m/z 70K @ 200m/z 
MSMS Resolution 17.5K 35.0K 
MS Injection Time (ms) 250 250 
MSn Injection Time (ms) 64 120 
AGC Target (MS) 3E6 3E6 
AGC Target (MSn) 2E5 1E6 
Preview Scan n/a n/a 
Threshold (counts) 2.0E3 n/a 
Minimum AGC Target 3.1E4 n/a 
Data Dependent Acquisition Top12 Loop Count 30 
Dynamic Exclusion (s) 30 Inclusion List 
Exclusion Mass Width (m/z) n/a n/a 
Exclude Isotopes/ 
Monoisotopic precursor 
Selection 
Enabled Enabled 
Fragmentation Type HCD HCD 
Normalized Collision 
Energy 
25 25 
Lock Mass 
(445.120025m/z) 
Best Best 
Charge State Rejection Unassigned, +1,7,8,>8 n/a 
Default Charge State +2 +2 
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Table A5.1 Fold change of proteins during Wnt-modulation. All secreted 
proteins differentially expressed between Wnt-activated, Wnt-inhibited and 
untreated hMSC CM. 
 
Accession Number Gene Name F.C (Wnt+/hMSC) F.C (Wnt+/Wnt-) 
P27487 DPP4 4.579510 0.054511 
Q8WZ78 TUBB8 3.775380 0.769514 
Q16778 HIST2H2BE 3.448830 0.720582 
P10606 COX5B 3.383160 2.056420 
Q99985 SEMA3C 3.351510 2.515130 
P20674 COX5A 3.047730 1.792340 
P05161 ISG15 2.997400 2.049760 
P61026 RAB10 2.975210 3.269350 
B4DKM5 VDAC2 2.848110 1.280320 
P39026 RPL11 2.811480 0.532597 
P15018 LIF 2.781470 2.763490 
P08195 SLC3A2 2.773380 3.447360 
Q9H0B8 CRISPLD2 2.685340 1.567540 
B3KUF5 TOM1 2.541680 2.020100 
A1L4P6 AKR1D1 2.447030 1.853950 
B4DW94 RAP1B 2.446660 0.380342 
Q6UVK1 CSPG4 2.397310 0.549941 
Q3SXN8 NEDD8 2.357050 2.558250 
A0A024R5J8 TSKU 2.335850 2.410870 
B3KXM0 PIN4 2.331660 1.130390 
Q96QL0 RPL3 2.273780 0.610528 
A8K538 DDX3X 2.261690 1.159570 
Q16641 LAMP2 2.261320 1.661700 
Q96C49 SLC25A6 2.242380 0.391869 
A8K4I2 HIST1H1C 2.209940 0.297064 
Q9HD42 CHMP1A 2.192860 0.078407 
Q9UGJ9 PGRMC1 2.162670 0.121006 
Q9UP99 CSE1L 2.148670 2.472240 
Q01813 PFKP 2.097090 1.914970 
A6NKY0 H2AFV 2.090800 1.612350 
Q6IB98 EIF3H 2.078410 0.941184 
B7Z1N7 ATP1B3 2.051660 1.001310 
A0A024R4D1 COPS8 2.046190 0.110893 
Q14467 CYFIP1 2.037050 2.320730 
Q5TEE6 MARCKSL1 2.030850 0.616287 
D3DUT6 CLSTN3 2.019180 1.904560 
A8K879 NAPA 2.007760 1.358000 
B7Z5K8 CUL4B 2.006380 0.020088 
Q504S5 CKAP4 2.005710 0.817987 
B7Z6V1 EIF4E 2.000910 1.167210 
B2RC19 DKK1 -1.243730 -1.000200 
Q5TZY5 GSTM2 -1.251380 0.271942 
Q8WWI9 TNFAIP6 -1.253530 -1.795970 
Q96JJ0 CXCL1 -1.266380 -0.367760 
Q9BWC4 PTX3 -1.266680 -0.480790 
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Q96A79 KIAA0319L -1.272620 0.495421 
P98160 JUP -1.273010 0.380095 
P48669 CTGF -1.280530 -1.083540 
O43479 HSPG2 -1.289480 -1.442840 
Q9HB01 KRT6B -1.302050 -0.796300 
Q68D21 RBP4 -1.303350 -1.054570 
P10645 DSC1 -1.359340 0.365096 
Q9UNA0 MASP1 -1.416630 -0.943110 
Q04756 CHGA -1.446660 -2.263450 
P49746 ADAMTS5 -1.475220 -0.706500 
O94955 HGFAC -1.586710 0.260090 
C7S7T9 THBS3 -1.665760 -0.992860 
Q99806 RHOBTB3 -1.695530 -0.066970 
P19883 SSC5D -1.778390 -0.222490 
E9PBV3 VWF -1.912120 0.011694 
Q5T749 FST -1.918420 -1.047180 
Q149N0 SBSN -1.975900 1.233270 
Q7Z2X9 KPRP -1.987160 1.008220 
P00746 COL11A1 -2.067740 -1.199500 
Q96KY1 CEP164 -2.101500 -2.087610 
C9JAB2 CFD -2.211990 -1.840850 
P27487 C1QTNF3 -2.470000 -2.198390 
Q8WZ78 SRSF7 -3.183980 -0.385980 
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Table A5.2 Antibody concentration and manufacture information. All 
antibodies used in immunohistochemistry and immunofluorescence analysis 
of mouse pancreatic tissue. 
 
Reagent Source Identifier Concentration 
Mouse anti-insulin Sigma I2018 1/500 
Guinea pig anti-insulin Abcam AB7842 1/40 
Rabbit anti-insulin Abcam AB181547 1/500 
Mouse β-catenin ThermoFisher 53-2567-42 1/67 
Mouse anti-glucagon Abcam AB10988 1/500 
Rat anti-CD31 BD 550274 1/100 
Rabbit anti-vWF Millipore Sigma AB7356 1/200 
Rabbit anti-ck19 Abcam AB52625 1/400 
Rabbit anti-NKX2.2 Abcam AB191077 1/1000 
Rabbit anti-NKX6.1 Abcam AB221549 1/2000 
Goal anti-NKX6.1 R&D Systems AF5857 1/80 
Mouse anti-NKX2.2 Novus Biologicals NBP2-29432 1/400 
Rabbit anti-LIFR Abcam AB101228 1/2000 
Rabbit anti-IGFR1 Abcam AB39675 1/1000 
Rabbit anti-TGFBR1 Abcam AB31013 1/200 
Guinea pig anti-vimentin Antibodiesonline ABIN126094 1/200 
Horse anti-igG (H+L) MJS Biolynx VECTPI2000 1/250 
DAB peroxidase MJS Biolynx VECTSK4105 1/33 
DAPI solution ThermoFisher 62248 1/1000 
Goat fluorescein MJS Biolynx VECTFI1000 1/400 
Horse Texas red MJS Biolynx VECTFI2000 1/400 
Goat Texas red MJS Biolynx VECTTI1000 1/400 
Donkey cy5 Cedarlane 706-175-148 1/400 
EdU Alexa 488 ThermoFisher C10637 n/a 
Vectashield DAPI MJS Biolynx VECTH1200 1/667 
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Appendix II 
 
Supporting figures for proteomic characterization of conditioned media 
generated from human multipotent stromal cells (hMSC). 
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Figure A3.1 Condition media generated by hMSCR augments 
spontaneous HMVEC tube formation after 24 hrs in vitro. Representative 
photomicrographs of HMVEC tube formation after 24 hrs on growth factor 
reduced GeltrexTM supplemented with (a) EGM-2, (b) EBM-2, (c) condition 
media generated by hMSCR and (d) condition media generated by hMSCNR. 
Scale bar, 100 μm. 
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Figure A3.2  Total β-catenin levels in hMSC treated with CHIR99201 
quantified using flow cytometry. Flow representative dot plots showing 
intracellular levels of β-catenin in hMSC treated with DMSO (control) or 10 μM 
of CHIR99201. hMSC were treated for 24 h prior to analysis by flow 
cytometry. Cells were fixed using 1% formalin and permeabilized using 
Saponin buffer. Cells were incubated with an isotype control (left) or with a 
FITC conjugated antibody. hMSCs treated with CHIR99201 showed a 
significant increased in total β-catenin (top panel). To quantify total levels of β-
catenin, the geometric mean fluorescence intensity was calculated and 
normalized to the isotype control. 
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Figure A3.3 Culture conditions for human pancreatic islets using 
condition media generated by hMSC samples. Human islets were plated at 
200 islets equivalence (IEQ) in 3 mL of RPMI media (6-well plate). A total of 
five different conditions were tested. Islets grown in RPMI media served are a 
negative control, RPMI supplemented with 10% FBS served as a positive 
control to ensure islet survival and growth. Concentrated condition media from 
hMSC treated with DMSO (drug control) are labeled as basal CM, hMSC 
treated with CHIR99201 are labeled as GSK3i CM. Also 10 μM of CHIR99201 
was directly added to one culture condition. β-cell survival and proliferation 
was quantified using flow cytometry after 1, 3, 7 days of culture. 
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Figure A3.4  Flow cytometry analysis of human pancreatic islets for β-
cell content and survival. Human pancreatic islets preparations were 
obtained from the IIDP. Before analysis using flow cytometry, islet 
preparations were dissociated using trypsin and stained using Fluozin3 for β-
cell content. (a)  Representative dot plots for β-cell content using Fluozin3 
gating and corresponding FMO. Islets were cultured using RPMI alone (b) and 
condition media from CHIR99201 treaded hMSC (WNT+ CM) (c). Survival 
was quantified using 7AAD and AnnexinV. Representative dot plots gated on 
Fluozin3 positive cells for survival using corresponding FMO (d), RPMI alone 
(e), WNT+ CM (f). Total parent frequencies are shown inside each gate. 
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Figure A5.1 hMSC conditioned media transplanted increased islet 
vascularization. Representative photomicrographs of vWF+ blood vessels 
(green) associated with insulin+ islets (red) at day 42 after injection of (a) 
media control, (b) basal CM (4 µg), (c) WNT+ CM (4 µg).  Arrows mark vWF+ 
vessels within islets (outlined with dashed lines). Representative 
photomicrographs of CD31+ (green) within insulin+ islets (red) at day 42 after 
injection of (d) media control, (e) basal CM (4 µg), (f) WNT+ CM (4 µg). 
Arrows mark CD31+ microvessicles within islets (outlined with dashed lines). 
Compared to media control, mice injected with 8µg of basal CM or mice 
injected with WNT+CM (4 or 8 µg) showed increased vWF islet 
vascularization (g) and total number of CD31+ capillaries (h). No significant 
difference was observed in the normalized (for size) microvasculature. Scale 
bar=200 µm. Data is represented as mean ± S.E.M. (**p<0.01, ***p<0.001)
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Figure A5.2  Intrapancreatic-injection of Wnt-activated hMSC CM shown 
no difference in endocrine marker NKX2.2. (a-c) Representative 
photomicrographs of NKX2.2+ cells within islets at day 11, 14, and 42 in mice 
injected with unconditioned media, or 8 µg hMSC CM, or 8 µg WNT+ CM. (d) 
Mice injected with hMSC CM showed no difference in frequency of NKX2.2+ 
cells per islet compared to mice injected with r unconditioned media. (e) Mice 
injected with WNT+ CM showed no difference in frequency of NKX2.2+ cells 
per islet compared to mice injected with WNT- CM or unconditioned media. 
Scale bar=200 µm. Data is represented as mean ± S.E.M.  
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